<!DOCTYPE us-patent-grant SYSTEM "us-patent-grant-v44-2013-05-16.dtd" [ ]>
<us-patent-grant lang="EN" dtd-version="v4.4 2013-05-16" file="US08623918-20140107.XML" status="PRODUCTION" id="us-patent-grant" country="US" date-produced="20131224" date-publ="20140107">
<us-bibliographic-data-grant>
<publication-reference>
<document-id>
<country>US</country>
<doc-number>08623918</doc-number>
<kind>B2</kind>
<date>20140107</date>
</document-id>
</publication-reference>
<application-reference appl-type="utility">
<document-id>
<country>US</country>
<doc-number>12260534</doc-number>
<date>20081029</date>
</document-id>
</application-reference>
<us-application-series-code>12</us-application-series-code>
<us-term-of-grant>
<us-term-extension>875</us-term-extension>
</us-term-of-grant>
<classifications-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>31</main-group>
<subgroup>5575</subgroup>
<symbol-position>F</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20140107</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>C</section>
<class>07</class>
<subclass>C</subclass>
<main-group>57</main-group>
<subgroup>26</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20140107</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>C</section>
<class>07</class>
<subclass>C</subclass>
<main-group>229</main-group>
<subgroup>26</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20140107</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
</classifications-ipcr>
<classifications-cpc>
<main-cpc>
<classification-cpc>
<cpc-version-indicator><date>20130101</date></cpc-version-indicator>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>31</main-group>
<subgroup>5575</subgroup>
<symbol-position>F</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20140107</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
</main-cpc>
<further-cpc>
<classification-cpc>
<cpc-version-indicator><date>20130101</date></cpc-version-indicator>
<section>C</section>
<class>07</class>
<subclass>C</subclass>
<main-group>57</main-group>
<subgroup>26</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20140107</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
<classification-cpc>
<cpc-version-indicator><date>20130101</date></cpc-version-indicator>
<section>C</section>
<class>07</class>
<subclass>C</subclass>
<main-group>229</main-group>
<subgroup>26</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20140107</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
<scheme-origination-code>C</scheme-origination-code>
</classification-cpc>
</further-cpc>
</classifications-cpc>
<classification-national>
<country>US</country>
<main-classification>514559</main-classification>
<further-classification>554222</further-classification>
</classification-national>
<invention-title id="d2e53">Amino acid salts of prostaglandins</invention-title>
<us-references-cited>
<us-citation>
<patcit num="00001">
<document-id>
<country>US</country>
<doc-number>13294</doc-number>
<kind>A</kind>
<name>Reynolds</name>
<date>18550700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00002">
<document-id>
<country>US</country>
<doc-number>37913</doc-number>
<kind>A</kind>
<name>Howe</name>
<date>18630300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00003">
<document-id>
<country>US</country>
<doc-number>37914</doc-number>
<kind>A</kind>
<name>Hankinson</name>
<date>18630300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00004">
<document-id>
<country>US</country>
<doc-number>146439</doc-number>
<kind>A</kind>
<name>Ellis</name>
<date>18740100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00005">
<document-id>
<country>US</country>
<doc-number>3382247</doc-number>
<kind>A</kind>
<name>Anthony</name>
<date>19680500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00006">
<document-id>
<country>US</country>
<doc-number>3435053</doc-number>
<kind>A</kind>
<name>Beal et al.</name>
<date>19690300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00007">
<document-id>
<country>US</country>
<doc-number>3524867</doc-number>
<kind>A</kind>
<name>Beal et al.</name>
<date>19700800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00008">
<document-id>
<country>US</country>
<doc-number>3598858</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19710800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00009">
<document-id>
<country>US</country>
<doc-number>3636120</doc-number>
<kind>A</kind>
<name>Pike</name>
<date>19720100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00010">
<document-id>
<country>US</country>
<doc-number>3644363</doc-number>
<kind>A</kind>
<name>Kim</name>
<date>19720200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00011">
<document-id>
<country>US</country>
<doc-number>3691216</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19720900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00012">
<document-id>
<country>US</country>
<doc-number>3706789</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19721200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00013">
<document-id>
<country>US</country>
<doc-number>3723427</doc-number>
<kind>A</kind>
<name>Susi</name>
<date>19730300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00014">
<document-id>
<country>US</country>
<doc-number>3776938</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19731200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00015">
<document-id>
<country>US</country>
<doc-number>3776939</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19731200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00016">
<document-id>
<country>US</country>
<doc-number>3798275</doc-number>
<kind>A</kind>
<name>Finch et al.</name>
<date>19740300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00017">
<document-id>
<country>US</country>
<doc-number>3839409</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19741000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00018">
<document-id>
<country>US</country>
<doc-number>3852337</doc-number>
<kind>A</kind>
<name>Bergstrom et al.</name>
<date>19741200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00019">
<document-id>
<country>US</country>
<doc-number>3882241</doc-number>
<kind>A</kind>
<name>Pharriss</name>
<date>19750500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00020">
<document-id>
<country>US</country>
<doc-number>3882245</doc-number>
<kind>A</kind>
<name>DuCharme</name>
<date>19750500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00021">
<document-id>
<country>US</country>
<doc-number>3896156</doc-number>
<kind>A</kind>
<name>Beal et al.</name>
<date>19750700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00022">
<document-id>
<country>US</country>
<doc-number>3928588</doc-number>
<kind>A</kind>
<name>Robert</name>
<date>19751200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00023">
<document-id>
<country>US</country>
<doc-number>3931282</doc-number>
<kind>A</kind>
<name>Muchowski et al.</name>
<date>19760100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00024">
<document-id>
<country>US</country>
<doc-number>3934013</doc-number>
<kind>A</kind>
<name>Poulsen</name>
<date>19760100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00025">
<document-id>
<country>US</country>
<doc-number>3966792</doc-number>
<kind>A</kind>
<name>Hayashi et al.</name>
<date>19760600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00026">
<document-id>
<country>US</country>
<doc-number>3974213</doc-number>
<kind>A</kind>
<name>Hess et al.</name>
<date>19760800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00027">
<document-id>
<country>US</country>
<doc-number>3984424</doc-number>
<kind>A</kind>
<name>Schaf</name>
<date>19761000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00028">
<document-id>
<country>US</country>
<doc-number>3984455</doc-number>
<kind>A</kind>
<name>Beal et al.</name>
<date>19761000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00029">
<document-id>
<country>US</country>
<doc-number>3985791</doc-number>
<kind>A</kind>
<name>Muchowski et al.</name>
<date>19761000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00030">
<document-id>
<country>US</country>
<doc-number>4004020</doc-number>
<kind>A</kind>
<name>Skuballa et al.</name>
<date>19770100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00031">
<document-id>
<country>US</country>
<doc-number>4005133</doc-number>
<kind>A</kind>
<name>Morozowich</name>
<date>19770100</date>
</document-id>
</patcit>
<category>cited by examiner</category>
<classification-national><country>US</country><main-classification>562503</main-classification></classification-national>
</us-citation>
<us-citation>
<patcit num="00032">
<document-id>
<country>US</country>
<doc-number>4011262</doc-number>
<kind>A</kind>
<name>Hess et al.</name>
<date>19770300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00033">
<document-id>
<country>US</country>
<doc-number>4018812</doc-number>
<kind>A</kind>
<name>Hayashi et al.</name>
<date>19770400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00034">
<document-id>
<country>US</country>
<doc-number>4024179</doc-number>
<kind>A</kind>
<name>Bindra et al.</name>
<date>19770500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00035">
<document-id>
<country>US</country>
<doc-number>4051238</doc-number>
<kind>A</kind>
<name>Sokolowski</name>
<date>19770900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00036">
<document-id>
<country>US</country>
<doc-number>4061671</doc-number>
<kind>A</kind>
<name>Beck et al.</name>
<date>19771200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00037">
<document-id>
<country>US</country>
<doc-number>4073934</doc-number>
<kind>A</kind>
<name>Skuballa et al.</name>
<date>19780200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00038">
<document-id>
<country>US</country>
<doc-number>4089885</doc-number>
<kind>A</kind>
<name>Husbands</name>
<date>19780500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00039">
<document-id>
<country>US</country>
<doc-number>4105854</doc-number>
<kind>A</kind>
<name>Gibson</name>
<date>19780800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00040">
<document-id>
<country>US</country>
<doc-number>4116989</doc-number>
<kind>A</kind>
<name>Nelson</name>
<date>19780900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00041">
<document-id>
<country>US</country>
<doc-number>4123441</doc-number>
<kind>A</kind>
<name>Johnson</name>
<date>19781000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00042">
<document-id>
<country>US</country>
<doc-number>4128577</doc-number>
<kind>A</kind>
<name>Nelson</name>
<date>19781200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00043">
<document-id>
<country>US</country>
<doc-number>4128720</doc-number>
<kind>A</kind>
<name>Hayashi et al.</name>
<date>19781200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00044">
<document-id>
<country>US</country>
<doc-number>4139619</doc-number>
<kind>A</kind>
<name>Chidsey, III</name>
<date>19790200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00045">
<document-id>
<country>US</country>
<doc-number>4152527</doc-number>
<kind>A</kind>
<name>Hess et al.</name>
<date>19790500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00046">
<document-id>
<country>US</country>
<doc-number>4154950</doc-number>
<kind>A</kind>
<name>Nelson</name>
<date>19790500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00047">
<document-id>
<country>US</country>
<doc-number>4158667</doc-number>
<kind>A</kind>
<name>Axen</name>
<date>19790600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00048">
<document-id>
<country>US</country>
<doc-number>4171331</doc-number>
<kind>A</kind>
<name>Biddlecom et al.</name>
<date>19791000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00049">
<document-id>
<country>US</country>
<doc-number>4206151</doc-number>
<kind>A</kind>
<name>Grudzinskas</name>
<date>19800600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00050">
<document-id>
<country>US</country>
<doc-number>4217360</doc-number>
<kind>A</kind>
<name>Vorbruggen et al.</name>
<date>19800800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00051">
<document-id>
<country>US</country>
<doc-number>4225507</doc-number>
<kind>A</kind>
<name>Sih</name>
<date>19800900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00052">
<document-id>
<country>US</country>
<doc-number>4225508</doc-number>
<kind>A</kind>
<name>Sih</name>
<date>19800900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00053">
<document-id>
<country>US</country>
<doc-number>4268522</doc-number>
<kind>A</kind>
<name>Eggler et al.</name>
<date>19810500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00054">
<document-id>
<country>US</country>
<doc-number>4284646</doc-number>
<kind>A</kind>
<name>Vorbruggen et al.</name>
<date>19810800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00055">
<document-id>
<country>US</country>
<doc-number>4296504</doc-number>
<kind>A</kind>
<name>Lawson</name>
<date>19811000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00056">
<document-id>
<country>US</country>
<doc-number>4311707</doc-number>
<kind>A</kind>
<name>Birnbaum et al.</name>
<date>19820100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00057">
<document-id>
<country>US</country>
<doc-number>4489092</doc-number>
<kind>A</kind>
<name>Vorbruggen et al.</name>
<date>19841200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00058">
<document-id>
<country>US</country>
<doc-number>4499293</doc-number>
<kind>A</kind>
<name>Johnson et al.</name>
<date>19850200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00059">
<document-id>
<country>US</country>
<doc-number>4543353</doc-number>
<kind>A</kind>
<name>Faustini et al.</name>
<date>19850900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00060">
<document-id>
<country>US</country>
<doc-number>4596812</doc-number>
<kind>A</kind>
<name>Chidsey</name>
<date>19860600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00061">
<document-id>
<country>US</country>
<doc-number>4599353</doc-number>
<kind>A</kind>
<name>Bito</name>
<date>19860700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00062">
<document-id>
<country>US</country>
<doc-number>4621100</doc-number>
<kind>A</kind>
<name>Lund et al.</name>
<date>19861100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00063">
<document-id>
<country>US</country>
<doc-number>4704386</doc-number>
<kind>A</kind>
<name>Mueller</name>
<date>19871100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00064">
<document-id>
<country>US</country>
<doc-number>4757089</doc-number>
<kind>A</kind>
<name>Epstein</name>
<date>19880700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00065">
<document-id>
<country>US</country>
<doc-number>4812457</doc-number>
<kind>A</kind>
<name>Narumiya et al.</name>
<date>19890300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00066">
<document-id>
<country>US</country>
<doc-number>4883819</doc-number>
<kind>A</kind>
<name>Bito</name>
<date>19891100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00067">
<document-id>
<country>US</country>
<doc-number>4889845</doc-number>
<kind>A</kind>
<name>Ritter et al.</name>
<date>19891200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00068">
<document-id>
<country>US</country>
<doc-number>4912235</doc-number>
<kind>A</kind>
<name>Cooper et al.</name>
<date>19900300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00069">
<document-id>
<country>US</country>
<doc-number>4952581</doc-number>
<kind>A</kind>
<name>Bito et al.</name>
<date>19900800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00070">
<document-id>
<country>US</country>
<doc-number>4968812</doc-number>
<kind>A</kind>
<name>Wang et al.</name>
<date>19901100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00071">
<document-id>
<country>US</country>
<doc-number>5001153</doc-number>
<kind>A</kind>
<name>Ueno</name>
<date>19910300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00072">
<document-id>
<country>US</country>
<doc-number>5041439</doc-number>
<kind>A</kind>
<name>Kasting et al.</name>
<date>19910800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00073">
<document-id>
<country>US</country>
<doc-number>5063057</doc-number>
<kind>A</kind>
<name>Spellman et al.</name>
<date>19911100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00074">
<document-id>
<country>US</country>
<doc-number>5166178</doc-number>
<kind>A</kind>
<name>Ueno et al.</name>
<date>19921100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00075">
<document-id>
<country>US</country>
<doc-number>5194429</doc-number>
<kind>A</kind>
<name>Ueno</name>
<date>19930300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00076">
<document-id>
<country>US</country>
<doc-number>5212324</doc-number>
<kind>A</kind>
<name>Ueno et al.</name>
<date>19930500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00077">
<document-id>
<country>US</country>
<doc-number>5219885</doc-number>
<kind>A</kind>
<name>Frolich et al.</name>
<date>19930600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00078">
<document-id>
<country>US</country>
<doc-number>5280018</doc-number>
<kind>A</kind>
<name>Ritter et al.</name>
<date>19940100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00079">
<document-id>
<country>US</country>
<doc-number>5288754</doc-number>
<kind>A</kind>
<name>Woodward et al.</name>
<date>19940200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00080">
<document-id>
<country>US</country>
<doc-number>5296504</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>19940300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00081">
<document-id>
<country>US</country>
<doc-number>5302617</doc-number>
<kind>A</kind>
<name>Ueno</name>
<date>19940400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00082">
<document-id>
<country>US</country>
<doc-number>5312832</doc-number>
<kind>A</kind>
<name>Chan</name>
<date>19940500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00083">
<document-id>
<country>US</country>
<doc-number>5321128</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>19940600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00084">
<document-id>
<country>US</country>
<doc-number>5332730</doc-number>
<kind>A</kind>
<name>Chan</name>
<date>19940700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00085">
<document-id>
<country>US</country>
<doc-number>5340813</doc-number>
<kind>A</kind>
<name>Klein et al.</name>
<date>19940800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00086">
<document-id>
<country>US</country>
<doc-number>5352708</doc-number>
<kind>A</kind>
<name>Woodward et al.</name>
<date>19941000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00087">
<document-id>
<country>US</country>
<doc-number>5409911</doc-number>
<kind>A</kind>
<name>Tyler et al.</name>
<date>19950400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00088">
<document-id>
<country>US</country>
<doc-number>5422368</doc-number>
<kind>A</kind>
<name>Stjernschantz</name>
<date>19950600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00089">
<document-id>
<country>US</country>
<doc-number>5422369</doc-number>
<kind>A</kind>
<name>Stjernschantz</name>
<date>19950600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00090">
<document-id>
<country>US</country>
<doc-number>5422371</doc-number>
<kind>A</kind>
<name>Liao et al.</name>
<date>19950600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00091">
<document-id>
<country>US</country>
<doc-number>5426115</doc-number>
<kind>A</kind>
<name>Ueno et al.</name>
<date>19950600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00092">
<document-id>
<country>US</country>
<doc-number>5431881</doc-number>
<kind>A</kind>
<name>Palacios</name>
<date>19950700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00093">
<document-id>
<country>US</country>
<doc-number>5458883</doc-number>
<kind>A</kind>
<name>Epstein</name>
<date>19951000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00094">
<document-id>
<country>US</country>
<doc-number>5464868</doc-number>
<kind>A</kind>
<name>Frolich et al.</name>
<date>19951100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00095">
<document-id>
<country>US</country>
<doc-number>5480900</doc-number>
<kind>A</kind>
<name>DeSantis, Jr. et al.</name>
<date>19960100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00096">
<document-id>
<country>US</country>
<doc-number>5500230</doc-number>
<kind>A</kind>
<name>Nathanson</name>
<date>19960300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00097">
<document-id>
<country>US</country>
<doc-number>5508303</doc-number>
<kind>A</kind>
<name>Isogaya et al.</name>
<date>19960400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00098">
<document-id>
<country>US</country>
<doc-number>5510383</doc-number>
<kind>A</kind>
<name>Bishop</name>
<date>19960400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00099">
<document-id>
<country>US</country>
<doc-number>5516652</doc-number>
<kind>A</kind>
<name>Abramovitz et al.</name>
<date>19960500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00100">
<document-id>
<country>US</country>
<doc-number>5567079</doc-number>
<kind>A</kind>
<name>Felder</name>
<date>19961000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00101">
<document-id>
<country>US</country>
<doc-number>5576315</doc-number>
<kind>A</kind>
<name>Hallinan et al.</name>
<date>19961100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00102">
<document-id>
<country>US</country>
<doc-number>5578618</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>19961100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00103">
<document-id>
<country>US</country>
<doc-number>5578640</doc-number>
<kind>A</kind>
<name>Hanson</name>
<date>19961100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00104">
<document-id>
<country>US</country>
<doc-number>5578643</doc-number>
<kind>A</kind>
<name>Hanson</name>
<date>19961100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00105">
<document-id>
<country>US</country>
<doc-number>5587391</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>19961200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00106">
<document-id>
<country>US</country>
<doc-number>5605814</doc-number>
<kind>A</kind>
<name>Abramovitz et al.</name>
<date>19970200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00107">
<document-id>
<country>US</country>
<doc-number>5605931</doc-number>
<kind>A</kind>
<name>Hanson</name>
<date>19970200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00108">
<document-id>
<country>US</country>
<doc-number>5607978</doc-number>
<kind>A</kind>
<name>Woodward et al.</name>
<date>19970300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00109">
<document-id>
<country>US</country>
<doc-number>5627208</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>19970500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00110">
<document-id>
<country>US</country>
<doc-number>5641494</doc-number>
<kind>A</kind>
<name>Cauwenbergh</name>
<date>19970600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00111">
<document-id>
<country>US</country>
<doc-number>5658897</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>19970800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00112">
<document-id>
<country>US</country>
<doc-number>5663203</doc-number>
<kind>A</kind>
<name>Ekerdt et al.</name>
<date>19970900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00113">
<document-id>
<country>US</country>
<doc-number>5665773</doc-number>
<kind>A</kind>
<name>Klimko et al.</name>
<date>19970900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00114">
<document-id>
<country>US</country>
<doc-number>5670506</doc-number>
<kind>A</kind>
<name>Leigh et al.</name>
<date>19970900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00115">
<document-id>
<country>US</country>
<doc-number>5681850</doc-number>
<kind>A</kind>
<name>Frolich et al.</name>
<date>19971000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00116">
<document-id>
<country>US</country>
<doc-number>5688819</doc-number>
<kind>A</kind>
<name>Woodward et al.</name>
<date>19971100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00117">
<document-id>
<country>US</country>
<doc-number>5698733</doc-number>
<kind>A</kind>
<name>Hellberg et al.</name>
<date>19971200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00118">
<document-id>
<country>US</country>
<doc-number>5703108</doc-number>
<kind>A</kind>
<name>Cameron et al.</name>
<date>19971200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00119">
<document-id>
<country>US</country>
<doc-number>5716609</doc-number>
<kind>A</kind>
<name>Jain et al.</name>
<date>19980200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00120">
<document-id>
<country>US</country>
<doc-number>5719140</doc-number>
<kind>A</kind>
<name>Chandrakumar et al.</name>
<date>19980200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00121">
<document-id>
<country>US</country>
<doc-number>5741810</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>19980400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00122">
<document-id>
<country>US</country>
<doc-number>5759789</doc-number>
<kind>A</kind>
<name>Abramovitz et al.</name>
<date>19980600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00123">
<document-id>
<country>US</country>
<doc-number>5770759</doc-number>
<kind>A</kind>
<name>Ueno et al.</name>
<date>19980600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00124">
<document-id>
<country>US</country>
<doc-number>5773472</doc-number>
<kind>A</kind>
<name>Stjernschantz</name>
<date>19980600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00125">
<document-id>
<country>US</country>
<doc-number>5792851</doc-number>
<kind>A</kind>
<name>Schuster et al.</name>
<date>19980800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00126">
<document-id>
<country>US</country>
<doc-number>5834498</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>19981100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00127">
<document-id>
<country>US</country>
<doc-number>5840847</doc-number>
<kind>A</kind>
<name>Abramovitz et al.</name>
<date>19981100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00128">
<document-id>
<country>US</country>
<doc-number>5849791</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>19981200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00129">
<document-id>
<country>US</country>
<doc-number>5863948</doc-number>
<kind>A</kind>
<name>Epstein et al.</name>
<date>19990100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00130">
<document-id>
<country>US</country>
<doc-number>5869281</doc-number>
<kind>A</kind>
<name>Abramovitz et al.</name>
<date>19990200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00131">
<document-id>
<country>US</country>
<doc-number>5877211</doc-number>
<kind>A</kind>
<name>Woodward</name>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00132">
<document-id>
<country>US</country>
<doc-number>5885766</doc-number>
<kind>A</kind>
<name>Mahe et al.</name>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00133">
<document-id>
<country>US</country>
<doc-number>5885974</doc-number>
<kind>A</kind>
<name>Danielov</name>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00134">
<document-id>
<country>US</country>
<doc-number>5889052</doc-number>
<kind>A</kind>
<name>Klimko et al.</name>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00135">
<document-id>
<country>US</country>
<doc-number>5892099</doc-number>
<kind>A</kind>
<name>Maruyama et al.</name>
<date>19990400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00136">
<document-id>
<country>US</country>
<doc-number>5958723</doc-number>
<kind>A</kind>
<name>Abramovitz et al.</name>
<date>19990900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00137">
<document-id>
<country>US</country>
<doc-number>5972965</doc-number>
<kind>A</kind>
<name>Taniguchi et al.</name>
<date>19991000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00138">
<document-id>
<country>US</country>
<doc-number>5973002</doc-number>
<kind>A</kind>
<name>Frolich et al.</name>
<date>19991000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00139">
<document-id>
<country>US</country>
<doc-number>5977173</doc-number>
<kind>A</kind>
<name>Wos et al.</name>
<date>19991100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00140">
<document-id>
<country>US</country>
<doc-number>5985597</doc-number>
<kind>A</kind>
<name>Ford-Hutchinson et al.</name>
<date>19991100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00141">
<document-id>
<country>US</country>
<doc-number>5990346</doc-number>
<kind>A</kind>
<name>Kataoka et al.</name>
<date>19991100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00142">
<document-id>
<country>US</country>
<doc-number>5994397</doc-number>
<kind>A</kind>
<name>Selliah et al.</name>
<date>19991100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00143">
<document-id>
<country>US</country>
<doc-number>6013823</doc-number>
<kind>A</kind>
<name>Mamarella et al.</name>
<date>20000100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00144">
<document-id>
<country>US</country>
<doc-number>6025375</doc-number>
<kind>A</kind>
<name>Taniguchi et al.</name>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00145">
<document-id>
<country>US</country>
<doc-number>6025392</doc-number>
<kind>A</kind>
<name>Selliah et al.</name>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00146">
<document-id>
<country>US</country>
<doc-number>6030959</doc-number>
<kind>A</kind>
<name>Tremont et al.</name>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00147">
<document-id>
<country>US</country>
<doc-number>6030999</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00148">
<document-id>
<country>US</country>
<doc-number>6031001</doc-number>
<kind>A</kind>
<name>Stjernschantz et al.</name>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00149">
<document-id>
<country>US</country>
<doc-number>6031079</doc-number>
<kind>A</kind>
<name>Ford-Hutchinson et al.</name>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00150">
<document-id>
<country>US</country>
<doc-number>6037364</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>20000300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00151">
<document-id>
<country>US</country>
<doc-number>6037368</doc-number>
<kind>A</kind>
<name>Podos et al.</name>
<date>20000300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00152">
<document-id>
<country>US</country>
<doc-number>6043264</doc-number>
<kind>A</kind>
<name>Ohtake et al.</name>
<date>20000300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00153">
<document-id>
<country>US</country>
<doc-number>6048895</doc-number>
<kind>A</kind>
<name>Wos et al.</name>
<date>20000400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00154">
<document-id>
<country>US</country>
<doc-number>6107338</doc-number>
<kind>A</kind>
<name>Wos et al.</name>
<date>20000800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00155">
<document-id>
<country>US</country>
<doc-number>6110969</doc-number>
<kind>A</kind>
<name>Tani et al.</name>
<date>20000800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00156">
<document-id>
<country>US</country>
<doc-number>6121253</doc-number>
<kind>A</kind>
<name>Han et al.</name>
<date>20000900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00157">
<document-id>
<country>US</country>
<doc-number>6124344</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>20000900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00158">
<document-id>
<country>US</country>
<doc-number>6126957</doc-number>
<kind>A</kind>
<name>Epstein</name>
<date>20001000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00159">
<document-id>
<country>US</country>
<doc-number>6160129</doc-number>
<kind>A</kind>
<name>Burk</name>
<date>20001200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00160">
<document-id>
<country>US</country>
<doc-number>6169111</doc-number>
<kind>B1</kind>
<name>Zinke et al.</name>
<date>20010100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00161">
<document-id>
<country>US</country>
<doc-number>6232344</doc-number>
<kind>B1</kind>
<name>Feng</name>
<date>20010500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00162">
<document-id>
<country>US</country>
<doc-number>6262105</doc-number>
<kind>B1</kind>
<name>Johnstone</name>
<date>20010700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00163">
<document-id>
<country>US</country>
<doc-number>6372730</doc-number>
<kind>B1</kind>
<name>deLong et al.</name>
<date>20020400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00164">
<document-id>
<country>US</country>
<doc-number>6403649</doc-number>
<kind>B1</kind>
<name>Woodward et al.</name>
<date>20020600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00165">
<document-id>
<country>US</country>
<doc-number>6410780</doc-number>
<kind>B1</kind>
<name>deLong et al.</name>
<date>20020600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00166">
<document-id>
<country>US</country>
<doc-number>6444840</doc-number>
<kind>B1</kind>
<name>deLong et al.</name>
<date>20020900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00167">
<document-id>
<country>US</country>
<doc-number>6451859</doc-number>
<kind>B1</kind>
<name>deLong et al.</name>
<date>20020900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00168">
<document-id>
<country>US</country>
<doc-number>6534082</doc-number>
<kind>B1</kind>
<name>Epstein</name>
<date>20030300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00169">
<document-id>
<country>US</country>
<doc-number>6548535</doc-number>
<kind>B2</kind>
<name>Garcia et al.</name>
<date>20030400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00170">
<document-id>
<country>US</country>
<doc-number>6586463</doc-number>
<kind>B2</kind>
<name>deLong et al.</name>
<date>20030700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00171">
<document-id>
<country>US</country>
<doc-number>6716876</doc-number>
<kind>B2</kind>
<name>Burk</name>
<date>20040400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00172">
<document-id>
<country>US</country>
<doc-number>6894175</doc-number>
<kind>B1</kind>
<name>deLong et al.</name>
<date>20050500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00173">
<document-id>
<country>US</country>
<doc-number>7045634</doc-number>
<kind>B2</kind>
<name>Krauss et al.</name>
<date>20060500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00174">
<document-id>
<country>US</country>
<doc-number>7070768</doc-number>
<kind>B2</kind>
<name>Krauss</name>
<date>20060700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00175">
<document-id>
<country>US</country>
<doc-number>7074942</doc-number>
<kind>B2</kind>
<name>deLong</name>
<date>20060700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00176">
<document-id>
<country>US</country>
<doc-number>7115659</doc-number>
<kind>B2</kind>
<name>deLong</name>
<date>20061000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00177">
<document-id>
<country>US</country>
<doc-number>7157590</doc-number>
<kind>B2</kind>
<name>Gutman et al.</name>
<date>20070100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00178">
<document-id>
<country>US</country>
<doc-number>7288029</doc-number>
<kind>B1</kind>
<name>Lyon</name>
<date>20071000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00179">
<document-id>
<country>US</country>
<doc-number>7388029</doc-number>
<kind>B2</kind>
<name>deLong et al.</name>
<date>20080600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00180">
<document-id>
<country>US</country>
<doc-number>7407987</doc-number>
<kind>B2</kind>
<name>deLong et al.</name>
<date>20080800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00181">
<document-id>
<country>US</country>
<doc-number>7521530</doc-number>
<kind>B2</kind>
<name>Peri et al.</name>
<date>20090400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00182">
<document-id>
<country>US</country>
<doc-number>7589233</doc-number>
<kind>B2</kind>
<name>Chandran</name>
<date>20090900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00183">
<document-id>
<country>US</country>
<doc-number>2001/0047025</doc-number>
<kind>A1</kind>
<name>Garcia et al.</name>
<date>20011100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00184">
<document-id>
<country>US</country>
<doc-number>2002/0013294</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20020100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00185">
<document-id>
<country>US</country>
<doc-number>2002/0037914</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20020300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00186">
<document-id>
<country>US</country>
<doc-number>2002/0044953</doc-number>
<kind>A1</kind>
<name>Michelet et al.</name>
<date>20020400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00187">
<document-id>
<country>US</country>
<doc-number>2002/0045659</doc-number>
<kind>A1</kind>
<name>Michelet et al.</name>
<date>20020400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00188">
<document-id>
<country>US</country>
<doc-number>2002/0052414</doc-number>
<kind>A1</kind>
<name>Bernard et al.</name>
<date>20020500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00189">
<document-id>
<country>US</country>
<doc-number>2002/0146439</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20021000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00190">
<document-id>
<country>US</country>
<doc-number>2002/0172693</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20021100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00191">
<document-id>
<country>US</country>
<doc-number>2003/0083381</doc-number>
<kind>A1</kind>
<name>Kumagai et al.</name>
<date>20030500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00192">
<document-id>
<country>US</country>
<doc-number>2003/0147823</doc-number>
<kind>A1</kind>
<name>Woodward et al.</name>
<date>20030800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00193">
<document-id>
<country>US</country>
<doc-number>2003/0165549</doc-number>
<kind>A1</kind>
<name>Bernard et al.</name>
<date>20030900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00194">
<document-id>
<country>US</country>
<doc-number>2003/0191173</doc-number>
<kind>A1</kind>
<name>Garcia et al.</name>
<date>20031000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00195">
<document-id>
<country>US</country>
<doc-number>2003/0199590</doc-number>
<kind>A1</kind>
<name>Cagle</name>
<date>20031000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00196">
<document-id>
<country>US</country>
<doc-number>2004/0082013</doc-number>
<kind>A1</kind>
<name>Regan</name>
<date>20040400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00197">
<document-id>
<country>US</country>
<doc-number>2004/0157912</doc-number>
<kind>A1</kind>
<name>Old et al.</name>
<date>20040800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00198">
<document-id>
<country>US</country>
<doc-number>2004/0167190</doc-number>
<kind>A1</kind>
<name>Stjernschantz et al.</name>
<date>20040800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00199">
<document-id>
<country>US</country>
<doc-number>2004/0171596</doc-number>
<kind>A1</kind>
<name>Prokai et al.</name>
<date>20040900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00200">
<document-id>
<country>US</country>
<doc-number>2005/0058614</doc-number>
<kind>A1</kind>
<name>Krauss</name>
<date>20050300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00201">
<document-id>
<country>US</country>
<doc-number>2005/0112075</doc-number>
<kind>A1</kind>
<name>Hwang et al.</name>
<date>20050500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00202">
<document-id>
<country>US</country>
<doc-number>2006/0106078</doc-number>
<kind>A1</kind>
<name>Krauss et al.</name>
<date>20060500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00203">
<document-id>
<country>US</country>
<doc-number>2006/0121069</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20060600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00204">
<document-id>
<country>US</country>
<doc-number>2006/0135609</doc-number>
<kind>A1</kind>
<name>Toone et al.</name>
<date>20060600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00205">
<document-id>
<country>US</country>
<doc-number>2006/0247214</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20061100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00206">
<document-id>
<country>US</country>
<doc-number>2007/0004620</doc-number>
<kind>A1</kind>
<name>Jabbour et al.</name>
<date>20070100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00207">
<document-id>
<country>US</country>
<doc-number>2007/0161699</doc-number>
<kind>A1</kind>
<name>Epstein et al.</name>
<date>20070700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00208">
<document-id>
<country>US</country>
<doc-number>2007/0254920</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20071100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00209">
<document-id>
<country>US</country>
<doc-number>2007/0282006</doc-number>
<kind>A1</kind>
<name>Woodward et al.</name>
<date>20071200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00210">
<document-id>
<country>US</country>
<doc-number>2008/0070988</doc-number>
<kind>A1</kind>
<name>Woodward et al.</name>
<date>20080300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00211">
<document-id>
<country>US</country>
<doc-number>2008/0096240</doc-number>
<kind>A1</kind>
<name>Woodward et al.</name>
<date>20080400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00212">
<document-id>
<country>US</country>
<doc-number>2008/0103184</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20080500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00213">
<document-id>
<country>US</country>
<doc-number>2008/0241078</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20081000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00214">
<document-id>
<country>US</country>
<doc-number>2009/0018204</doc-number>
<kind>A1</kind>
<name>Brinkenhoff</name>
<date>20090100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00215">
<document-id>
<country>US</country>
<doc-number>2009/0203659</doc-number>
<kind>A1</kind>
<name>Woodward et al.</name>
<date>20090800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00216">
<document-id>
<country>US</country>
<doc-number>2009/0286769</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20091100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00217">
<document-id>
<country>US</country>
<doc-number>2010/0105771</doc-number>
<kind>A1</kind>
<name>deLong et al.</name>
<date>20100400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00218">
<document-id>
<country>BE</country>
<doc-number>746615</doc-number>
<date>19700700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00219">
<document-id>
<country>CA</country>
<doc-number>1339132</doc-number>
<date>19970700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00220">
<document-id>
<country>DE</country>
<doc-number>1801750</doc-number>
<date>19690700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00221">
<document-id>
<country>DE</country>
<doc-number>1617477</doc-number>
<date>19700100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00222">
<document-id>
<country>DE</country>
<doc-number>2255731</doc-number>
<date>19730500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00223">
<document-id>
<country>DE</country>
<doc-number>2355731</doc-number>
<date>19740500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00224">
<document-id>
<country>DE</country>
<doc-number>2409460</doc-number>
<date>19740800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00225">
<document-id>
<country>DE</country>
<doc-number>2460990</doc-number>
<date>19741200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00226">
<document-id>
<country>DE</country>
<doc-number>2365101</doc-number>
<date>19750700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00227">
<document-id>
<country>DE</country>
<doc-number>24 60 990</doc-number>
<date>19760700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00228">
<document-id>
<country>DE</country>
<doc-number>2605584</doc-number>
<date>19760800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00229">
<document-id>
<country>DE</country>
<doc-number>2605242</doc-number>
<date>19760900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00230">
<document-id>
<country>DE</country>
<doc-number>2517771</doc-number>
<date>19761000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00231">
<document-id>
<country>DE</country>
<doc-number>2737808</doc-number>
<date>19780300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00232">
<document-id>
<country>EP</country>
<doc-number>0170258</doc-number>
<date>19860200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00233">
<document-id>
<country>EP</country>
<doc-number>249194</doc-number>
<date>19860600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00234">
<document-id>
<country>EP</country>
<doc-number>0295092</doc-number>
<date>19881200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00235">
<document-id>
<country>EP</country>
<doc-number>0308135</doc-number>
<date>19890300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00236">
<document-id>
<country>EP</country>
<doc-number>572014</doc-number>
<date>19930100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00237">
<document-id>
<country>EP</country>
<doc-number>639563</doc-number>
<date>19950200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00238">
<document-id>
<country>EP</country>
<doc-number>648488</doc-number>
<date>19950400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00239">
<document-id>
<country>EP</country>
<doc-number>1008588</doc-number>
<date>19980200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00240">
<document-id>
<country>EP</country>
<doc-number>857718</doc-number>
<date>19980800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00241">
<document-id>
<country>EP</country>
<doc-number>1016660</doc-number>
<date>19980900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00242">
<document-id>
<country>EP</country>
<doc-number>911321</doc-number>
<date>19990400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00243">
<document-id>
<country>EP</country>
<doc-number>925787</doc-number>
<date>19990600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00244">
<document-id>
<country>EP</country>
<doc-number>970697</doc-number>
<date>19990900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00245">
<document-id>
<country>EP</country>
<doc-number>947500</doc-number>
<date>19991000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00246">
<document-id>
<country>FR</country>
<doc-number>2108027</doc-number>
<date>19710900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00247">
<document-id>
<country>FR</country>
<doc-number>2182928</doc-number>
<date>19731200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00248">
<document-id>
<country>FR</country>
<doc-number>2239458</doc-number>
<date>19750200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00249">
<document-id>
<country>FR</country>
<doc-number>2314712</doc-number>
<date>19770100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00250">
<document-id>
<country>FR</country>
<doc-number>2730811</doc-number>
<date>19950200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00251">
<document-id>
<country>GB</country>
<doc-number>1236227</doc-number>
<date>19710600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00252">
<document-id>
<country>GB</country>
<doc-number>1251750</doc-number>
<date>19711000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00253">
<document-id>
<country>GB</country>
<doc-number>1285371</doc-number>
<date>19720800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00254">
<document-id>
<country>GB</country>
<doc-number>1285372</doc-number>
<date>19720800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00255">
<document-id>
<country>GB</country>
<doc-number>1456512</doc-number>
<date>19761100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00256">
<document-id>
<country>GB</country>
<doc-number>1456513</doc-number>
<date>19761100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00257">
<document-id>
<country>GB</country>
<doc-number>1456514</doc-number>
<date>19761100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00258">
<document-id>
<country>GB</country>
<doc-number>1456838</doc-number>
<date>19761100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00259">
<document-id>
<country>GB</country>
<doc-number>1542569</doc-number>
<date>19790300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00260">
<document-id>
<country>GB</country>
<doc-number>1545411</doc-number>
<date>19790500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00261">
<document-id>
<country>GB</country>
<doc-number>2025413</doc-number>
<date>19800100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00262">
<document-id>
<country>GB</country>
<doc-number>2048254</doc-number>
<date>19801200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00263">
<document-id>
<country>GB</country>
<doc-number>2330307</doc-number>
<date>19990400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00264">
<document-id>
<country>JP</country>
<doc-number>49-069636</doc-number>
<date>19740700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00265">
<document-id>
<country>JP</country>
<doc-number>49-093342</doc-number>
<date>19740900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00266">
<document-id>
<country>JP</country>
<doc-number>49-101356</doc-number>
<date>19740900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00267">
<document-id>
<country>JP</country>
<doc-number>49-102647</doc-number>
<date>19740900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00268">
<document-id>
<country>JP</country>
<doc-number>51-086449</doc-number>
<date>19760700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00269">
<document-id>
<country>JP</country>
<doc-number>52-053841</doc-number>
<date>19770400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00270">
<document-id>
<country>JP</country>
<doc-number>53-028160</doc-number>
<date>19780300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00271">
<document-id>
<country>JP</country>
<doc-number>58-029710</doc-number>
<date>19830200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00272">
<document-id>
<country>JP</country>
<doc-number>61-218510</doc-number>
<date>19860900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00273">
<document-id>
<country>JP</country>
<doc-number>02 022226</doc-number>
<date>19900100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00274">
<document-id>
<country>JP</country>
<doc-number>03034934</doc-number>
<date>19910200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00275">
<document-id>
<country>JP</country>
<doc-number>3-83925</doc-number>
<date>19910400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00276">
<document-id>
<country>JP</country>
<doc-number>3-83926</doc-number>
<date>19910400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00277">
<document-id>
<country>JP</country>
<doc-number>4-300833</doc-number>
<date>19921000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00278">
<document-id>
<country>JP</country>
<doc-number>5-331025</doc-number>
<date>19931200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00279">
<document-id>
<country>JP</country>
<doc-number>9-295921</doc-number>
<date>19971100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00280">
<document-id>
<country>JP</country>
<doc-number>10-251225</doc-number>
<date>19980900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00281">
<document-id>
<country>JP</country>
<doc-number>10-287532</doc-number>
<date>19981000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00282">
<document-id>
<country>JP</country>
<doc-number>2003180399</doc-number>
<date>20030700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00283">
<document-id>
<country>WO</country>
<doc-number>WO 86/00616</doc-number>
<date>19860100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00284">
<document-id>
<country>WO</country>
<doc-number>WO 89/03384</doc-number>
<date>19890400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00285">
<document-id>
<country>WO</country>
<doc-number>WO 90/02553</doc-number>
<date>19900300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00286">
<document-id>
<country>WO</country>
<doc-number>WO 92/02495</doc-number>
<date>19920200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00287">
<document-id>
<country>WO</country>
<doc-number>WO 94/08585</doc-number>
<date>19940400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00288">
<document-id>
<country>WO</country>
<doc-number>WO 95/00552</doc-number>
<date>19950100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00289">
<document-id>
<country>WO</country>
<doc-number>WO 95/11003</doc-number>
<date>19950400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00290">
<document-id>
<country>WO</country>
<doc-number>WO 95/11033</doc-number>
<date>19950400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00291">
<document-id>
<country>WO</country>
<doc-number>WO 95/18102</doc-number>
<date>19950700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00292">
<document-id>
<country>WO</country>
<doc-number>WO 95/19165</doc-number>
<date>19950700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00293">
<document-id>
<country>WO</country>
<doc-number>WO 95/19964</doc-number>
<date>19950700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00294">
<document-id>
<country>WO</country>
<doc-number>WO 96/10407</doc-number>
<date>19960400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00295">
<document-id>
<country>WO</country>
<doc-number>WO 96/36599</doc-number>
<date>19961100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00296">
<document-id>
<country>WO</country>
<doc-number>WO 97/03973</doc-number>
<date>19970200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00297">
<document-id>
<country>WO</country>
<doc-number>WO 97/09049</doc-number>
<date>19970300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00298">
<document-id>
<country>WO</country>
<doc-number>WO 97/15319</doc-number>
<date>19970500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00299">
<document-id>
<country>WO</country>
<doc-number>WO 97/23223</doc-number>
<date>19970700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00300">
<document-id>
<country>WO</country>
<doc-number>WO 97/23225</doc-number>
<date>19970700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00301">
<document-id>
<country>WO</country>
<doc-number>WO 97/23226</doc-number>
<date>19970700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00302">
<document-id>
<country>WO</country>
<doc-number>WO 97/29735</doc-number>
<date>19970800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00303">
<document-id>
<country>WO</country>
<doc-number>WO 97/31895</doc-number>
<date>19970900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00304">
<document-id>
<country>WO</country>
<doc-number>WO 97/39754</doc-number>
<date>19971000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00305">
<document-id>
<country>WO</country>
<doc-number>WO 98/00100</doc-number>
<date>19980100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00306">
<document-id>
<country>WO</country>
<doc-number>WO 98/12175</doc-number>
<date>19980300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00307">
<document-id>
<country>WO</country>
<doc-number>WO 98/13016</doc-number>
<date>19980400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00308">
<document-id>
<country>WO</country>
<doc-number>WO 98/19680</doc-number>
<date>19980500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00309">
<document-id>
<country>WO</country>
<doc-number>WO 98/20880</doc-number>
<date>19980500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00310">
<document-id>
<country>WO</country>
<doc-number>WO 98/20881</doc-number>
<date>19980500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00311">
<document-id>
<country>WO</country>
<doc-number>WO 98/21180</doc-number>
<date>19980500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00312">
<document-id>
<country>WO</country>
<doc-number>WO 98/21181</doc-number>
<date>19980500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00313">
<document-id>
<country>WO</country>
<doc-number>WO 98/21182</doc-number>
<date>19980500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00314">
<document-id>
<country>WO</country>
<doc-number>WO 98/27976</doc-number>
<date>19980700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00315">
<document-id>
<country>WO</country>
<doc-number>WO 98/28264</doc-number>
<date>19980700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00316">
<document-id>
<country>WO</country>
<doc-number>WO 98/33497</doc-number>
<date>19980800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00317">
<document-id>
<country>WO</country>
<doc-number>WO 98/39293</doc-number>
<date>19980900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00318">
<document-id>
<country>WO</country>
<doc-number>98/47515</doc-number>
<date>19981000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00319">
<document-id>
<country>WO</country>
<doc-number>WO 98/50024</doc-number>
<date>19981100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00320">
<document-id>
<country>WO</country>
<doc-number>WO 98/53809</doc-number>
<date>19981200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00321">
<document-id>
<country>WO</country>
<doc-number>WO 98/57930</doc-number>
<date>19981200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00322">
<document-id>
<country>WO</country>
<doc-number>WO 98/57942</doc-number>
<date>19981200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00323">
<document-id>
<country>WO</country>
<doc-number>WO 98/58911</doc-number>
<date>19981200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00324">
<document-id>
<country>WO</country>
<doc-number>WO 99/02165</doc-number>
<date>19990100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00325">
<document-id>
<country>WO</country>
<doc-number>WO 99/12550</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00326">
<document-id>
<country>WO</country>
<doc-number>WO 99/12551</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00327">
<document-id>
<country>WO</country>
<doc-number>WO 99/12552</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00328">
<document-id>
<country>WO</country>
<doc-number>WO 99/12553</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00329">
<document-id>
<country>WO</country>
<doc-number>WO 99/12554</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00330">
<document-id>
<country>WO</country>
<doc-number>WO 99/12555</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00331">
<document-id>
<country>WO</country>
<doc-number>WO 99/12556</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00332">
<document-id>
<country>WO</country>
<doc-number>WO 99/12557</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00333">
<document-id>
<country>WO</country>
<doc-number>WO 99/12558</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00334">
<document-id>
<country>WO</country>
<doc-number>WO 99/12559</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00335">
<document-id>
<country>WO</country>
<doc-number>WO 99/12560</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00336">
<document-id>
<country>WO</country>
<doc-number>WO 99/12561</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00337">
<document-id>
<country>WO</country>
<doc-number>WO 99/12563</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00338">
<document-id>
<country>WO</country>
<doc-number>WO 99/12895</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00339">
<document-id>
<country>WO</country>
<doc-number>WO 99/12896</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00340">
<document-id>
<country>WO</country>
<doc-number>WO 99/12897</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00341">
<document-id>
<country>WO</country>
<doc-number>WO 99/12898</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00342">
<document-id>
<country>WO</country>
<doc-number>WO 99/12899</doc-number>
<date>19990300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00343">
<document-id>
<country>WO</country>
<doc-number>WO 99/19300</doc-number>
<date>19990400</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00344">
<document-id>
<country>WO</country>
<doc-number>WO 99/21562</doc-number>
<date>19990500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00345">
<document-id>
<country>WO</country>
<doc-number>WO 99/22731</doc-number>
<date>19990500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00346">
<document-id>
<country>WO</country>
<doc-number>WO 99/25357</doc-number>
<date>19990500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00347">
<document-id>
<country>WO</country>
<doc-number>WO 99/25358</doc-number>
<date>19990500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00348">
<document-id>
<country>WO</country>
<doc-number>WO 99/30675</doc-number>
<date>19990600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00349">
<document-id>
<country>WO</country>
<doc-number>WO 99/30718</doc-number>
<date>19990600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00350">
<document-id>
<country>WO</country>
<doc-number>WO 99/32441</doc-number>
<date>19990700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00351">
<document-id>
<country>WO</country>
<doc-number>WO 99/32640</doc-number>
<date>19990700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00352">
<document-id>
<country>WO</country>
<doc-number>WO 99/32641</doc-number>
<date>19990700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00353">
<document-id>
<country>WO</country>
<doc-number>WO 99/33794</doc-number>
<date>19990700</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00354">
<document-id>
<country>WO</country>
<doc-number>WO 99/47497</doc-number>
<date>19990900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00355">
<document-id>
<country>WO</country>
<doc-number>WO 99/50241</doc-number>
<date>19991000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00356">
<document-id>
<country>WO</country>
<doc-number>WO 99/50242</doc-number>
<date>19991000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00357">
<document-id>
<country>WO</country>
<doc-number>WO 99/61029</doc-number>
<date>19991200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00358">
<document-id>
<country>WO</country>
<doc-number>WO 99/64621</doc-number>
<date>19991200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00359">
<document-id>
<country>WO</country>
<doc-number>WO 99/65303</doc-number>
<date>19991200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00360">
<document-id>
<country>WO</country>
<doc-number>WO 99/65527</doc-number>
<date>19991200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00361">
<document-id>
<country>WO</country>
<doc-number>WO 00/02450</doc-number>
<date>20000100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00362">
<document-id>
<country>WO</country>
<doc-number>WO 00/03736</doc-number>
<date>20000100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00363">
<document-id>
<country>WO</country>
<doc-number>WO 00/03980</doc-number>
<date>20000100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00364">
<document-id>
<country>WO</country>
<doc-number>WO 00/04898</doc-number>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00365">
<document-id>
<country>WO</country>
<doc-number>WO 00/04899</doc-number>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00366">
<document-id>
<country>WO</country>
<doc-number>WO 00/07627</doc-number>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00367">
<document-id>
<country>WO</country>
<doc-number>WO 00/09557</doc-number>
<date>20000200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00368">
<document-id>
<country>WO</country>
<doc-number>WO 00/13664</doc-number>
<date>20000300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00369">
<document-id>
<country>WO</country>
<doc-number>WO 00/15608</doc-number>
<date>20000300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00370">
<document-id>
<country>WO</country>
<doc-number>WO 00/16760</doc-number>
<date>20000300</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00371">
<document-id>
<country>WO</country>
<doc-number>WO 00/51971</doc-number>
<date>20000900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00372">
<document-id>
<country>WO</country>
<doc-number>WO 00/51979</doc-number>
<date>20000900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00373">
<document-id>
<country>WO</country>
<doc-number>WO 00/51980</doc-number>
<date>20000900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00374">
<document-id>
<country>WO</country>
<doc-number>WO 00/54810</doc-number>
<date>20000900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00375">
<document-id>
<country>WO</country>
<doc-number>WO 01/10873</doc-number>
<date>20010200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00376">
<document-id>
<country>WO</country>
<doc-number>WO 01/74307</doc-number>
<date>20011000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00377">
<document-id>
<country>WO</country>
<doc-number>WO 01/74313</doc-number>
<date>20011000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00378">
<document-id>
<country>WO</country>
<doc-number>WO 01/74314</doc-number>
<date>20011000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00379">
<document-id>
<country>WO</country>
<doc-number>WO 01/74315</doc-number>
<date>20011000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00380">
<document-id>
<country>WO</country>
<doc-number>02/067901</doc-number>
<date>20020900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00381">
<document-id>
<country>WO</country>
<doc-number>02/096868</doc-number>
<date>20021200</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00382">
<document-id>
<country>WO</country>
<doc-number>03/051822</doc-number>
<date>20030600</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00383">
<document-id>
<country>WO</country>
<doc-number>WO 03/066008</doc-number>
<date>20030800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00384">
<document-id>
<country>WO</country>
<doc-number>03/077910</doc-number>
<date>20030900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00385">
<document-id>
<country>WO</country>
<doc-number>WO 2006/047466</doc-number>
<date>20060500</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00386">
<document-id>
<country>WO</country>
<doc-number>2006/106311</doc-number>
<date>20061000</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00387">
<document-id>
<country>WO</country>
<doc-number>WO 2007/123818</doc-number>
<kind>A2</kind>
<date>20071100</date>
</document-id>
</patcit>
<category>cited by examiner</category>
</us-citation>
<us-citation>
<patcit num="00388">
<document-id>
<country>WO</country>
<doc-number>WO 2007/127639</doc-number>
<date>20071100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00389">
<document-id>
<country>WO</country>
<doc-number>WO 2009/011744</doc-number>
<date>20090100</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00390">
<document-id>
<country>WO</country>
<doc-number>2010/096123</doc-number>
<date>20100800</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<patcit num="00391">
<document-id>
<country>WO</country>
<doc-number>2010/108012</doc-number>
<date>20100900</date>
</document-id>
</patcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00392">
<othercit>Final Office Action in U.S. Appl. No. 12/260,522 mailed May 25, 2011.</othercit>
</nplcit>
<category>cited by examiner</category>
</us-citation>
<us-citation>
<nplcit num="00393">
<othercit>&#x201c;Phase III lumigan&#x2014;AGN 192024&#x2014;data presented at American Academy of Ophthalmology,&#x201d; Business Wire (Oct. 23, 2000) 3 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00394">
<othercit>Badawy, S.I. et al., &#x201c;Salt selection for pharmaceutical compounds,&#x201d; Adeyeye, J. editor, Preformulation in Solid Dosage Form Development, Informa Healthcare (2008) Chapter 2.3, 63-80.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00395">
<othercit>Bastin, R.J. et al., &#x201c;Salt selection and optimisation procedures for pharmaceutical new chemical entities,&#x201d; Organic Process R&#x26;D (2000) 4(5):427-435.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00396">
<othercit>Berge, S.M. et al., &#x201c;Pharmaceutical salts,&#x201d; J. Pharm. Sci. (1997) 66(1):1-19.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00397">
<othercit>Brubaker, R.F. et al., &#x201c;Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics,&#x201d; Am. J. Opthal. (2001) 131(1):19-24.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00398">
<othercit>Mansberger, S.L. et al., &#x201c;Eyelash formation secondary to latanoprost treatment in a patient with alopecia,&#x201d; Arch. Ophthalmol. (2000) 118:718-719.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00399">
<othercit>Neau, S.H., &#x201c;Pharmaceutical salts,&#x201d; Water-Insoluble Drug Formulation, Rong Liu editor, CRC Press (2008) 15:417-435.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00400">
<othercit>Stahl, P.H. et al., editors, Handbook of Pharmaceutical Salts, Properties, Selection and Use, Wiley-Vch (2008) Chapter 12, 265-327.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00401">
<othercit>Swarbrick, J. et al., editors, Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. (1988) 13:453-499.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00402">
<othercit>Invitation to Pay Additional Fees and Partial International Search for Application No. PCT/US2009/062590 dated Aug. 19, 2010 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00403">
<othercit>International Search Report and Written Opinion for Application No. PCT/US2009/062590 dated Nov. 16, 2010 (16 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00404">
<othercit>Invitation to Pay Additional Fees and Partial International Search for Application No. PCT/US2010/43701 dated Sep. 28, 2010 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00405">
<othercit>International Search Report and Written Opinion for Application No. PCT/US2010/43701 dated Dec. 7, 2010 (10 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00406">
<othercit>International Search Report and Written Opinion for Application No. PCT/US2010/27831 dated Apr. 26, 2010 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00407">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/479,532 dated Oct. 28, 2010 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00408">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/260,522 dated Dec. 10, 2010 (22 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00409">
<othercit>United States Patent Office Action for U.S. Appl. No. 11/476,246 dated Sep. 14, 2010 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00410">
<othercit>Wand, M., &#x201c;Latanoprost and hyperpigmentation of eyelashes,&#x201d; Archives of Ophthalmology (1997) 115(9):1206-1208.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00411">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/138,733 dated Nov. 24, 2009 (10 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00412">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/479,532 dated Oct. 6, 2009 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00413">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/535,513 dated Dec. 18, 2009 (10 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00414">
<othercit>United States Patent Office Action for U.S. Appl. No. 11/174,420 dated Feb. 3, 2010 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00415">
<othercit>United States Patent Office Notice of Allowance for U.S. Appl. No. 11/174,420 dated Jan. 12, 2011 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00416">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/138,733 dated Feb. 23, 2011 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00417">
<othercit>U.S. Appl. No. 90/009,430, filed Mar. 15, 2009, Woodward.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00418">
<othercit>U.S. Appl. No. 90/009,431, filed Mar. 10, 2009, Johnstone.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00419">
<othercit>&#x201c;Agents for Glaucoma,&#x201d; Journal of the American Pharmaceutical Association, New Drugs of 2001, http://www.edscape.com/viewarticle/436631<sub>&#x2014;</sub>22 (2007) 4 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00420">
<othercit>&#x201c;Bimatoprost (ophthalmic)&#x201d; Medlineplus, Health information online (Jul. 24, 2001) 4 pages, www.nlm.nih.gov/medlineplus/druginfor/uspdi/500295.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00421">
<othercit>Letter from Bernice Tao at Apotex, Inc. to the General Counsels at Allergan, Inc. and Duke University regarding &#x201c;Apotex Bimatoprost Topical Solution 0.03% Paragraph IV Certification&#x2014;U.S. Patent Nos. 7,351,404 and 7,388,029&#x201d; (Jul. 26, 2010) 49 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00422">
<othercit>Allergan Press Release, &#x201c;Phase III Lumigan? (AGN 192024) data presented at American Academy of Ophthalmology,&#x201d; Mar. 1, 2000, 5 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00423">
<othercit>Alm, A. et al., &#x201c;Phase III latanoprost studies in Scandanavia, the United Kingdom and the United States,&#x201d; Surv. Ophthalmol. (1997) 41(Suppl 2):S105-S110.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00424">
<othercit>Alm, A. et al., &#x201c;Uveoscleral outflow&#x2014;a review,&#x201d; Exp. Eye Res. (2009) 88(4):760-768, Epub Jan. 3, 2009.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00425">
<othercit>Bean, G.W., &#x201c;Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences,&#x201d; Survey of Ophthalmology (2008) 53(1):S69-84.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00426">
<othercit>Berglund, B.A. et al., &#x201c;Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils,&#x201d; Adv. Exp. Med. Biol. (1999) 469:527-533.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00427">
<othercit>Bito, L., &#x201c;A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond,&#x201d; The Proctor Lecture (2001) 42(6):1126-1133.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00428">
<othercit>Bito, L.Z. et al., &#x201c;Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of psotaglandins to cat or rhesus monkey eyes,&#x201d; Invest. Ophthalmol. Vis. Sci. (1983) 24(3):312-319.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00429">
<othercit>Brandt, J.D. et al., &#x201c;Comparison of once-or twice-daily bimatoprost with twice-daily timolol in pateints with elevated IPO. A three month clinical tril,&#x201d; Ophthalmology (2001) 108(6):1023-1031.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00430">
<othercit>Cadet, P. et al., &#x201c;Molecular identification and functional expression of mu3, a novel alternatively apliced variant of the human mu opiate receptor gene,&#x201d; J. Immunol. (2003) 170(10):5118-5123.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00431">
<othercit>Camras, C.B. et al., &#x201c;Latanoprost, a prostaglandin analog, for glaucoma therapy,&#x201d; Ophthalmology (1996) 103(11):1916-1924.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00432">
<othercit>Camras, C.B. et al., &#x201c;Multiple dosing of prostaglandin F2alpha or epinephrine on cynomolgus monkey eyes,&#x201d; Invest. Ophthalmol. Vis. Sci. (1987) 28(3):463-469.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00433">
<othercit>Camras, C.B. et al., &#x201c;Multiple dosing of prostaglandin F2alpha or epinephrine on cynomolgus monkey eyes,&#x201d; Invest. Ophthalmol. Vis. Sci. (1988) 29(9):1428-1436.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00434">
<othercit>Camras, C.B. et al., &#x201c;Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2alpha,&#x201d; Curr. Eye Res. (1981) 1(4):205-209.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00435">
<othercit>Camras, C.B. et al., &#x201c;Multiple dosing of prostaglandin F2alpha or epinephrine on cynomolgus monkey eyes,&#x201d; Invest. Ophthalmol. Vis. Sci. (1987) 28(6):921-926.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00436">
<othercit>Camras, C.B. et al. &#x201c;Bimatoprost, the prodrug of a prostaglandin analogue,&#x201d; Br. J. Ophthalmol. (2008) 92:862-863.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00437">
<othercit>Camras, C.B., &#x201c;Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma,&#x201d; Ophthalmology (1996) 103(1):138-147.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00438">
<othercit>Camras, C.B., &#x201c;Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery,&#x201d; American Academy of Ophthalmology (2004) 2193-2198.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00439">
<othercit>Cantor, L.B. et al., &#x201c;Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract,&#x201d; Br. J. Ophthalmol. (2007) 91:629-632.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00440">
<othercit>Cantor, L.B., &#x201c;Reply&#x2014;bimatoprost, the prodrug of a prostaglandin analogue,&#x201d; Br. J. Ophthalmol. (2008) 92:863-864.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00441">
<othercit>CAS RN 155206-00-1 (May 20, 1994).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00442">
<othercit>Center for Drug Evaluation and Research, &#x201c;Medical Officer's Review of NDA, Application No. 21-275,&#x201d; Mar. 14, 2001; 120-day safety update Jan. 23, 2001; Mar. 2, 2001; Sep. 18, 2000, 63 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00443">
<othercit>Crowston, J.G. et al., &#x201c;Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice,&#x201d; Invest. Ophthal. Vis. Sci. (2005) 46:4571-4577.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00444">
<othercit>Darnell, J. et al., &#x201c;Cell-to-cell signaling: hormones and receptors,&#x201d; Mol. Cell. Biol. (1990) 738-743.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00445">
<othercit>Davies, S.S., &#x201c;Hydrolysis of bimatoprost (lumigan) to its free acid by ocular tissue in vitro,&#x201d; J. Ocular Pharm. Thera. (2003) 19(1):45-54.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00446">
<othercit>DuBiner, H. et al., &#x201c;Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost,&#x201d; Survey of Ophthal. (2001) 45(S4):S353-S360.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00447">
<othercit>Fagot, D. et al., &#x201c;Mitogenic signaling by prostaglandins in chemically transformed mouse fibroblasts: comparison with phorbol esters and insulin,&#x201d; Endocrinology (1993) 132(4):1729-1734.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00448">
<othercit>Faulkner, R., &#x201c;Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN&#xae; or TRAVATAN&#xae;,&#x201d; J. Ocular Pharm. Thera. (2010) 26(2):147-156.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00449">
<othercit>FDA Label for Approved NDA 22-184&#x2014;Lumigan 0.01% and Lumigan 0.03% (Aug. 31, 2010) 5 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00450">
<othercit>FDA Press Release, &#x201c;FDA News&#x201d; of Mar. 16, 2001 entitled &#x201c;FDA approves two new intraocular pressure lowering drugs for the management of glaucoma,&#x201d; 2 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00451">
<othercit>Fiscella, R.G., &#x201c;Peek into the drug pipeline,&#x201d; Review of Optometery Online, Jan. 15, 2001, pp. 1-5.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00452">
<othercit>Frenkel, R.E. et al., &#x201c;Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%,&#x201d; Curr. Med. Res. Opin. (2008) 24(4):919-923, epub Feb. 8, 2008.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00453">
<othercit>Gandolfini, S. et al., &#x201c;Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension,&#x201d; Adv. In Therapy (2001) 18(3):110-121.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00454">
<othercit>Gerth, J. et al., &#x201c;Drug makers reap profits on tax-backed research,&#x201d; New York Times, Apr. 23, 2000, 10 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00455">
<othercit>Giuffre, G., &#x201c;The effects of prostaglandin F2alpha in the human eye,&#x201d; Graefe's Arch. Clin. Exp. Ophthalmol. (1985) 222:139-141.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00456">
<othercit>Hellberg, M.R. et al., &#x201c;The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyltrinor PGF2a by human and rabbit ocular tissue,&#x201d; J. Ocular Pharmacol. Ther. (2003) 19:97-103.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00457">
<othercit>Jimenez De Asua, L. et al., &#x201c;The stimulation of the initiation of DNA synthesis and cell division in Swiss mouse 3T3 cells by prostaglandin F2alpha requires specific functional groups in the molecule,&#x201d; J. Biol. Chem. (1983) 256(14):8774-8780.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00458">
<othercit>Jordan, B.A. et al., &#x201c;G-protein coupled receptor heterodimerization modulates receptor function,&#x201d; Nature (1999) 399(6737):697-700.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00459">
<othercit>Kaufman, P.L., &#x201c;Effects of intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle,&#x201d; Exp. Eye Res. (1986) 43:819-827.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00460">
<othercit>Lee, P.-Y. et al., &#x201c;The effect of prostaglandin F2alpha on intraocular pressure in mormotensive human subjects,&#x201d; Invest. Ophthalmol. Vis. Sci. (1988) 29(10):1474-1477.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00461">
<othercit>Liang, Y. et all., &#x201c;Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor varian complexes,&#x201d; Br. J. Pharmacol. (2008) 154:1079-1093.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00462">
<othercit>Lumigan 6-month phase 3 data presented at American Glaucoma Society Meeting, Mar. 2, 2001, Business Wire, 3 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00463">
<othercit>Maxey, K.M., &#x201c;The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist,&#x201d; Survey of Ophthalmology (2002) 47(1):S34-40.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00464">
<othercit>Mishima, H.K. et al., &#x201c;A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension,&#x201d; Arch. Ophthalmol. (1996) 114:929-932.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00465">
<othercit>Ortonne, J-P. et al., &#x201c;Hair melanin's and hair color: ultrastructural and biochemical aspects,&#x201d; J. Soc. Inv. Derm. (1993) 82S-89S.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00466">
<othercit>Pfeiffer, N., &#x201c;New developments in glaucoma drug therapy,&#x201d; Ophthalmologist (1992) 89:W1-W13.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00467">
<othercit>Poyer, J.F. et al., &#x201c;Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle,&#x201d; Invest. Ophthalmol. Vis. Sci. (1995) 36(12):2461-2465.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00468">
<othercit>Response from the Food and Drug Administration to Pfizer's Citizen Petition and a Supplement (Aug. 31, 2010) at 23 (Exhibit 5), 26 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00469">
<othercit>Resul, B. et al., &#x201c;Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents,&#x201d; J. Med. Chem. (1993) 36(2):243-248.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00470">
<othercit>Romano, M.R., &#x201c;Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle,&#x201d; Invest. Opthal. Vis. Sci. (2007) 48(8):3677-3682.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00471">
<othercit>Sharif, N.A. et al., &#x201c;Bimatoprost and its free acid are prostaglandin FP receptor agonists,&#x201d; Eur. J. Pharmacol. (2001) 432(2-3):211-213.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00472">
<othercit>Sharif, N.A. et al., &#x201c;Cat iris sphincter smooth-muscle contraction: comparison of FP-class prostaglandin analog agonist activities,&#x201d; J. Ocul. Pharmacol. Ther. (2008) 24(2):152-163.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00473">
<othercit>Sharif, N.A. et al., &#x201c;Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation,&#x201d; J. Ocul. Pharmacol. Ther. (2003) 19:437-455.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00474">
<othercit>Sharif, N.A. et al., &#x201c;Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues,&#x201d; Invest. Ophthalmol. Vis. Sci. (2003) 44:715-721.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00475">
<othercit>Sharif, N.A., &#x201c;Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells,&#x201d; J. Ocular Pharm. Thera. (2003) 19(6):501-515.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00476">
<othercit>Sharif, N.A., &#x201c;Update and commentary on the pro-drug bimatoprost and a putative &#x2018;prostamide receptor&#x2019;,&#x201d; Expert Rev. Ophthalmol. (2009) 4(5):477-489.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00477">
<othercit>Sherwood, M. et al., &#x201c;Six-month comparison of bimatoprost once-daily and twice-daily with timomol twice-daily in patients with elevated intraocular pressure,&#x201d; Surv. Ophthal. (2001) 45(4):S361-S368.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00478">
<othercit>Sjoquist, B. et al., &#x201c;Ocular and systemic pharmacokinetics of latanoprost in humans,&#x201d; Surv. Ophthalmol. (2002) 47(Supp 1):S6-12.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00479">
<othercit>Sjoquist, B. et al., &#x201c;Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography, Glacoma research laboratories,&#x201d; Arzneimittelforschung (1999) 49:240-249.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00480">
<othercit>Spada, C.S. et al., &#x201c;Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells,&#x201d; Exp. Eye Res. (2005) 80(1):135-145.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00481">
<othercit>Stamer, W.D. et al., &#x201c;Cellular basis for bimatoprost effects on human conventional outflow,&#x201d; Invest. Ophthalmol. Vis. Sci. (2010) 51(10):5176-5181, Epub Apr. 30, 2010.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00482">
<othercit>Stjernschantz, J. et al., &#x201c;Phenyl substituted prostaglandin analogs for glaucoma treatment,&#x201d; Drugs of the Future (1992) 17(8):691-704.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00483">
<othercit>Stjernschantz, J., &#x201c;Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment,&#x201d; Exp. Eye Res. (2004) 78(4):759-766.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00484">
<othercit>Stjernschantz, J.W., &#x201c;From PGF2alpha-isopropyl ester to latanoprost: a review of the development of Xalatan: the Proctor lecture,&#x201d; Invest. Ophthalmol. Vis. Sci. (2001) 42(6):1134-1145.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00485">
<othercit>The Newsletter of the Glaucoma Foundation, Fall 2000, vol. 11, No. 2, 11 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00486">
<othercit>Van Alphen, G.W.H.M. et al., &#x201c;The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man,&#x201d; Documenta Ophthalmologica (1977) 42(2):397-415.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00487">
<othercit>Vielhauer, G.A. et al., &#x201c;Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor,&#x201d; Arch. Biochem. Biophys. (2004) 421(2):175-185.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00488">
<othercit>Villumsen, J. et al., &#x201c;Prostaglandin F2alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma,&#x201d; Br. J. Ophthalmol. (1989) 73:975-979.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00489">
<othercit>White, J.H. et al., &#x201c;Heterodimerization is required for the formation of a functional GABA(B) receptor,&#x201d; Nature (1998) 396(6712):679-682.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00490">
<othercit>Wilson, S.J. et al., &#x201c;Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation,&#x201d; J. Biol. Chem. (2004) 279(51):53036-53047.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00491">
<othercit>Woodward, D., &#x201c;Replacement of carboxylic acid group of prostaglandin F2a with a hydroxyl or methoxy substituent provides biologically unique compounds,&#x201d; Br. J. Pharma. (2000) 130(8):1933-1943.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00492">
<othercit>Woodward, D.F. et al., &#x201c;Bimatoprost effects on aqueous humor dynamics in monkeys,&#x201d; J. Ophthalmol. (2010) Article ID 926192, 5 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00493">
<othercit>Woodward, D.F. et al., &#x201c;Bimatoprost: a novel antiglaucoma agent,&#x201d; Cardiovasc. Drug Rev. (2004) 22(2):103-120.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00494">
<othercit>Woodward, D.F. et al., &#x201c;Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris,&#x201d; Br. J. Pharmacol. (2007) 150:342-352.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00495">
<othercit>Woodward, D.F. et al., &#x201c;Pharmacological characterization of a novel anti-glaucoma agent,&#x201d; J. Pharmacol. Exp. Ther. (2003) 305:772-785.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00496">
<othercit>Woodward, D.F. et al., &#x201c;The pharmacology of bimatoprost (Lumigan),&#x201d; Surv. Ophthalmol. (2001) 45(Suppl 4):S337-45.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00497">
<othercit>Yamaji, K. et al., &#x201c;Prostaglandins E1 and E2, but not F2alpha or latanoprost, inhibit monkey ciliary muscle contraction,&#x201d; Curr. Eye Res. (2005) 30(8):661-665.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00498">
<othercit>Zeigler, T., &#x201c;Old drug, new use: new research shows common cholesterol-lowering drug reduces multiple sclerosis symptoms in mice,&#x201d; Natl. Institute of Neurological Disorders and Stroke (2003) 2 pages.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00499">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/535,513 dated Mar. 3, 2011 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00500">
<othercit>Abramovitz, M. et al., &#x201c;Cloning and expression of a cDNA for the human prostanoid FP receptor,&#x201d; J. Biol. Chem. (1994) 269:2632-2636.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00501">
<othercit>Abramovitz, M. et al., &#x201c;The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs,&#x201d; Biochimica et Biophysica Acta (2000) 1483(2):285-293.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00502">
<othercit>Adis, Adisinsight: ZD-6416, AstraZeneca (United Kingdom) Mar. 27, 2000, 1 page.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00503">
<othercit>AGN-192024, Pharmaprojects, HB4 S1G (2006).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00504">
<othercit>Alm, A., &#x201c;The potential of prostaglandin derivates in glaucoma therapy; prostaglandins and derivates,&#x201d; Curr. Opin. Opthalmol. (1993) 4(11):44-50.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00505">
<othercit>Alm et al., &#x201c;Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning,&#x201d; Ophthalmology (1995) 102(12):1743-1752.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00506">
<othercit>Al-Sereiti, M.R., et al., &#x201c;Pharmacology of Rosemary (Rosmarinus Officinalis Linn.) and Its Therapeutic Potentials,&#x201d; Indian Journal of Experimental Biology, vol. 37, Feb. 1999, pp. 124-130.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00507">
<othercit>Anonymous, &#x201c;Alprostadil (nexmed):Alprox-TD, Befar, Femprox, Prostaglandin E1 (nexmed),&#x201d; Drugs R&#x26;D (1999) 2(6):413-414.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00508">
<othercit>Audoly, L.P. et al., &#x201c;Identification of specific EP receptors responsible for the hemodynamic effects of PGE2,&#x201d; Am. J. Physiol. (1999) 46(3):H924-930.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00509">
<othercit>Bartman, W., et al., &#x201c;Leutolytic Prostaglandins Synthesis and Biological Activity&#x201d;, Prostaglandins, vol. 17, No. 2, pp. 301-311, 1979.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00510">
<othercit>Bundy, G. L., and Lincoln, F. H., &#x201c;Synthesis of 17-Phenyl-18, 19, 20-Trinoprostaglandins 1. The PG, Series,&#x201d; Prostaglandins, vol. 9, No. 1, (Jan. 1975), pp. 1-4.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00511">
<othercit>Cayatte, A.J. et al., &#x201c;The thromboxane A2 receptor antagonist S18886 decreases atheroschlerotic lesions and serum intracellular adhesion molecule-1 in the Apo E knockout mouse,&#x201d; Circulation (1998) 96:115.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00512">
<othercit>Chen, J. et al., &#x201c;AGN 191129: a neutral prostaglandin F-2 alpha (PGF2a) analog that lacks the mitogenic and uterotonic effects typical of FP receptor agonists,&#x201d; IOVS (1999) 40:3562-B420, p. S675.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00513">
<othercit>Chyun, Y.S. et al., &#x201c;Stimulation of bone formation by prostaglandin E2,&#x201d; Prostaglandins (1984) 27:97-103.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00514">
<othercit>Clissold, D., &#x201c;The potential for prostaglandin pharmaceuticals,&#x201d; Spec. Publ.&#x2014;R. Soc. Chem. (1999) 244:115-129.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00515">
<othercit>Coleman, R.A. et al., &#x201c;Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes,&#x201d; Pharmacol. Rev. (1994) 46(2):205-229.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00516">
<othercit>Coleman, R.A. et al., &#x201c;Prostanoids and their receptors,&#x201d; Comprehensive Med. Chem., Membranes and Receptors (1990) 3:643-714.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00517">
<othercit>Collins, P.W. et al., &#x201c;Synthesis of therapeutically useful prostaglandin and prostacyclin analogs,&#x201d; Chem. Rev. (1993) 93:1533-1564.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00518">
<othercit>Corsini, A. et al., &#x201c;(5Z)-Carbacyclin discriminates between prostacyclin receptors coupled to adenylate cyclase in vascular smooth muscle and platelets,&#x201d; Br. J. Pharmacol. (1987) 90:255-261.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00519">
<othercit>Dean, T.R. et al., &#x201c;Improvement of optic nerve head blood flow after one-week topical treatment with travoprost (AL-06221) in the rabbit,&#x201d; IOVS (1999) 40():2688-B563, p. S509.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00520">
<othercit>Delong, M.A., &#x201c;Prostaglandin receptor ligands: recent patent activity,&#x201d; Drugs (2000) 3(9):1039-1052.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00521">
<othercit>Del Toro, F. et al., &#x201c;Characterization of prostaglandin E2 receptors and their role in 24,25-(OH)2D2-mediated effects on resting zone chondrocytes,&#x201d; J. Cell Physiol. (2000) 182(2):196-208.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00522">
<othercit>Depperman, W.J., Jr., &#x201c;Up-to-date scalp tonic,&#x201d; New Eng. J. Med. (1970) 283(2):1115.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00523">
<othercit>Eisenberg, D.L. et al., &#x201c;A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension,&#x201d; Drug Safety (1999) 20(6):505-514.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00524">
<othercit>Ellis, C. K., et al., &#x201c;Metabolism of Prostaglandin D<sub>2 </sub>in the Monkey,&#x201d; J. of Biological Chem., vol. 254, No. 10, pp. 4152-4163 (1979).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00525">
<othercit>Fall, P. M., et al. &#x201c;Inhibition of Collagen Synthesis by Prostaglandins in the Immortalized Rat Osteoblastic Cell Line Pyla: Structure-Activity Relations and Signal Transduction Mechanisms,&#x201d; J. Bone Miner. Res. (1994) 9:1935-1943 (abstract).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00526">
<othercit>Fitzpatrick, F. A., &#x201c;Separation of Prostaglandins and Thromboxanes by Gas Chromatography with Glass Capillary Columns,&#x201d; Analytical Chemistry, vol. 50, No. 1, pp. 47-52, 1978.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00527">
<othercit>Flisiak, R. et al., &#x201c;Effect of misoprostol on the course of viral hepatitis B,&#x201d; Hepato-Gastroenterology (1997) 44(17):1419-1425.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00528">
<othercit>Funk, C.D. et al., &#x201c;Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype,&#x201d; J. Biol. Chem. (1993) 268:26767-26772.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00529">
<othercit>Garadi, R. et al., &#x201c;Travoprost: a new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure,&#x201d; IOVS (1999) 40(4):4378-B181, p. S831.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00530">
<othercit>Geng, L. et al., &#x201c;Topical or systemic 16,16 dm-prostaglandin E2 or WR-2721 (WR-1065) protects mice and alopecia after fractionated irradiation,&#x201d; Int. J. Radiat. Biol. (1992) 61(4):533-537.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00531">
<othercit>Geng, L., Malkinson, F.D., Hanson, W.R., &#x201c;Misoprostol, A PGE<sub>1</sub>, Analog that is Radioprotective for Murine Intestine and Hair, Induces Widely Different Cytokinetic Changes in these Tissues,&#x201d; Journal of Investigative Dermatology, 1996, vol. 106, No. 4, p. 858.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00532">
<othercit>Griffin, B.W. et al., &#x201c;AL-8810: a novel prostaglandin F2a analog with selective antagonist effects at the prostaglandin F2a (FP) receptor,&#x201d; J. Pharmacol. Exp. Ther. (1999) 290(3);1278-1284.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00533">
<othercit>Hall, A., Smith, W. H. T., &#x201c;Clinprost Teijin,&#x201d; Current Opinion in Cardiovascular, Pulmonary &#x26; Renal Investigation Drugs, 1999, 1(5), pp. 605-610.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00534">
<othercit>Hallinan, E.A. et al., &#x201c;Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs,&#x201d; J. Med. Chem. (1996) 39:609-613.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00535">
<othercit>Hanson, W.R. et al., &#x201c;16,16 dm prostaglandin 2 protects from acute radiation-induced alopecia in mice,&#x201d; Clin. Res. (1988) 36(6):906a.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00536">
<othercit>Hanson, W.R. et al., &#x201c;Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice,&#x201d; Int. J. Radiat. Oncol. Biol. Phys. (1992) 23(2):333-337.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00537">
<othercit>Hartke, J.R. et al., &#x201c;Prostanoid FP agonists build bone in the ovariectomized rat,&#x201d; J. Bone Min. Res. (1999) 14(T326):S207.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00538">
<othercit>Hayashi, M. et al., &#x201c;Prostaglandin Analogues Possessing Antinidatory Effects. 1. Modification of the &#x3c9; Chain,&#x201d; J. Med. Chem. (1980) 23(5):519-524.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00539">
<othercit>Hecker, M. et al., &#x201c;Studies on the interaction of minoxidil with prostacyclin synthase in-vitro,&#x201d; Biochem. Pharmacol. (1988) 37(17):3363-3365.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00540">
<othercit>Houssay, A.B. et al., &#x201c;Effects of prostaglandins upon hair growth in mice,&#x201d; Acta Physiol. Let. Am. (1976) 266(3):186-191.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00541">
<othercit>Huang, A. et al., &#x201c;Different modes of inhibition of increase in cytosolic calcium and aggregation of rabbit platelets by two thromboxane A2 antagonists,&#x201d; Asia Pacific Journal of Pharmacology (1994) 9:163-171.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00542">
<othercit>Hulan, H.W. et al., &#x201c;The development of dermal lesions and alopecia in male rats fed grapeseed oil,&#x201d; Can. J. Physiol. Pharmacol. (1976) 54(1):1-6.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00543">
<othercit>Hulan, H.W. et al., &#x201c;The effect of long-chain monoenes on prostaglandin E2 synthesis by rat skin,&#x201d; Lipids (1977) 12(7):604-609.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00544">
<othercit>Ichikawa, E.A. et al., &#x201c;Molecular aspects of the structures and functions of the prostaglandin E receptors,&#x201d; J. Lipid Mediators Cell Signaling (1996) 14:83-87.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00545">
<othercit>Inoue, H., &#x201c;Thromboxane A2 receptor antagonists,&#x201d; Farumashia (1996) 32(1):1221-1225 (no English translation available).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00546">
<othercit>Jakobsson, P.J. et al., &#x201c;Membrane-associated proteins in elcosanoid and glutathione metabolism (MAPEG)&#x2014;a widespread protein superfamily,&#x201d; Am J. Resp. Crit. Care Med. (2000) 161:S20-S24.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00547">
<othercit>Jimenez, J.J. et al., &#x201c;Stimulated monocyte-conditioned media protect for cytosine arabinoside-induced alopecia in rat,&#x201d; Clin. Res. (1990) 38(4):973a.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00548">
<othercit>Johnstone, M.A., &#x201c;Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost,&#x201d; Amer. J. Ophthal. (1997) 544-547.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00549">
<othercit>Johnstone, M.A., Brief latanoprost Rx induces hypertrichosis, IOVS (1998) 39(4):1180-B61.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00550">
<othercit>Karim, S.M.M. et al., &#x201c;Prostaglandins and human respiratory tract smooth muscle: structure activity relationship,&#x201d; Adv. Prostaglandin Thromboxane Res. (1980) 7:969-980.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00551">
<othercit>Kende, et, al., &#x201c;Prostaglandin Phosphonic Acids Through Homolytic Halodecarboxylation of Prostaglandins F<sub>1&#x3b1;</sub>and F<sub>2&#x3b1;,</sub>,&#x201d; Tetrahedron Letters, vol. 40, pp. 8189-8192 (1999).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00552">
<othercit>Kerstetter, J.R. et al., &#x201c;Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow,&#x201d; Am. J. Ophthalmology (1988) 105:30-34.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00553">
<othercit>Kiriyama, M. et al., &#x201c;Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells,&#x201d; Br. J. Pharm. (1997) 122:217-224.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00554">
<othercit>Kluender, H.C. et al., &#x201c;The Synthesis of Diethylphosphonoprostaglandin Analogs&#x201d; Prostaglandins and Medicine (1979) 2(6):441-444.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00555">
<othercit>Krauss, A.H.P. et al., &#x201c;Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin-F2-alpha,&#x201d; Br. J. Pharmacol. (1996) 117(6):1171-1180.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00556">
<othercit>Kvedar, J.C. et al., &#x201c;Topical minoxidil in the treatment of male pattern alopecia,&#x201d; Pharmacotherapy (1987) 7(6):191-197.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00557">
<othercit>Lachgar, S. et al., &#x201c;Effect of VEGF and minoxidil on the production of arachidonic acid metabolites by cultured hair, dermal papilla cells,&#x201d; Eur. J. Dermatol. (1996) 6(5):365-368.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00558">
<othercit>Lachgar, S. et al., &#x201c;Hair dermal papilla cell metabolism is influenced by minoxidil,&#x201d; Fundam. Clin. Pharmacol. (1997) 11(2):178.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00559">
<othercit>Lachgar, S. et al., &#x201c;Modulation by minoxidil and VEGF of the production of inflammatory mediators by hair follicle dermal papilla cells,&#x201d; J. Invest. Derm. (1995) 104(1):161.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00560">
<othercit>Lardy, C. et al., &#x201c;Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl) sulfonyl]amino] methyl] cyclopentyl] methyl] benzeneacetate,&#x201d; Arzneim.-Forsch./Drug Res. (1994) 44(11):1196-1202.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00561">
<othercit>Liljebris, C., Selen, G., Resul, B. Stjemschantz, J., and Hacksell, U., &#x201c;Derivatives of 17-Phenyl-18, 19, 20 Trinorprostaglan F<sub>2&#x3b1; </sub>Isopropyl Ester: Potential Antiglaucoma Agents,&#x201d; Journal of Medicinal Chemistry, vol. 38, No. 2, (1995), pp. 289-304.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00562">
<othercit>Ling, G. et al., &#x201c;16,16 dm prostaglandin E2 protects mice from fractionated radiation-induced alopecia,&#x201d; Clin. Res. (1990) 38(3):858a.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00563">
<othercit>Lundy, M.W. et al., &#x201c;Restoration of cancellous architecture and increased bone strength in aged osteopenic rats treated with fluprostenol,&#x201d; J. Bone Min. Res. (1999) 1(4)SA368:S401.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00564">
<othercit>Malkinson, F.D. et al., &#x201c;Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin,&#x201d; J. Invest. Dermatol. (1993) 101(1, Suppl):135S-137S.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00565">
<othercit>Maruyama, T. et al., &#x201c;EP1 receptor antagonists suppress tactile allodynia in rats,&#x201d; Prostaglandins Lipid Mediat. (1999) 59:217.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00566">
<othercit>Matsumura, H., &#x201c;Prostaglandins and Sleep,&#x201d; Saishin No to Shinkai Kagaku Shiritzu 10, 1998, pp. 79-89 (no English translation available).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00567">
<othercit>Maw, G.N., &#x201c;Pharmacological therapy for the treatment of erectile dysfunction,&#x201d; Annu. Rep. Med. Chem. (1999) 34:71-80.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00568">
<othercit>McCullough, P.A., &#x201c;Ridogrel,&#x201d;Current Opinion in Anti-inflammatory &#x26; Immunomodulatory Investigation Drugs (1999) 1(3):265-276.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00569">
<othercit>Michelet, J.F. et al., &#x201c;Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulation effect,&#x201d; J. Invest. Dermatol. (1997) 108(2):205-209.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00570">
<othercit>Mihele, D., &#x201c;The Testing of the Hepatoprotective Action of Some New Synthetic Prostaglandins,&#x201d; Farmacia (Bucharest) vol. 47 (5), 1999, pp. 43-58 (Abstract in English).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00571">
<othercit>Millikan, L.E., &#x201c;Treatment of alopecia,&#x201d; J. Clin. Pharmacol. (1987) 27(9):715.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00572">
<othercit>Millikan, L.E., &#x201c;Treatment of male pattern baldness,&#x201d; Drug Therapy (1989) 19(3):62-73.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00573">
<othercit>Miyamoto, T., et al., &#x201c;A comparison in the Efficacy and Safety between Ramatroban (BAY u 3405) and Ozargrel HC1 for Bronchial Asthma: A Phase III, Multi-Center, Randomized, Double-Blind, Group Comparative Study,&#x201d; 13, 1997, pp. 599-639 Abstract (in English).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00574">
<othercit>Mori, S. et al., &#x201c;Effects of prostaglandin E2 on production of new cancellous bone in the axial skeleton of overlectomized rats,&#x201d; Bone (1990) 11:103-113.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00575">
<othercit>Murakami, T. et al., &#x201c;Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease,&#x201d; Arzheim.-Forsh/Drug Res. (1995) 45(II)(9):991-994.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00576">
<othercit>Narumiya, S., &#x201c;Roles of prostanoids in health and disease, lessons from receptor-knockout mice,&#x201d; Int. Congr. Ser. (1999) 1181:261-269.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00577">
<othercit>Negishi, M. et al., &#x201c;Molecular mechanisms of diverse actions of prostanoid receptors,&#x201d; Biochimica et Biophysica Acta (1995) 1259:109-120.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00578">
<othercit>Norridin, R.W. et al., &#x201c;The role of prostaglandins in bone in vivo,&#x201d; Prostaglandins, Leukotrienes and Essential Fatty Acids (1990) 41:139-149.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00579">
<othercit>Olsen, E.A. et al., &#x201c;Transdermal viprostol in the treatment of male pattern baldness,&#x201d; J. Amer. Acad. Dermatol. (1990) 23(3 Part 1):470-472.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00580">
<othercit>Orlicky, D.J., &#x201c;Negative regulatory activity of a prostaglandin F2a receptor associated protein (FPRP),&#x201d; Prostaglandins, Leukotrienes and Essential Fatty Acids (1996) 54(4):247-259.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00581">
<othercit>Phamaprojects, No. 6321, Merck &#x26; Co. (2006) 1 page.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00582">
<othercit>Rampton, D.S., Carty, E., Van Nueten, L., Anti-Inflammatory Profile in Vitro of Ridogrel, a Putative New Treatment for Inflammatory Bowel Disease, Gastroenterology, 1999, (116) G3477, p. 801.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00583">
<othercit>Roenigk, H.H., &#x201c;New topical agents for hair growth,&#x201d; Clinics in Dermatology (1988) 6(4):119-121.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00584">
<othercit>Roof, S.L. et al., &#x201c;mRNA expression of prostaglandin receptors EP1, EP2, EP3 and EP4 in human osteoblast-like cells and 23 human tissues,&#x201d; J. Bone Min. Res. (1996) 11:S337.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00585">
<othercit>Ruel, R. et al., &#x201c;New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor,&#x201d; Bioorg. Med. Chem. Lett. (1999) 9:2699-2704.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00586">
<othercit>Sakuma, Y. et al., &#x201c;Crucial involvement of the PE4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide,&#x201d; J. Bone Min. Res. (2000) 15(2):218-227.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00587">
<othercit>Sauk, J.J. et al., &#x201c;Influence of prostaglandin E-1 prostaglandin E-2 and arachidonate on melanosomes in melanocytes and keratinocytes of anagen bulbs in-vitro,&#x201d; J. Invest. Dermatol. (1975) 64(5):332-337.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00588">
<othercit>Sharif, N.A. et al., &#x201c;3H AL-5848 ([3H]9 beta-(+)-fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor,&#x201d; J. Phar. Pharmacol. (1999) 51(6):685-694.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00589">
<othercit>Shih, M.S. et al., &#x201c;PGE2 induces regional remodeling changes in Haversian envelope: a histomorphometric study of fractured ribs in beagles,&#x201d; Bone and Mineral (1986) 1:227-234.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00590">
<othercit>Shimazaki, A., et al. &#x201c;New Ethacrynic Acid Derivatives as Potent Cytoskeletal Modulators in Trabecular Meshwork Cells,&#x201d; Biol. Pharm. Bull. vol. 27, No. 6, 2004, pp. 846-850.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00591">
<othercit>Shimazaki, A., et al., &#x201c;Effects of the New Ethacrynic Acid Derivative SA9000 on Intraocular Pressure in Cats and Monkeys,&#x201d; Biol Pharm. Bull. vol. 27, No. 7, 2004, pp. 1019-1024.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00592">
<othercit>Souillac, P. et al., &#x201c;Characterization of delivery systems, differential scanning calorimetry,&#x201d; Encyclopedia of Controlled Drug Delivery, John Wiley &#x26; Sons (1999) 212-227.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00593">
<othercit>Sredni, B. et al., &#x201c;The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models,&#x201d; Int. J. Cancer (1996) 65(1):97-103.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00594">
<othercit>Tereda, N. et al., &#x201c;Effect of a thromboxane A2 receptor antagonist, ramatroban (BAY U3405), on inflammatory cells, chemical mediators and non-specific nasal hyperactivity after allergen challenge in patients with perennial allergic rhinitis,&#x201d; Allergology Int. (1998) 47(1):59-67.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00595">
<othercit>Tomita, Y. et al., &#x201c;Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation,&#x201d; Pigm. Cell Res. (1992) 5(5, Pt. 2):357-361.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00596">
<othercit>Ueda, K. et al., &#x201c;Brief clinical and laboratory observations: coritical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease,&#x201d; J. Pediatrics (1980) 97:834-836.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00597">
<othercit>Vandenburgh, A.M. et al., &#x201c;A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure,&#x201d; IOVS (1999) 40(4):4373-B176, p. S830.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00598">
<othercit>Vayssairat, M., Preventive Effect of an Oral Prostacyclin Analog, Beraprost Sodium, on Digital Necrosis in Systemic Scierosis, J. of Rheumatol., 1999, 26(10), pp. 2173-2178.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00599">
<othercit>Vengerovsky, A.I. et al., &#x201c;Hepatoprotective action of prostaglandins,&#x201d; Eksp. Kim. Farmakof. (1997) 60(5):78-82.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00600">
<othercit>Verbeuren, T., et al., &#x201c;The TP-Receptor Antagonist S 18886 Unmasks Vascular Relaxation and Potentiates the Anti-Platelet Action of PGD<sub>2</sub>,&#x201d; Journal of the International Society Thrombosis and Haemostasis, Jun. 6-12, 1997, p. 693.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00601">
<othercit>Vincent, J.E., &#x201c;Prostaglandin synthesis and selenium deficiency a hypothesis,&#x201d; Prostaglandins (1974) 8(4):339-340.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00602">
<othercit>Vippagunta, &#x201c;Crystalline solids,&#x201d; Adv. Drug Del. Rev. (2001) 48:3-26.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00603">
<othercit>Voss, N.G. et al., &#x201c;Induction of anagen hair growth in telogen mouse skin by topical latanoprost application,&#x201d; IOVS (1999) 40:3570-B428, p. 5676.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00604">
<othercit>Waddell, K. A., et al., &#x201c;Combined Capillary Column Gas Chromatography Negative Ion Chemical Ionization Mass Spectrometry of Prostanoids,&#x201d; Biomed. Mass Spectrom., vol. 10, No. 2, pp. 83-88 (1983).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00605">
<othercit>Wang, Y. et al., &#x201c;The design and synthesis of 13, 14-dihydro prostaglandin F1a analogs as potent and selective ligands for the human FP receptor,&#x201d; J. Med. Chem. (2000) 43(5):945-952.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00606">
<othercit>Watson et al., &#x201c;A six-month, randomized, double-masked study in comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension,&#x201d; Ophthalmology (1996) 103:126-137.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00607">
<othercit>Woodward, D.F. et al., &#x201c;Emerging evidence for additional prostanoid receptor subtypes,&#x201d; Curr. Top. Pharmacol. (1998) 4:153-163.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00608">
<othercit>Woodward, D.F. et al., &#x201c;Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor,&#x201d; J. Oc. Pharm. Therap. (1995) 11(3):447-454.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00609">
<othercit>Woodward, D.F. et al., &#x201c;Studies on the ocular effects of a pharmacologically novel agent prostaglandin F2 alpha 1-OCH3 (AGN 191129) N-S,&#x201d; Arch. Pharmacol. (1998) 358(1):P1713.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00610">
<othercit>Yoshida, K. et al., &#x201c;Synthesis and pharmacological activities of the new TXA2 receptor antagonist Z-335 and related compounds,&#x201d; AFMC (1995) 95:53.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00611">
<othercit>Zimbric, M.L. et al., &#x201c;Effects of latanoprost of hair growth in the bald scalp of stumptailed macaques,&#x201d; IOVS (1999) 40:3569-B427, p. S676.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00612">
<othercit>International Search Report for Application No. PCT/US00/05301 dated Jul. 21, 2000 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00613">
<othercit>Written Opinion for Application No. PCT/US00/05301 dated Oct. 20, 2000 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00614">
<othercit>International Preliminary Examination Report for Application No. PCT/US00/05301 dated Mar. 16, 2001 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00615">
<othercit>International Search Report for Application No. PCT/US00/20851 dated Nov. 7, 2000 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00616">
<othercit>Written Opinion for Application No. PCT/US00/20851 dated Jul. 10, 2001 (9 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00617">
<othercit>International Preliminary Examination Report for Application No. PCT/US00/20851 dated Oct. 12, 2001 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00618">
<othercit>International Search Report for Application No. PCT/US98/18339 dated Dec. 3, 1998 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00619">
<othercit>International Preliminary Examination Report for Application No. PCT/US98/18339 dated Jun. 28, 1999 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00620">
<othercit>International Search Report for Application No. PCT/US98/18340 dated Dec. 8, 1998 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00621">
<othercit>Written Opinion for Application No. PCT/US98/18340 dated Aug. 2, 1999 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00622">
<othercit>International Preliminary Examination Report for Application No. PCT/US98/18340 dated Dec. 6, 1999 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00623">
<othercit>International Search Report for Application No. PCT/US98/18594 dated Dec. 3, 1998 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00624">
<othercit>Written Opinion for Application No. PCT/US98/18594 dated May 25, 1999 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00625">
<othercit>International Preliminary Examination Report for Application No. PCT/US98/18594 dated Sep. 7, 1999 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00626">
<othercit>International Search Report for Application No. PCT/IB99/00478 dated Jul. 12, 1999 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00627">
<othercit>Written Opinion for Application No. PCT/IB99/00478 dated Feb. 21, 2004 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00628">
<othercit>International Preliminary Examination Report for Application No. PCT/IB99/00478 dated Jun. 23, 2000 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00629">
<othercit>International Search Report for Application No. PCT/IB99/00480 dated Jun. 25, 1999 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00630">
<othercit>Written Opinion for Application No. PCT/IB99/00480 dated Jan. 18, 2000 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00631">
<othercit>International Search Report for Application No. PCT/US00/05299 dated Jul. 28, 2000 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00632">
<othercit>Written Opinion for Application No. PCT/US00/05299 dated Oct. 20, 2000 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00633">
<othercit>International Preliminary Examination Report for Application No. PCT/US00/05299 dated Mar. 16, 2001 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00634">
<othercit>International Search Report for Application No. PCT/US01/10368 dated Nov. 7, 2001 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00635">
<othercit>International Preliminary Examination Report for Application No. PCT/US01/10368 dated Jun. 14, 2002 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00636">
<othercit>International Search Report for Application No. PCT/US01/10369 dated Nov. 7, 2001 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00637">
<othercit>International Preliminary Examination Report for Application No. PCT/US01/10369 dated Jun. 14, 2001 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00638">
<othercit>International Search Report for Application No. PCT/US01/10370 dated Nov. 7, 2001 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00639">
<othercit>International Preliminary Examination Report for Application No. PCT/US01/10370 dated Jun. 14, 2002 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00640">
<othercit>International Search Report for Application No. PCT/US01/10547 dated Jan. 2, 2002 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00641">
<othercit>International Preliminary Examination Report for Application No. PCT/USO1/10547 dated Jun. 14, 2002 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00642">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/479,532 dated Apr. 22, 2010 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00643">
<othercit>United States Patent Office Notice of Allowance for U.S. Appl. No. 12/138,733 dated Jun. 3, 2010 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00644">
<othercit>United States Patent Office Action for U.S. Appl. No. 11/476,246 dated Apr. 19, 2010 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00645">
<othercit>United States Patent Office Notice of Allowance for U.S. Appl. No. 12/535,513 dated Jun. 3, 2010 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00646">
<othercit>United States Patent Office Action for U.S. Appl. No. 11/334,689 dated Apr. 30, 2010 (11 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00647">
<othercit>Higginbotham, E.J. et al., &#x201c;One-year randomized study comparing bimatoprost and timololin in glaucoma and ocular hypertension,&#x201d; Arch. Ophthal. (2002) 120(10):1286-1293.</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00648">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/479,532 dated May 10, 2011 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00649">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/260,522 dated May 25, 2011 (14 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00650">
<othercit>United States Office Action for U.S. Appl. No. 09/946,021 dated Jan. 15, 2002 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00651">
<othercit>United States Office Action for U.S. Appl. No. 09/946,021 dated May 24, 2002 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00652">
<othercit>United States Office Action for U.S. Appl. No. 09/946,021 dated Oct. 15, 2002 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00653">
<othercit>United States Office Action for U.S. Appl. No. 11/174,420 dated Aug. 20, 2007 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00654">
<othercit>United States Office Action for U.S. Appl. No. 11/174,420 dated Dec. 5, 2008 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00655">
<othercit>United States Office Action for U.S. Appl. No. 11/174,420 dated Jul. 22, 2009 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00656">
<othercit>United States Office Action for U.S. Appl. No. 09/148,006 dated Jan. 29, 1999 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00657">
<othercit>United States Office Action for U.S. Appl. No. 09/148,374 dated Feb. 11, 1999 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00658">
<othercit>United States Office Action for U.S. Appl. No. 09/148,374 dated May 28, 1999 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00659">
<othercit>United States Office Action for U.S. Appl. No. 09/148,374 dated Oct. 1, 1999 (3 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00660">
<othercit>United States Office Action for U.S. Appl. No. 09/148,374 dated Jan. 10, 2000 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00661">
<othercit>United States Office Action for U.S. Appl. No. 09/148,538 dated Apr. 8, 1999 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00662">
<othercit>United States Office Action for U.S. Appl. No. 09/647,381 dated Sep. 20, 2001 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00663">
<othercit>United States Office Action for U.S. Appl. No. 09/647,380 dated Sep. 18, 2001 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00664">
<othercit>United States Office Action for U.S. Appl. No. 09/914,531 dated Dec. 7, 2001 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00665">
<othercit>United States Office Action for U.S. Appl. No. 09/774,555 dated Jul. 9, 2002 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00666">
<othercit>United States Office Action for U.S. Appl. No. 09/774,555 dated May 23, 2005 (7 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00667">
<othercit>United States Office Action for U.S. Appl. No. 09/774,555 dated Jan. 6, 2006 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00668">
<othercit>United States Office Action for U.S. Appl. No. 09/774,555 dated Aug. 31, 2006 (9 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00669">
<othercit>United States Office Action for U.S. Appl. No. 11/565,297 dated Jul. 12, 2007 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00670">
<othercit>United States Office Action for U.S. Appl. No. 11/565,297 dated Jul. 31, 2007 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00671">
<othercit>United States Office Action for U.S. Appl. No. 09/774,558 dated Apr. 25, 2002 (13 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00672">
<othercit>United States Office Action for U.S. Appl. No. 09/774,558 dated Apr. 15, 2003 (11 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00673">
<othercit>United States Office Action for U.S. Appl. No. 09/774,558 dated Dec. 4, 2003 (11 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00674">
<othercit>United States Office Action for U.S. Appl. No. 09/774,558 dated Nov. 5, 2004 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00675">
<othercit>United States Office Action for U.S. Appl. No. 09/774,558 dated Mar. 28, 2006 (8 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00676">
<othercit>United States Office Action for U.S. Appl. No. 11/476,246 dated Jul. 22, 2009 (9 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00677">
<othercit>United States Office Action for U.S. Appl. No. 09/774,557 dated Mar. 5, 2003 (9 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00678">
<othercit>United States Office Action for U.S. Appl. No. 09/774,557 dated Nov. 26, 2004 (10 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00679">
<othercit>United States Office Action for U.S. Appl. No. 11/138,097 dated Jul. 16, 2007 (1 page).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00680">
<othercit>United States Office Action for U.S. Appl. No. 11/967,423 dated Feb. 4, 2009 (10 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00681">
<othercit>United States Office Action for U.S. Appl. No. 09/774,556 dated Mar. 19, 2002 (11 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00682">
<othercit>United States Office Action for U.S. Appl. No. 09/774,556 dated May 14, 2003 (2 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00683">
<othercit>United States Office Action for U.S. Appl. No. 09/774,556 dated Mar. 23, 2004 (10 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00684">
<othercit>United States Office Action for U.S. Appl. No. 09/774,556 dated Dec. 14, 2004 (5 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00685">
<othercit>United States Office Action for U.S. Appl. No. 09/774,556 dated Jul. 18, 2005 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00686">
<othercit>United States Office Action for U.S. Appl. No. 11/334,689 dated Aug. 25, 2009 (11 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00687">
<othercit>United States Patent Office Notice of Allowance for U.S. Appl. No. 12/479,532 dated Dec. 16, 2011 (4 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00688">
<othercit>Office Action from the European Patent Office for Application No. 09748621.1 dated Jan. 16, 2013 (6 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
<us-citation>
<nplcit num="00689">
<othercit>United States Patent Office Action for U.S. Appl. No. 12/260,522 dated May 31, 2013 (14 pages).</othercit>
</nplcit>
<category>cited by applicant</category>
</us-citation>
</us-references-cited>
<number-of-claims>11</number-of-claims>
<us-exemplary-claim>1</us-exemplary-claim>
<us-field-of-classification-search>
<classification-cpc-text>A61K 31/5575</classification-cpc-text>
<classification-cpc-text>C07C 57/26</classification-cpc-text>
<classification-cpc-text>C07C 229/26</classification-cpc-text>
</us-field-of-classification-search>
<us-related-documents>
<related-publication>
<document-id>
<country>US</country>
<doc-number>20100105775</doc-number>
<kind>A1</kind>
<date>20100429</date>
</document-id>
</related-publication>
</us-related-documents>
<us-parties>
<us-applicants>
<us-applicant sequence="001" app-type="applicant" designation="us-only">
<addressbook>
<last-name>deLong</last-name>
<first-name>Mitchell A.</first-name>
<address>
<city>Raleigh</city>
<state>NC</state>
<country>US</country>
</address>
</addressbook>
<residence>
<country>US</country>
</residence>
</us-applicant>
<us-applicant sequence="002" app-type="applicant" designation="us-only">
<addressbook>
<last-name>Sturdivant</last-name>
<first-name>Jill Marie</first-name>
<address>
<city>Chapel Hill</city>
<state>NC</state>
<country>US</country>
</address>
</addressbook>
<residence>
<country>US</country>
</residence>
</us-applicant>
</us-applicants>
<inventors>
<inventor sequence="001" designation="us-only">
<addressbook>
<last-name>deLong</last-name>
<first-name>Mitchell A.</first-name>
<address>
<city>Raleigh</city>
<state>NC</state>
<country>US</country>
</address>
</addressbook>
</inventor>
<inventor sequence="002" designation="us-only">
<addressbook>
<last-name>Sturdivant</last-name>
<first-name>Jill Marie</first-name>
<address>
<city>Chapel Hill</city>
<state>NC</state>
<country>US</country>
</address>
</addressbook>
</inventor>
</inventors>
<agents>
<agent sequence="01" rep-type="attorney">
<addressbook>
<orgname>Michael Best &#x26; Friedrich LLP</orgname>
<address>
<country>unknown</country>
</address>
</addressbook>
</agent>
</agents>
</us-parties>
<assignees>
<assignee>
<addressbook>
<orgname>Novaer Holdings, Inc.</orgname>
<role>02</role>
<address>
<city>Bedminster</city>
<state>NJ</state>
<country>US</country>
</address>
</addressbook>
</assignee>
</assignees>
<examiners>
<primary-examiner>
<last-name>Zucker</last-name>
<first-name>Paul A</first-name>
<department>1621</department>
</primary-examiner>
</examiners>
</us-bibliographic-data-grant>
<abstract id="abstract">
<p id="p-0001" num="0000">The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.</p>
</abstract>
<description id="description">
<?BRFSUM description="Brief Summary" end="lead"?>
<heading id="h-0001" level="1">TECHNICAL FIELD</heading>
<p id="p-0002" num="0001">The present invention is directed to novel amino acid salts of prostaglandins and methods of making and using the same.</p>
<heading id="h-0002" level="1">BACKGROUND OF THE INVENTION</heading>
<p id="p-0003" num="0002">Various prostaglandins are useful for the treatment of medical conditions including, for example: ocular disorders, such as glaucoma; skin disorders; circulatory disorders, such as hypertension; gastrointestinal disorders; hair loss; respiratory disorders; fertility control; and bone disorders, such as osteoporosis. Information regarding the biological effects of Prostaglandin F analogs is disclosed in the following references: PCT Publication No. WO 99/12895, 1999; PCT Publication No. WO 99/12896, 1999; PCT Publication No. WO 99/12898; <i>Abstr. </i>1999, 194116 &#x201c;Molecular mechanisms of diverse actions of prostanoid receptors&#x201d;, <i>Biochimica et Biophysica Acta, </i>1259 (1995) 109-120; U.S. Pat. No. 3,776,938 issued to Bergstrom, S., and Sjovall, J., Dec. 4, 1973; U.S. Pat. No. 3,882,241 issued to Pharriss, G., May 6, 1975; G.B. Patent No. 1,456,512 (1976) issued to Pfizer Inc., Bundy, G. L.; Lincoln, F. H., &#x201c;Synthesis of 17-Phenyl-18,19,20-trinor prostaglandins I. The PG1 Series&#x201d;, <i>Prostaglandins </i>Vol. 9 (1975) pp. 1-4.; CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids Vol. 1, Chemical and Biochemical Aspects, Parts A &#x26; B, A. L. Willis, eds., CRC Press (1987); Liljebris, C.; et. al. &#x201c;Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F2&#x3b1; Isopropyl Ester: Potential Antiglaucoma Agents&#x201d;, <i>Journal of Medicinal Chemistry </i>Vol. 38, (1995), pp. 289-304; Collins, P. W.; Djuric, S. W. &#x201c;Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs&#x201d;, <i>Chemical Reviews </i>93 (1993), pp. 1533-1564.</p>
<p id="p-0004" num="0003">All naturally occurring prostaglandins, including PGF<sub>2&#x3b1;</sub>, and almost all non-naturally-occurring prostaglandins possess a carboxylic acid moiety at the C<sub>1 </sub>position. The carboxylic acid moiety is a site for metabolic degradation by beta oxidation, which contributes to the rapid metabolism of the naturally occurring prostaglandins. Attempts to prevent beta oxidation by modifying the carboxylic acid moiety at the 1 position as an ester moiety, a sulfonamide moiety, and as a tetrazole are known in the art (See e.g. PCT Publication No. WO 99/12895, 1999; PCT Publication No. WO 99/12896, 1999; PCT Publication No. WO 99/12898). However, such modifications have either resulted in only modest increases in half-life (such as the esters) or resulted in compounds with diminished potency.</p>
<p id="p-0005" num="0004">Prostaglandin F analogs wherein C<sub>1 </sub>itself is replaced with a heteroatom have also been described in the art. For example, PGF analogs containing a sulfonic acid moiety at C<sub>1 </sub>(The chemistry of prostaglandins containing the sulfo group. Iguchi, Y.; Kori, S.; Hayashi, M. <i>J. Org. Chem., </i>40, pp. 521-523 1975) and PGF analogs containing a phosphonic acid moiety at C<sub>1 </sub>(The Synthesis of dimethylphosphonoprostaglandin analogs, Kluender, H. C. &#x26; Woessner, W. <i>Prostaglandins and Medicine, </i>2: pp. 441-444, 1979) have been disclosed. However, such compounds suffer from significantly diminished potency. However, the potent C<sub>1 </sub>carboxylic acids are difficult to purify as they are most often synthesized as oils. There is a need for solid forms of prostaglandins, both naturally and non-naturally occurring, for the purposes of purification and as intermediates in synthesis, as well as the direct use of these solids in drug products.</p>
<heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading>
<p id="p-0006" num="0005">The present invention provides an amino acid prostaglandin free acid salt, wherein the amino acid is selected from the group consisting of arginine, homoarginine, N(delta)-methyl-L-arginine, L-canavanine, D-canavanine, DL-canavanine, L-&#x3b1;-amino-&#x3b2;-guanidinopropionic acid, &#x3b3;-guanidinobutyric acid, and citrulene; and wherein the prostaglandin free acid is selected from the group consisting of latanoprost free acid, travoprost free acid, fluprostenol free acid, tafluprost free acid, and bitamoprost free acid.</p>
<p id="p-0007" num="0006">In another embodiment, the present invention provides a pharmaceutical composition including the salt and a pharmaceutically acceptable carrier. The present invention also provides methods of making the salt comprising reacting an amino acid with a prostaglandin free acid.</p>
<p id="p-0008" num="0007">Further, the invention provides methods of making a prostaglandin analog from the salt. In addition, the invention provides methods of making prostaglandins from the salts.</p>
<p id="p-0009" num="0008">The present invention also provides methods of treating eye diseases, such as glaucoma, treating bone disorders, such as osteoporosis, treating skin disorders, treating respiratory disorders, treating circulatory disorders such as hypertension, treating gastrointestinal disorders, treating hair loss, fertility control, improving nasal patency or treating neurogenic bladder comprising administering an amino acid salt of a prostaglandin free acid. In addition, the present invention provides method of reducing ocular pressure comprising contacting a cell with an amount of the salt effective to reduce ocular pressure.</p>
<?BRFSUM description="Brief Summary" end="tail"?>
<?DETDESC description="Detailed Description" end="lead"?>
<heading id="h-0004" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading>
<p id="p-0010" num="0009">The present invention is directed to novel amino acid salts of prostaglandin free acids and methods of making and using the amino acid prostaglandin salts of the present invention. The amino acid prostaglandin salts are useful in methods of treating eye diseases, such as glaucoma. The amino acid prostaglandin salts of the present invention are also useful in a method of treating bone disorders, such as osteoporosis, treating skin disorders, treating respiratory disorders, treating circulatory disorders such as hypertension, treating gastrointestinal disorders, treating hair loss, fertility control, improving nasal patency or treating neurogenic bladder. Further, the amino acid prostaglandin salts of the present invention are useful for purifying prostaglandins and prostaglandin intermediates and as intermediates in the production of both protected and unprotected prostaglandin analogs.</p>
<heading id="h-0005" level="1">DEFINITIONS AND USAGE OF TERMS</heading>
<p id="p-0011" num="0010">&#x201c;Alcohol protecting group&#x201d; refers to a protecting group that replaces the active hydrogen of a hydroxyl moiety thus preventing undesired side reaction at the hydroxyl moiety. Use of alcohol protecting groups in organic synthesis is well known in the art. Examples of alcohol protecting groups are found in Chapter 2 of Theodora W. Greene's text entitled: &#x201c;Protective Groups in Organic Synthesis&#x201d; (3<sup>rd </sup>Edition). Suitable alcohol protecting groups include silyl ethers, alkoxymethyl ethers, tetrahydropyranyl, tetrahydrofuranyl, esters, and substituted or unsubstituted benzyl ethers. If more than one alcohol protecting group is present, the alcohol protecting groups may be the same or different. In some embodiments, the alcohol protecting groups may be orthogonal.</p>
<p id="p-0012" num="0011">&#x201c;Alkyl&#x201d; refers to a saturated or unsaturated hydrocarbon chain having 1 to 18 carbon atoms, suitably 1 to 12 carbon atoms, or 1 to 6 carbon atoms, or 1 to 4 carbon atoms. Alkyl gropus may be straight or branched. In some embodiments, branched alkyl groups have one or two branches. Unsaturated alkyl groups have one or more double bonds and/or one or more triple bonds. Suitably, unsaturated alkyl groups have one or two double bonds or one triple bond. Alkyl chains may be unsubstituted or substituted with from 1 to about 4 substituents unless otherwise specified. Suitably, alkyl groups are mono-, di-, or tri-substituted. Suitable alkyl substituents include, but are not limited to, cyano, halo, hydroxy, aryl (e.g., phenyl, tolyl, alkyloxphenyl, alkyloxycarbonylphenyl, halophenyl), heterocyclyl, and heteroaryl.</p>
<p id="p-0013" num="0012">&#x201c;Aromatic ring&#x201d; refers to an aromatic hydrocarbon ring system. Aromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic aromatic rings contain from about 5 to about 10 carbon atoms, suitably from 5 to 7 carbon atoms, or from 5 to 6 carbon atoms in the ring. Bicyclic aromatic rings contain from 8 to 12 carbon atoms, suitably 9 or 10 carbon atoms in the ring. Aromatic rings may be unsubstituted or substituted with from 1 to about 4 substituents on the ring. Suitable aromatic ring substituents include, but are not limited to, halo, cyano, lower alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Suitably, the aromatic ring substituents are lower alkyl, cyano, halo or halo alkyl.</p>
<p id="p-0014" num="0013">&#x201c;Basic amino acid&#x201d; refers to naturally-occurring and non-naturally-occurring alpha, beta and gamma amino acids, including all enantiomers and diastereomers, whether protected or unprotected, provided that the amino acids have a net positive charge at neutral pH. Neutral pH is a pH from about 6.5 to about 7.5. The basic amino acid may be basic when it is the free acid form, or it may only be basic as the ester or amide form of the amino acid. Suitable basic amino acids that are basic in the free acid form include, but are not limited to, arginine, lysine, histidine, L-Arginine, D-Arginine, DL-Arginine, homoarginine, 3- and 4-substituted arginine analogs, N(delta)-methyl-L-arginine (deltaMA), L-canavanine, D-canavanine, DL-canavanine, protected and/or substituted analogs of canavanine, L-&#x3b1;-Amino-&#x3b2;-guanidinopropionic acid, &#x3b3;-guanidinobutyric acid, citrulline, 3-guanidinopropionic acid, 4-{[amino(imino)methyl]amino}butanoic acid, 6-{[amino(imino)methyl]amino}hexanoic acid, L-2-Amino-3-guanidinopropionic acid, L-Homoarginine, L-Arginine hydroxamate, Agmatine (CAS #: 2482-00-0), and NG-Methyl-L-arginine (CAS #: 53308-83-1). Other amino acids can be made into a basic amino acid if the acid group or groups are suitably protected. Suitable examples of basic amino acids that are esters include L-Arginine ethyl ester. Suitable examples of basic amino acids that are protected as amides include, but are not limited to, L-Argininamide, L-Arginine N-ethylamide, and Arg-beta-Ala hydrochloride, (CAS #: 98957-79-0). In some embodiments, the basic amino acid comprises a guanidino group.</p>
<p id="p-0015" num="0014">&#x201c;Carbocycle&#x201d; refers to a saturated or unsaturated hydrocarbon ring. Carbocycles are not aromatic. Carbocycles are monocyclic, or are fused, spiro, or bridged bicyclic ring systems. Monocyclic carbocycles contain from about 4 to about 10 carbon atoms, suitably from 4 to 7 carbon atoms, or from 5 to 6 carbon atoms in the ring. Bicyclic carbocycles contain from 8 to 12 carbon atoms, suitably from 9 to 10 carbon atoms in the ring. Carbocycles may be unsubstituted or substituted with from 1 to about 4 substituents on the ring. Suitable carbocycle substituents include, but are not limited to, halo, cyano, lower alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Suitably, the carbocycle substituents are halo or haloalkyl. Suitable carbocycles include, but are not limited to, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.</p>
<p id="p-0016" num="0015">&#x201c;Halo&#x201d; refers to fluoro, chloro, bromo or iodo.</p>
<p id="p-0017" num="0016">&#x201c;Haloalkyl&#x201d; refers to a straight, branched, or cyclic hydrocarbon substituted with one or more halo substituents. Suitably, the haloalkyl is C<sub>1</sub>-C<sub>12</sub>, or C<sub>1</sub>-C<sub>6</sub>, or C<sub>1</sub>-C<sub>3</sub>. Suitable halo substituents include fluoro and chloro. One suitable haloalkyl is trifluoromethyl.</p>
<p id="p-0018" num="0017">&#x201c;Heteroalkyl&#x201d; refers to a saturated or unsaturated chain containing carbon and at least one heteroatom, wherein no two heteroatoms are adjacent. Heteroalkyl groups contain from 1 to 18 member atoms (carbon and heteroatoms) in the chain, or 1 to 12 member atoms, or 1 to 6 member atoms, or 1 to 4 member atoms. Heteroalkyl groups may be straight or branched. Suitably, the branched heteroalkyl may have one or two branches. Unsaturated heteroalkyl have one or more double bonds and/or one or more triple bonds. Suitably, heteroalkyl groups have one or two double bonds or one triple bond. Heteroalkyl groups may be unsubstituted or substituted with from 1 to about 4 substituents unless otherwise specified. Suitable heteroalkyl substituents include halo, aryl (e.g., phenyl, tolyl, alkyloxyphenyl, alkyloxycarbonylphenyl, halophenyl), heterocyclyl, heteroaryl. For example, alkyl chains substituted with the following substituents are heteroalkyl: alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, pentoxy), aryloxy (e.g., phenoxy, chlorophenoxy, tolyloxy, methoxyphenoxy, benzyloxy, alkyloxycarbonylphenoxy, acyloxyphenoxy), acyloxy (e.g., propionyloxy, benzoyloxy, acetoxy), carbamoyloxy, carboxy, mercapto, alkylthio, acylthio, arylthio (e.g., phenylthio, chlorophenylthio, alkylphenylthio, alkoxyphenylthio, benzylthio, alkyloxycarbonylphenylthio), amino (e.g., amino, mono- and di-C<sub>1</sub>-C<sub>3 </sub>alkanylamino, methylphenylamino, methylbenzylamino, C<sub>1</sub>-C<sub>3 </sub>alkanylamido, carbamamido, ureido, guanidino).</p>
<p id="p-0019" num="0018">&#x201c;Heteroatom&#x201d; refers to a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms. As used herein, halogens are not heteroatoms.</p>
<p id="p-0020" num="0019">&#x201c;Heterocycle&#x201d; refers to a saturated or unsaturated ring containing carbon and from 1 to about 4 heteroatoms in the ring, wherein no two heteroatoms are adjacent in the ring and no carbon in the ring that has a heteroatom attached to it also has a hydroxyl, amino, or thiol group attached to it. Heterocycles are not aromatic. Heterocycles are monocyclic, or are fused or bridged bicyclic ring systems. Monocyclic heterocycles contain from about 4 to about 10 member atoms (carbon and heteroatoms), suitably from 4 to 7 member atoms, or from 5 to 6 member atoms in the ring. Bicyclic heterocycles contain from 8 to 12 member atoms, suitably 9 or 10 member atoms in the ring. Heterocycles may be unsubstituted or substituted with from 1 to about 4 substituents on the ring. Suitably, the substituents are halo or haloalkyl. Suitable heterocycle substituents include: halo, cyano, lower alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Suitable heterocycles include, but are not limited to, piperzyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl and piperdyl.</p>
<p id="p-0021" num="0020">&#x201c;Heteroaryl&#x201d; refers to an aromatic ring system containing carbon and from 1 to about 4 heteroatoms in the ring. Heteroaryls are monocyclic or fused bicyclic ring systems. Monocyclic heteroaryls contain from about 5 to about 10 member atoms (carbon and heteroatoms), or from 5 to 7 member atoms, or from 5 to 6 member atoms in the ring. Bicyclic heteroaryls contain from 8 to 12 member atoms, or 9 or 10 member atoms in the ring. Heteroaryls may be unsubstituted or substituted with from 1 to about 4 substituents on the ring. Suitable heteroaryl substituents include: halo, cyano, lower alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Suitably, the substituents are halo, haloalkyl or phenyl. Suitable heteroaryls include, but are not limited to, benzothienyl, benzofuranyl, thienyl, thiazolo, purinyl, pyrimidyl, pyridyl, and furanyl.</p>
<p id="p-0022" num="0021">&#x201c;Lower alkyl&#x201d; refers to an alkyl chain comprised of 1 to 4 carbon atoms, suitably 1 to 3 carbon atoms or 1 to 2 carbon atoms. Lower alkyl groups may be saturated or unsaturated and substituted or unsubstituted. Lower alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl.</p>
<p id="p-0023" num="0022">&#x201c;Lower heteroalkyl&#x201d; refers to a heteroalkyl chain comprised of 1 to 4 member atoms. Lower heteroalkyl groups may be saturated or unsaturated and substituted or unsubstituted.</p>
<p id="p-0024" num="0023">&#x201c;Member atom&#x201d; refers to a polyvalent atom (C, O, N, or S atom) in a chain or ring system that continues the chain or ring system. For example, in benzene the six carbon atoms are member atoms and the six hydrogen atoms are not member atoms.</p>
<p id="p-0025" num="0024">&#x201c;Phenyl&#x201d; refers to a six-membered monocyclic aromatic ring which may or may not be substituted with from about 1 to about 4 substituents. The substituents may be substituted at the ortho, meta or para position on the phenyl ring, or any combination thereof. Suitable phenyl substituents include: halo, cyano, lower alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof.</p>
<p id="p-0026" num="0025">&#x201c;Prostaglandin analog&#x201d; refers to a compound that is designed to bind to a prostaglandin receptor. Prostaglandin analogs include protected prostaglandins, e.g. prostaglandins with esters or amides at the C1 position.</p>
<p id="p-0027" num="0026">&#x201c;Prostaglandin free acid&#x201d; refers to a prostaglandin, prostaglandin analog or prostaglandin intermediate that has a carboxylic acid moiety at the C1 position.</p>
<p id="p-0028" num="0027">&#x201c;Prostaglandin intermediate&#x201d; refers to a compound that is on the synthetic pathway to a compound that, in its active form, stimulates one or more of the prostaglandin receptors. Prostaglandin intermediates may be a protected prostaglandin or prostaglandin analog or they may have parts of their structures not yet attached. An example of a prostaglandin intermediate is a latanoprost free acid containing one or more silyl protecting groups on an alcohol moiety.</p>
<p id="p-0029" num="0028">&#x201c;Prostaglandin F analog&#x201d; or &#x201c;PGF analog&#x201d; or &#x201c;analog of PGF<sub>2&#x3b1;</sub>&#x201d; refers to a compound that is structurally similar to naturally occurring PGF<sub>2&#x3b1;</sub>.</p>
<p id="p-0030" num="0029">&#x201c;Prostaglandin E analog&#x201d; or &#x201c;PGE analog&#x201d; or &#x201c;analog of PGE<sub>2</sub>&#x201d; or &#x201c;analog of PGE<sub>1</sub>&#x201d; refers to a compound that is structurally similar to naturally occurring PGE<sub>2</sub>.</p>
<p id="p-0031" num="0030">&#x201c;Prostaglandin D analog&#x201d; or &#x201c;PGD analog&#x201d; or &#x201c;analog of PGD<sub>2</sub>&#x201d; refers to a compound that is structurally similar to naturally occurring PGD<sub>2</sub>.</p>
<p id="p-0032" num="0031">&#x201c;Protected&#x201d; refers to a chemical structure wherein one or more of the chemically-sensitive groups in the molecule have been modified to reduce its activity and allow for better synthetic techniques to be used. In prostaglandins, typical groups where protection is used are the hydroxy groups and the carboxcyclic acid group. Less commonly protected are the ketones found in PGD and PGE analogues. Protecting groups vary but are generally found in &#x201c;Protecting Groups in Organic Synthesis&#x201d; by Theadora Green.</p>
<p id="p-0033" num="0032">&#x201c;Unprotected&#x201d; refers to a chemical structure that does not contain any groups that have been added to protect sensitive functional moieties such as hydroxy groups or carboxcylic acid groups.</p>
<p id="p-0034" num="0033">&#x201c;Pharmaceutically acceptable carrier&#x201d; refers to a carrier that is useful for the preparation of a pharmaceutical composition that is: generally compatible with the other ingredients of the composition, not deleterious to the recipient, and neither biologically nor otherwise undesirable.</p>
<p id="p-0035" num="0034">&#x201c;A pharmaceutically acceptable carrier&#x201d; includes both one and more than one carrier. Embodiments include carriers for topical, ocular, parenteral, intravenous, intraperitoneal intramuscular, sublingual, nasal and oral administration. &#x201c;Pharmaceutically acceptable carrier&#x201d; also includes agents for preparation of aqueous dispersions and sterile powders for injection or dispersions.</p>
<p id="p-0036" num="0035">&#x201c;Excipient&#x201d; refers to a physiologically compatible additives useful in preparation of a pharmaceutical composition. Examples of pharmaceutically acceptable carriers and excipients can for example be found in Remington Pharmaceutical Science, 16th Ed.</p>
<p id="p-0037" num="0036">&#x201c;Therapeutically effective amount&#x201d; refers to a dosage of the compounds or compositions effective for influencing, increasing, decreasing the activity of a receptor, in particular a prostaglandin receptor in a mammal. This term as used herein may also refer to an amount effective at bringing about a desired in vivo effect in a mammal, preferably, a human, such as reduction in intraocular pressure.</p>
<p id="p-0038" num="0037">&#x201c;Administering&#x201d; refers to administration of the compounds as needed to achieve the desired effect.</p>
<p id="p-0039" num="0038">&#x201c;Eye disease&#x201d; includes, but is not limited to, glaucoma, allergy, cancers of the eye, neurodegenerative diseases of the eye, and dry eye.</p>
<p id="p-0040" num="0039">The term &#x201c;contacting a cell&#x201d; is used to mean contacting a cell in vitro or in vivo (i.e. within a subject, such as a mammal, including humans, rabbits, cats and dogs).</p>
<p id="h-0006" num="0000">Amino Acid Prostaglandin Salts</p>
<p id="p-0041" num="0040">The present invention is directed to novel amino acid salts of prostaglandin free acids. Suitable salts include those of Formula I below:
<br/>
<?in-line-formulae description="In-line Formulae" end="lead"?>[A]<sup>&#x2212;</sup>[Amino Acid]<sup>+</sup>&#x2003;&#x2003;I<?in-line-formulae description="In-line Formulae" end="tail"?>
</p>
<p id="p-0042" num="0041">wherein [A]<sup>&#x2212;</sup> is an anion of a prostaglandin free acid. The invention also includes all optical isomers, diastereomers and enantiomers of the above salts. In one embodiment, the stereochemistry at all stereocenters is that of the naturally-occurring amino acid and naturally-occurring prostaglandin.</p>
<p id="p-0043" num="0042">In some embodiments, the amino acid is a basic amino acid.</p>
<p id="p-0044" num="0043">In some embodiments, the amino acid prostaglandin salts according to the present invention comprise a prostaglandin free acid of Formula II shown below:</p>
<p id="p-0045" num="0044"><chemistry id="CHEM-US-00001" num="00001">
<img id="EMI-C00001" he="40.39mm" wi="69.93mm" file="US08623918-20140107-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0046" num="0045">or optical isomers, diastereomers, or enantiomers thereof;</p>
<p id="p-0047" num="0046">wherein a and b are, independently, single, double or triple bonds;</p>
<p id="p-0048" num="0047">wherein Q<sub>1</sub>, Q<sub>2</sub>, and Q<sub>3 </sub>are independently selected from hydrogen or an alcohol protecting group;</p>
<p id="p-0049" num="0048">wherein each R<sub>1 </sub>is, independently selected from hydrogen or lower alkyl;</p>
<p id="p-0050" num="0049">wherein Y is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;S(O), &#x2014;SO<sub>2</sub>&#x2014;, &#x2014;C(R<sup>2</sup>)<sub>2</sub>&#x2014;, &#x2014;NR<sup>1</sup>&#x2014;, &#x2014;CR<sup>2</sup>&#x2550;CR<sup>2</sup>&#x2014;, or &#x2014;C&#x2550;C&#x2014;;</p>
<p id="p-0051" num="0050">wherein Z is selected from hydrogen, carbocycle, aryl or heteroaryl;</p>
<p id="p-0052" num="0051">wherein each R<sup>2</sup>, if present, is independently selected from hydrogen, lower alkyl, alkoxy, or hydroxyl; and</p>
<p id="p-0053" num="0052">wherein p, and q are independently an integer of from 0 to 4.</p>
<p id="p-0054" num="0053">Suitably, no carbon atom in Formula II has two or more heteroatoms attached to it unless the two or more heteroatoms are member atoms in a heteroaromatic ring system.</p>
<p id="p-0055" num="0054">In Formula II above, the relative stereochemistry at C<sub>8</sub>, C<sub>9</sub>, and C<sub>12 </sub>is as specified above. That is, the bond between C<sub>7 </sub>and C<sub>8 </sub>is in the &#x3b1; orientation, the alcohol (protected or unprotected) at C<sub>9 </sub>is in the &#x3b1; orientation, and the bond between C<sub>12 </sub>and C<sub>13 </sub>is in the &#x3b2; orientation. The invention also includes optical isomers, diastereomers and enantiomers of the above structure. At all stereocenters where stereochemistry is not defined (e.g. C<sub>11 </sub>and C<sub>15</sub>), both epimers are envisioned. In some embodiments of the present invention, stereochemistry at all such stereocenters of the invention mimic that of naturally occurring PGF<sub>2&#x3b1;</sub>.</p>
<p id="p-0056" num="0055">In some embodiments, Q<sub>1 </sub>is either H or an alcohol protecting group and Q<sub>2 </sub>and Q<sub>3 </sub>are alcohol protecting groups. In other embodiments, Q<sub>1</sub>, Q<sub>2</sub>, and Q<sub>3 </sub>are all alcohol protecting groups and may be different alcohol protecting groups and may be the same alcohol protecting group.</p>
<p id="p-0057" num="0056">Suitable prostaglandin free acids include bimatoprost free acid, fluprostenol free acid, latanoprost free acid, tafluprost free acid and travoprost free acid.</p>
<p id="p-0058" num="0057"><chemistry id="CHEM-US-00002" num="00002">
<img id="EMI-C00002" he="231.65mm" wi="58.00mm" file="US08623918-20140107-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
<chemistry id="CHEM-US-00003" num="00003">
<img id="EMI-C00003" he="151.98mm" wi="58.00mm" file="US08623918-20140107-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0059" num="0058">The amino acid prostaglandin salts of the present invention are readily formulatable and recrystallizable. They generally are dry free-flowing powders with relatively low tackiness and thus are useful in manufacture. Suitably, the salts have a melting point of at least about 35&#xb0; C. or at least about 50&#xb0; C.</p>
<p id="p-0060" num="0059">Amino acid prostaglandin salts according to the present invention include, but are not limited to, those shown below:</p>
<heading id="h-0007" level="1">7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-enyl)cyclopentyl)heptanoic acid, arginine salt</heading>
<p id="p-0061" num="0060"><chemistry id="CHEM-US-00004" num="00004">
<img id="EMI-C00004" he="51.56mm" wi="56.98mm" file="US08623918-20140107-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0008" level="1">7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-4-phenoxybutyl)cyclopentyl)heptanoate, arginine salt</heading>
<p id="p-0062" num="0061"><chemistry id="CHEM-US-00005" num="00005">
<img id="EMI-C00005" he="51.65mm" wi="56.98mm" file="US08623918-20140107-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0009" level="1">Arginyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-phenoxybut-1-enyl)cyclopentyl)hept-5-enoate</heading>
<p id="p-0063" num="0062"><chemistry id="CHEM-US-00006" num="00006">
<img id="EMI-C00006" he="73.15mm" wi="57.91mm" file="US08623918-20140107-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0010" level="1">Arginyl (Z)-7-((1R,2R,3R,5S)-2-((R,E)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl)-3,5-dihydroxy cyclopentyl)hept-5-enoate</heading>
<p id="p-0064" num="0063"><chemistry id="CHEM-US-00007" num="00007">
<img id="EMI-C00007" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0011" level="1">Arginyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoate</heading>
<p id="p-0065" num="0064"><chemistry id="CHEM-US-00008" num="00008">
<img id="EMI-C00008" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0012" level="1">Arginyl (Z)-7-((1R,2R,3R,5S)-2-((R,E)-4-(2-fluorophenoxy)-3-hydroxybut-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoate</heading>
<p id="p-0066" num="0065"><chemistry id="CHEM-US-00009" num="00009">
<img id="EMI-C00009" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0013" level="1">Arginyl (Z)-7-((1R,2R,3R,5S)-2-((R,E)-4-(2-fluorophenylthio)-3-hydroxybut-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoate</heading>
<p id="p-0067" num="0066"><chemistry id="CHEM-US-00010" num="00010">
<img id="EMI-C00010" he="73.15mm" wi="57.91mm" file="US08623918-20140107-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0014" level="1">Arginyl 7-((1R,2R,3R,5S)-2-((R)-5-(2-fluorophenyl)-3-hydroxypent-4-ynyl)-3,5-dihydroxycyclopentyl)heptanoate</heading>
<p id="p-0068" num="0067"><chemistry id="CHEM-US-00011" num="00011">
<img id="EMI-C00011" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0015" level="1">Arginyl 7-((1R,2R,3R,5S)-2-((R)-4-(2-fluorophenylthio)-3-hydroxybutyl)-3,5-dihydroxycyclopentyl)heptanoate</heading>
<p id="p-0069" num="0068"><chemistry id="CHEM-US-00012" num="00012">
<img id="EMI-C00012" he="73.15mm" wi="57.91mm" file="US08623918-20140107-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0016" level="1">Arginyl (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-enyl)-5-oxocyclopentyl)hept-5-enoate</heading>
<p id="p-0070" num="0069"><chemistry id="CHEM-US-00013" num="00013">
<img id="EMI-C00013" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0017" level="1">Arginyl 7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-enyl)-5-oxocyclopentyl)heptanoate</heading>
<p id="p-0071" num="0070"><chemistry id="CHEM-US-00014" num="00014">
<img id="EMI-C00014" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0018" level="1">PGE<sub>1</sub>, Arginine Salt</heading>
<p id="p-0072" num="0071"><chemistry id="CHEM-US-00015" num="00015">
<img id="EMI-C00015" he="73.07mm" wi="57.91mm" file="US08623918-20140107-C00015.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0019" level="1">PGE<sub>2</sub>, Arginine Salt</heading>
<p id="p-0073" num="0072"><chemistry id="CHEM-US-00016" num="00016">
<img id="EMI-C00016" he="73.15mm" wi="57.91mm" file="US08623918-20140107-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<heading id="h-0020" level="1">PGD2 Arginine Salt</heading>
<p id="p-0074" num="0073"><chemistry id="CHEM-US-00017" num="00017">
<img id="EMI-C00017" he="73.15mm" wi="57.91mm" file="US08623918-20140107-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0075" num="0074">Other prostaglandins and related compounds suitable for use in the present invention include, but are not limited to, those found in the following US and World Patents and patent applications, which are incorporated herein by reference.</p>
<p id="p-0076" num="0075">1. 5-Thia-omega substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient. WO 00/3980.</p>
<p id="p-0077" num="0076">2. Aromatic C<sub>16</sub>-C<sub>20</sub>-substituted tetrahydro prostaglandins useful as FP agonists WO 99/12895; U.S. Pat. No. 5,977,173, Nov. 2, 1999.</p>
<p id="p-0078" num="0077">3. Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists WO 99/12898.</p>
<p id="p-0079" num="0078">4. Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists. WO 99/12896, U.S. Pat. No. 6,048,895 Apr. 11, 2000.</p>
<p id="p-0080" num="0079">5. Prostaglandins of the F series U.S. Pat. No. 5,770,759. Jun. 23 1998.</p>
<p id="p-0081" num="0080">6. EP<sub>2</sub>-receptor agonists as neuroprotective agents for the eye WO 99/26629.</p>
<p id="p-0082" num="0081">7. Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension. U.S. Pat. No. 6,030,999, Feb. 29, 2000.</p>
<p id="p-0083" num="0082">8. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents WO 99/25358; U.S. Pat. No. 6,037,364 Mar. 14, 2000.</p>
<p id="p-0084" num="0083">9. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension U.S. Pat. No. 5,889,052, Mar. 30, 1999.</p>
<p id="p-0085" num="0084">10. Cis-delta-4-analogs of prostaglandins as ocular hypotensives. WO 98/21182; U.S. Pat. No. 5,994,397 Nov. 30, 1999.</p>
<p id="p-0086" num="0085">11. Tetrahydrofuran analogs of prostaglandins as ocular hypotensives. WO 98/57930; U.S. Pat. No. 6,025,392 Mar. 14, 2000.</p>
<p id="p-0087" num="0086">12. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy. WO 98/21180.</p>
<p id="p-0088" num="0087">13. Ostaglandins as ocular hypotensives WO 98/57930.</p>
<p id="p-0089" num="0088">14. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives WO 98/57930.</p>
<p id="p-0090" num="0089">15. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension WO 99/32441.</p>
<p id="p-0091" num="0090">16. 13-Thia prostaglandins for use in glaucoma therapy WO 98/39293.</p>
<p id="p-0092" num="0091">17. 162. Alcon Laboratories, Inc. (Sallee V L, Hellberg M R, Klimko P G) 15-Ketal prostaglandins for the treatment of glaucoma or ocular hypertension WO 98/20881.</p>
<p id="p-0093" num="0092">18. 9-Oxa prostaglandin analogs as ocular hypotensives. WO 98/57942.</p>
<p id="p-0094" num="0093">19. 15-Fluoro prostaglandins as ocular hypotensives WO 98/21181.</p>
<p id="p-0095" num="0094">20. 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension WO 98/20880.</p>
<p id="p-0096" num="0095">21. Use of 9-deoxy prostaglandin derivatives to treat glaucoma WO 96/10407.</p>
<p id="p-0097" num="0096">22. Prostaglandin product WO 00/3736.</p>
<p id="p-0098" num="0097">23. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives WO 97/23223.</p>
<p id="p-0099" num="0098">24. EP<sub>2</sub>-receptor agonists as agents for lowering intraocular pressure WO 95/19964.</p>
<p id="p-0100" num="0099">25. Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma. WO 99/02165.</p>
<p id="p-0101" num="0100">26. 8-Iso prostaglandins for glaucoma therapy WO 98/50024; U.S. Pat. No. 6,037,368 Mar. 14 2000.</p>
<p id="p-0102" num="0101">27. Fluorinated prostaglandin derivatives and medicines WO 98/12175.</p>
<p id="h-0021" num="0000">Process for Making Amino Acid Prostaglandin Salts</p>
<p id="p-0103" num="0102">It has surprisingly been discovered that the disadvantages of the difficult procedures used to solidify prostaglandin free acids can be overcome by making a basic amino acid salt of the free acid which can be easily crystallized and/or recrystallized as needed.</p>
<p id="p-0104" num="0103">The general process for making the amino acid prostaglandin salts according to the present invention is depicted below in Scheme I:</p>
<p id="p-0105" num="0104"><chemistry id="CHEM-US-00018" num="00018">
<img id="EMI-C00018" he="53.59mm" wi="46.40mm" file="US08623918-20140107-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0106" num="0105">A prostaglandin free acid is reacted with an amino acid in an appropriate solvent to generate the amino acid prostaglandin salt. Solvents can vary but methanol, ethanol, water, THF are generally acceptable solvents.</p>
<p id="p-0107" num="0106">The temperature of the reaction is suitably kept between &#x2212;78&#xb0; C. and the ambient room temperature (about 20-25&#xb0; C.). Alternatively, the temperature is from about 0&#xb0; C. to about 20&#xb0; C. The reaction is stirred for about 5 minutes to about 4 hours under these conditions until a precipitate forms, at which point the amino acid prostaglandin salt is removed by filtration.</p>
<p id="p-0108" num="0107">The salt may be recrystallized by well-known methods in the art. One suitable method is to dissolve the salt in an alcohol, such as methanol, ethanol or isopropanol, and then add diethyl ether or ethyl acetate until the cloud point, then cool to create a precipitate. The nascent precipitate is then warmed to resolubilize the material and then slowly cooled to create crystals.</p>
<p id="p-0109" num="0108">Prostaglandin free acids can be made from known starting materials and methods known to one of ordinary skill in the art. For example, many are also available from Cayman Chemical Company, Ann Arbor, Mich. In addition, the following reference describes the synthesis of prostaglandins: Corey, E. J.; Weinshenker, N. M.; Schaaf, T. K.; Huber, W <i>J. Am. Chem. Soc., </i>1969, 91, 5675 and Corey, E. J.; Schaaf, T. K.; Huber, W; Koelliker, U.; Weinshenker, N. M.; <i>J. Am. Chem. Soc., </i>1970, 92, 397 (which is incorporated by reference herein).</p>
<p id="p-0110" num="0109">Suitably, the prostaglandin free acid is a compound of Formula II:</p>
<p id="p-0111" num="0110"><chemistry id="CHEM-US-00019" num="00019">
<img id="EMI-C00019" he="40.47mm" wi="69.93mm" file="US08623918-20140107-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0112" num="0111">or optical isomers, diastereomers, or enantiomers thereof;</p>
<p id="p-0113" num="0112">wherein a and b are, independently, single, double or triple bonds;</p>
<p id="p-0114" num="0113">wherein Q<sub>1</sub>, Q<sub>2</sub>, and Q<sub>3 </sub>are independently selected from hydrogen or an alcohol protecting group;</p>
<p id="p-0115" num="0114">wherein each R<sub>1 </sub>is, independently selected from hydrogen or lower alkyl;</p>
<p id="p-0116" num="0115">wherein Y is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;S(O), &#x2014;SO<sub>2</sub>&#x2014;, &#x2014;C(R<sup>2</sup>)<sub>2</sub>&#x2014;, &#x2014;NR<sup>1</sup>&#x2014;, &#x2014;CR<sup>2</sup>&#x2550;CR<sup>2</sup>&#x2014;, or &#x2014;C&#x2550;C&#x2014;;</p>
<p id="p-0117" num="0116">wherein Z is selected from hydrogen, carbocycle, aryl or heteroaryl;</p>
<p id="p-0118" num="0117">wherein each R<sup>2</sup>, if present, is independently selected from hydrogen, lower alkyl, alkoxy, or hydroxyl; and</p>
<p id="p-0119" num="0118">wherein p, and q are independently an integer of from 0 to 4.</p>
<p id="h-0022" num="0000">Synthesis of Prostaglandins</p>
<p id="p-0120" num="0119">The amino acid prostaglandin salts can be converted into prostaglandins or prostaglandin analogs in various ways. In one embodiment, the free acid is recovered by neutralizing the salt. The free acid can then be converted into a prostaglandin analog without isolation. Alternatively, the free acid can be isolated. Once the free acid is isolated, the free acid can be used itself or it can be converted to a prostaglandin analog. For example, the amino acid prostaglandin salts according to the present invention may be converted into prostaglandin analogs by neutralization of the salt, extraction of the free acid into an organic layer, leaving the amino acid behind in the aqueous layer. The organic layer can then, for example, be reacted with an additional reagent to provide a prostaglandin ester. In another embodiment, the salt can be directly converted to a prostaglandin analog without isolation of the free acid.</p>
<p id="p-0121" num="0120">In other embodiments, the salt may be directly converted to a prostaglandin analog by redissolving the salt in a suitable solvent, such as methanol, and adding an additional reagent to convert the salt directly into a prostaglandin analog. Suitable reagents include primary, allylic and benzylic bromides and primary and secondary iodides such as 2-iodopropane or compounds such as bromomethane or iodomethane which make the esters of the free acids, and primary or secondary amines which, in the presence of activating agents such as EDC, produce amides.</p>
<p id="p-0122" num="0121">For example, the salt of a PGF analog may be dissolved in methanol or acetone and 2 equivalents of isopropyl iodide are added. A reaction ensues to make the isopropyl ester of the PGF analog. Isopropyl esters of prostaglandins are suitable for use in the treatment of glaucoma with some PGF analogs. In another embodiment, the salt of a PGF analog may be reacted directly with N-ethyl amine to produce an amide by dissolving the salt in DMF, then adding the amine and EDC, with a small amount of DMAP, and isolating the n-ethyl amide product.</p>
<p id="p-0123" num="0122">If the prostaglandin free acid is desired, it can be recovered by neutralizing the salt. For example, the salt of a PGF analog is neutralized with a 3:1 mixture of saturated aqueous ammonium chloride and 1 molar hydrochloric acid, and then the organic layer, containing the free acid, can be separated from the aquous layer containing the amino acid.</p>
<p id="p-0124" num="0123">A prostaglandin intermediate salt may similarly be either directly converted to a prostaglandin analog by either isolation or by converting the salt directly into a prostaglandin analog or further intermediate thereof as is discussed above.</p>
<p id="h-0023" num="0000">Methods of Treatments Using Amino Acid Prostaglandin Salts</p>
<p id="p-0125" num="0124">The amino acid prostaglandin salts may be used to treat various conditions, including eye disorders, such as glaucoma, osteoporosis, improving nasal patency or treating neurogenic bladder. The amino acid prostaglandin salts of the present invention are also useful in a method of reducing or decreasing intraocular pressure.</p>
<p id="p-0126" num="0125">In one embodiment, a cell is contacted with an amount of an amino acid prostaglandin salt effective to reduce ocular pressure. The term &#x201c;contacting a cell&#x201d; is used to mean contacting a cell in vitro or in vivo (i.e., in a subject, such as a mammal, including humans, rabbits, cats and dogs). In some embodiments, the cell may be contacted as a result of administration of an amino acid prostaglandin salt to a subject. The term &#x201c;administration&#x201d; contemplates any route known to one of ordinary skill in the art, including, but not limited to, oral, topical, parenteral, injection, inhalation, implants, buccal and rectal.</p>
<p id="p-0127" num="0126">An effective amount of an amino acid prostaglandin salt according to the present invention will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the route of administration, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician. For example, an effective amount of the amino acid prostaglandin salts of the present invention for systemic administration is from about 0.01 to about 1000 &#x3bc;g/kg body weight, preferably from about 0.1 to about 100 &#x3bc;g/kg per body weight, most preferably form about 1 to about 50 &#x3bc;g/kg body weight per day. Transdermal dosages would be designed to attain similar serum or plasma levels, based upon techniques known to those skilled in the art of pharmacokinetics and transdermal formulations. Plasma levels for systemic administration are expected to be in the range of 0.01 to 100 ng/mL, more preferably from 0.05 to 50 ng/mL and most preferably from 0.1 to 10 ng/mL. While these dosages are based upon a daily administration rate, the amino acid prostaglandin salts of the present invention may also be administered at other intervals, such as twice per day, twice weekly, once weekly, or once a month. One of ordinary skill in the art would be able to calculate suitable effective amounts for other intervals of administration.</p>
<p id="h-0024" num="0000">Compositions Comprising Amino Acid Prostaglandin Salts</p>
<p id="p-0128" num="0127">In one embodiment, the amino acid prostaglandin salts are administered in a pharmaceutically acceptable composition, such as in or with a pharmaceutically acceptable carrier.</p>
<p id="p-0129" num="0128">Compositions may include one or more of the isoforms of the amino acid prostaglandin salts of the present invention. When racemates exists, each enantiomer or diastereomer may be separately used, or they may be combined in any proportion. Where tautomers exist all possible tautomers are specifically contemplated.</p>
<p id="p-0130" num="0129">Pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the amino acid prostaglandin salts may be formulated for administration by, for example, solid dosing, eyedrop, in a topical oil-based formulation, injection, inhalation (either through the mouth or the nose), implants, or oral, buccal, parenteral or rectal administration. Techniques and formulations may generally be found in &#x201c;Remington's Pharmaceutical Sciences&#x201d;, (Meade Publishing Co., Easton, Pa.).</p>
<p id="p-0131" num="0130">The route by which the amino acid prostaglandin salts of the present invention (component A) will be administered and the form of the composition will dictate the type of carrier (component B) to be used. The composition may be in a variety of forms, suitable, for example, for systemic administration (e.g., oral, rectal, nasal, sublingual, buccal, implants, or parenteral) or topical administration (e.g., local application on the skin, ocular, liposome delivery systems, or iontophoresis).</p>
<p id="p-0132" num="0131">Carriers for systemic administration typically comprise at least one of a) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, h) antioxidants, j) preservatives, k) glidants, m) solvents, n) suspending agents, o) wetting agents, p) surfactants, combinations thereof, and others. All carriers are optional in the systemic compositions.</p>
<p id="p-0133" num="0132">Ingredient a) is a diluent. Suitable diluents for solid dosage forms include sugars such as glucose, lactose, dextrose, and sucrose; diols such as propylene glycol; calcium carbonate; sodium carbonate; sugar alcohols, such as glycerin; mannitol; and sorbitol. The amount of ingredient a) in the systemic or topical composition is typically about 50 to about 90%.</p>
<p id="p-0134" num="0133">Ingredient b) is a lubricant. Suitable lubricants for solid dosage forms are exemplified by solid lubricants including silica, talc, stearic acid and its magnesium salts and calcium salts, calcium sulfate; and liquid lubricants such as polyethylene glycol and vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma. The amount of ingredient b) in the systemic or topical composition is typically about 5 to about 10%.</p>
<p id="p-0135" num="0134">Ingredient c) is a binder. Suitable binders for solid dosage forms include polyvinyl pyrrolidone; magnesium aluminum silicate; starches such as corn starch and potato starch; gelatin; tragacanth; and cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, methylcellulose, microcrystalline cellulose, and sodium carboxymethylcellulose. The amount of ingredient c) in the systemic composition is typically about 5 to about 50%, and in ocular solid dosing forms up to 99%.</p>
<p id="p-0136" num="0135">Ingredient d) is a disintegrant. Suitable disintegrants for solid dosage forms include agar, alginic acid and the sodium salt thereof, effervescent mixtures, croscarmelose, crospovidone, sodium carboxymethyl starch, sodium starch glycolate, clays, and ion exchange resins. The amount of ingredient d) in the systemic or topical composition is typically about 0.1 to about 10%.</p>
<p id="p-0137" num="0136">Ingredient e) for solid dosage forms is a colorant such as an FD&#x26;C dye. When used, the amount of ingredient e) in the systemic or topical composition is typically about 0.005 to about 0.1%.</p>
<p id="p-0138" num="0137">Ingredient f) for solid dosage forms is a flavor such as menthol, peppermint, and fruit flavors. The amount of ingredient f), when used, in the systemic or topical composition is typically about 0.1 to about 1.0%.</p>
<p id="p-0139" num="0138">Ingredient g) for solid dosage forms is a sweetener such as aspartame and saccharin. The amount of ingredient g) in the systemic or topical composition is typically about 0.001 to about 1%.</p>
<p id="p-0140" num="0139">Ingredient h) is an antioxidant such as butylated hydroxyanisole (&#x201c;BHA&#x201d;), butylated hydroxytoluene (&#x201c;BHT&#x201d;), and vitamin E. The amount of ingredient h) in the systemic or topical composition is typically about 0.1 to about 5%.</p>
<p id="p-0141" num="0140">Ingredient j) is a preservative such as benzalkonium chloride, methyl paraben and sodium benzoate. The amount of ingredient j) in the systemic or topical composition is typically about 0.01 to about 5%.</p>
<p id="p-0142" num="0141">Ingredient k) for solid dosage forms is a glidant such as silicon dioxide. The amount of ingredient k) in the systemic or topical composition is typically about 1 to about 5%.</p>
<p id="p-0143" num="0142">Ingredient m) is a solvent, such as water, isotonic saline, ethyl oleate, glycerine, hydroxylated castor oils, alcohols such as ethanol, and phosphate buffer solutions. The amount of ingredient m) in the systemic or topical composition is typically from about 0 to about 100%.</p>
<p id="p-0144" num="0143">Ingredient n) is a suspending agent. Suitable suspending agents include Avicel&#xae; RC-591 (from FMC Corporation of Philadelphia, Pa.) and sodium alginate. The amount of ingredient n) in the systemic or topical composition is typically about 1 to about 8%.</p>
<p id="p-0145" num="0144">Ingredient o) is a surfactant such as lecithin, Polysorbate 80, and sodium lauryl sulfate, and the TWEENS&#xae; from Atlas Powder Company of Wilmington, Del. Suitable surfactants include those disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592; Remington's Pharmaceutical Sciences, 15th Ed. 1975, pp. 335-337; and McCutcheon's Volume 1, Emulsifiers &#x26; Detergents, 1994, North American Edition, pp. 236-239. The amount of ingredient o) in the systemic or topical composition is typically about 0.1% to about 5%.</p>
<p id="p-0146" num="0145">Although the amounts of components A and B in the systemic compositions will vary depending on the type of systemic composition prepared, the specific derivative selected for component A and the ingredients of component B, in general, system compositions comprise 0.01% to 50% of component A and 50 to 99.99% of component B.</p>
<p id="p-0147" num="0146">Compositions for parenteral administration typically comprise A) 0.1 to 10% of the amino acid prostaglandin salts of the present invention and B) 90 to 99.9% of a carrier comprising a) a diluent and m) a solvent. In one embodiment, component a) comprises propylene glycol and m) comprises ethanol or ethyl oleate.</p>
<p id="p-0148" num="0147">Compositions for oral administration can have various dosage forms. For example, solid forms include tablets, capsules, granules, and bulk powders. These oral dosage forms comprise a safe and effective amount, usually at least about 5%, and more particularly from about 25% to about 50% of component A). The oral dosage compositions further comprise about 50 to about 95% of component B), and more particularly, from about 50 to about 75%.</p>
<p id="p-0149" num="0148">Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed. Tablets typically comprise component A, and component B a carrier comprising ingredients selected from the group consisting of a) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, k) glidants, and combinations thereof. Specific diluents include calcium carbonate, sodium carbonate, mannitol, lactose and cellulose. Specific binders include starch, gelatin, and sucrose. Specific disintegrants include alginic acid and croscarmelose. Specific lubricants include magnesium stearate, stearic acid, and talc. Specific colorants are the FD&#x26;C dyes, which can be added for appearance. Chewable tablets preferably contain g) sweeteners such as aspartame and saccharin, or f) flavors such as menthol, peppermint, fruit flavors, or a combination thereof.</p>
<p id="p-0150" num="0149">Capsules (including implants, time release and sustained release formulations) typically comprise component A, and a carrier comprising one or more a) diluents disclosed above in a capsule comprising gelatin. Granules typically comprise component A, and preferably further comprise k) glidants such as silicon dioxide to improve flow characteristics. Implants can be of the biodegradable or the non-biodegradable type. Implants may be prepared using any known biocompatible formulation.</p>
<p id="p-0151" num="0150">The selection of ingredients in the carrier for oral compositions depends on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of this invention. One skilled in the art would know how to select appropriate ingredients without undue experimentation.</p>
<p id="p-0152" num="0151">The solid compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that component A is released in the gastrointestinal tract in the vicinity of the desired application, or at various points and times to extend the desired action. The coatings typically comprise one or more components selected from the group consisting of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, EUDRAGIT&#xae; coatings (available from Rohm &#x26; Haas G.M.B.H. of Darmstadt, Germany), waxes and shellac.</p>
<p id="p-0153" num="0152">Compositions for oral administration can also have liquid forms. For example, suitable liquid forms include aqueous solutions, emulsions, suspensions, solutions reconstituted from non-effervescent granules, suspensions reconstituted from non-effervescent granules, effervescent preparations reconstituted from effervescent granules, elixirs, tinctures, syrups, and the like. Liquid orally administered compositions typically comprise component A and component B, namely, a carrier comprising ingredients selected from the group consisting of a) diluents, e) colorants, f) flavors, g) sweeteners, j) preservatives, m) solvents, n) suspending agents, and o) surfactants. Peroral liquid compositions preferably comprise one or more ingredients selected from the group consisting of e) colorants, f) flavors, and g) sweeteners.</p>
<p id="p-0154" num="0153">Other compositions useful for attaining systemic delivery of the subject amino acid prostaglandin salts include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as a) diluents including sucrose, sorbitol and mannitol; and c) binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Such compositions may further comprise b) lubricants, e) colorants, f) flavors, g) sweeteners, h) antioxidants, and k) glidants.</p>
<p id="p-0155" num="0154">In one embodiment of the invention, the amino acid prostaglandin salts of the present invention are topically administered. Topical compositions that can be applied locally to the eye may be in any form known in the art, non-limiting Examples of which include solids, gelable drops, sprays, ointments, or a sustained or non-sustained release unit placed in the conjunctival cul-du-sac of the eye or another appropriate location.</p>
<p id="p-0156" num="0155">Topical compositions that can be applied locally to the skin may be in any form including solids, solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, skin patches, and the like. Topical compositions comprise: component A, the amino acid prostaglandin salts described above, and component B, a carrier. The carrier of the topical composition preferably aids penetration of the amino acid prostaglandin salts into the eye. Component B may further comprise one or more optional components.</p>
<p id="p-0157" num="0156">The exact amounts of each component in the topical composition depend on various factors. The amount of component A added to the topical composition is dependent on the IC50 of component A, typically expressed in nanomolar (nM) units. For example, if the IC50 of the medicament is 1 nM, the amount of component A will be from about 0.001 to about 0.3%. If the IC50 of the medicament is 10 nM, the amount of component A) will be from about 0.01 to about 1%. If the IC50 of the medicament is 100 nM, the amount of component A will be from about 0.1 to about 10%. If the IC50 of the medicament is 1000 nM, the amount of component A will be 1 to 100%, preferably 5% to 50%. If the amount of component A is outside the ranges specified above (i.e., lower), efficacy of the treatment may be reduced. One skilled in the art understands how to calculate and understand an IC50. The remainder of the composition, up to 100%, is component B.</p>
<p id="p-0158" num="0157">The amount of the carrier employed in conjunction with component A is sufficient to provide a practical quantity of composition for administration per unit dose of the medicament. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references: Modern Pharmaceutics, Chapters 9 and 10, Banker &#x26; Rhodes, eds. (1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2nd Ed., (1976).</p>
<p id="p-0159" num="0158">Component B may comprise a single ingredient or a combination of two or more ingredients. In the topical compositions, component B comprises a topical carrier. Suitable topical carriers comprise one or more ingredients selected from the group consisting of phosphate buffered saline, isotonic water, deionized water, monofunctional alcohols, symmetrical alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, dimethyl isosorbide, castor oil, combinations thereof, and the like. More particularly, carriers for skin applications include propylene glycol, dimethyl isosorbide, and water, and even more particularly, phosphate buffered saline, isotonic water, deionized water, monofunctional alcohols and symmetrical alcohols.</p>
<p id="p-0160" num="0159">The carrier of the topical composition may further comprise one or more ingredients selected from the group consisting of q) emollients, r) propellants, s) solvents, t) humectants, u) thickeners, v) powders, w) fragrances, x) pigments, and y) preservatives.</p>
<p id="p-0161" num="0160">Ingredient q) is an emollient. The amount of ingredient q) in a skin-based topical composition is typically about 5 to about 95%. Suitable emollients include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate, and combinations thereof. Specific emollients for skin include stearyl alcohol and polydimethylsiloxane.</p>
<p id="p-0162" num="0161">Ingredient r) is a propellant. The amount of ingredient r) in the topical composition is typically about 0 to about 95%. Suitable propellants include propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide, and combinations thereof.</p>
<p id="p-0163" num="0162">Ingredient s) is a solvent. The amount of ingredient s) in the topical composition is typically about 0 to about 95%. Suitable solvents include water, ethyl alcohol, methylene chloride, isopropanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulfoxide, dimethyl formamide, tetrahydrofuran, and combinations thereof. Specific solvents include water, ethyl alcohol and propylene glycol.</p>
<p id="p-0164" num="0163">Ingredient t) is a humectant. The amount of ingredient t) in the topical composition is typically 0 to 95%. Suitable humectants include glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and combinations thereof. Specific humectants include glycerin.</p>
<p id="p-0165" num="0164">Ingredient u) is a thickener. The amount of ingredient u) in the topical composition is typically about 0 to about 95%.</p>
<p id="p-0166" num="0165">Ingredient v) is a powder. The amount of ingredient v) in the topical composition is typically 0 to 95%. Suitable powders include beta-cyclodextrins, hydroxypropyl cyclodextrins, chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically-modified magnesium aluminum silicate, organically-modified Montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, and combinations thereof. For ocular applications, specific powders include beta-cyclodextrin, hydroxypropyl cyclodextrin, and sodium polyacrylate. For gel dosing ocular formulations, sodium polyacrylate may be used.</p>
<p id="p-0167" num="0166">Ingredient w) is a fragrance. The amount of ingredient w) in the topical composition is typically about 0 to about 0.5%, particularly, about 0.001 to about 0.1%. For ocular applications a fragrance is not typically used.</p>
<p id="p-0168" num="0167">Ingredient x) is a pigment. Suitable pigments for skin applications include inorganic pigments, organic lake pigments, pearlescent pigments, and mixtures thereof. Inorganic pigments useful in this invention include those selected from the group consisting of rutile or anatase titanium dioxide, coded in the Color Index under the reference CI 77,891; black, yellow, red and brown iron oxides, coded under references CI 77,499, 77,492 and, 77,491; manganese violet (CI 77,742); ultramarine blue (CI 77,007); chromium oxide (CI 77,288); chromium hydrate (CI 77,289); and ferric blue (CI 77,510) and mixtures thereof.</p>
<p id="p-0169" num="0168">The organic pigments and lakes useful in this invention include those selected from the group consisting of D&#x26;C Red No. 19 (CI 45,170), D&#x26;C Red No. 9 (CI 15,585), D&#x26;C Red No. 21 (CI 45,380), D&#x26;C Orange No. 4 (CI 15,510), D&#x26;C Orange No. 5 (CI 45,370), D&#x26;C Red No. 27 (CI 45,410), D&#x26;C Red No. 13 (CI 15,630), D&#x26;C Red No. 7 (CI 15,850), D&#x26;C Red No. 6 (CI 15,850), D&#x26;C Yellow No. 5 (CI 19,140), D&#x26;C Red No. 36 (CI 12,085), D&#x26;C Orange No. 10 (CI 45,425), D&#x26;C Yellow No. 6 (CI 15,985), D&#x26;C Red No. 30 (CI 73,360), D&#x26;C Red No. 3 (CI 45,430), the dye or lakes based on Cochineal Carmine (CI 75,570) and mixtures thereof.</p>
<p id="p-0170" num="0169">The pearlescent pigments useful in this invention include those selected from the group consisting of the white pearlescent pigments such as mica coated with titanium oxide, bismuth oxychloride, colored pearlescent pigments such as titanium mica with iron oxides, titanium mica with ferric blue, chromium oxide and the like, titanium mica with an organic pigment of the above-mentioned type as well as those based on bismuth oxychloride and mixtures thereof. The amount of pigment in the topical composition is typically about 0 to about 10%. For ocular applications a pigment is generally not used.</p>
<p id="p-0171" num="0170">In a particularly preferred embodiment of the invention, topical pharmaceutical compositions for ocular administration are prepared typically comprising component A and B (a carrier), such as purified water, and one or more ingredients selected from the group consisting of y) sugars or sugar alcohols such as dextrans, particularly mannitol and dextran 70, z) cellulose or a derivative thereof, aa) a salt, bb) disodium EDTA (Edetate disodium), and cc) a pH adjusting additive.</p>
<p id="p-0172" num="0171">Examples of z) cellulose derivatives suitable for use in the topical pharmaceutical composition for ocular administration include sodium carboxymethylcellulose, ethylcellulose, methylcellulose, and hydroxypropyl-methylcellulose, particularly, hydroxypropyl-methylcellulose.</p>
<p id="p-0173" num="0172">Examples of aa) salts suitable for use in the topical pharmaceutical composition for ocular administration include mono-, di- and trisodium phosphate, sodium chloride, potassium chloride, and combinations thereof.</p>
<p id="p-0174" num="0173">Examples of cc) pH adjusting additives include HCl or NaOH in amounts sufficient to adjust the pH of the topical pharmaceutical composition for ocular administration to 5.0-7.5.</p>
<p id="p-0175" num="0174">Component A may be included in kits comprising component A, a systemic or topical composition described above, or both; and information, instructions, or both that use of the kit will provide treatment for cosmetic and medical conditions in mammals (particularly humans). The information and instructions may be in the form of words, pictures, or both, and the like. In addition or in the alternative, the kit may comprise the medicament, a composition, or both; and information, instructions, or both, regarding methods of application of medicament, or of composition, preferably with the benefit of treating or preventing cosmetic and medical conditions in mammals (e.g., humans).</p>
<heading id="h-0025" level="1">EXAMPLES</heading>
<p id="p-0176" num="0175">The following non-limiting examples further illustrate the processes of the present invention:</p>
<heading id="h-0026" level="1">Example 1</heading>
<p id="h-0027" num="0000">Preparation of Latanoprost Arginine Salt (E1):</p>
<p id="p-0177" num="0176"><chemistry id="CHEM-US-00020" num="00020">
<img id="EMI-C00020" he="72.56mm" wi="75.86mm" file="US08623918-20140107-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0178" num="0177">To Latanoprost free acid (CAS #41639-83-2) (1, 21.2 mg, 0.054 mmol) in MeOH/H<sub>2</sub>O (4:1, 0.65 mL) was added L-Arginine (&#x3e;98%, Sigma-Aldrich, St. Louis, Mo.). (72 mM solution in MeOH/H<sub>2</sub>O [4:1]) (754 &#x3bc;L, 0.054 mmol) and the solution was stirred for 30 minutes. The solvents were evaporated then azeotroped with Et<sub>2</sub>O and hexanes to give white crystalline Latanoprost-L-Arginine salt 2 (quantitative).</p>
<p id="p-0179" num="0178">Recrystallization:</p>
<p id="p-0180" num="0179">To 26.5 mg of 1 in a 4 mL vial was added approx 0.5 mL of MeOH to dissolve, followed by 1.2-1.5 mL of Et<sub>2</sub>O which precipitated out the product. The vial was put on ice for 5 min. The liquid was decanted and the solid dried to give pure 2, 22.9 mg.</p>
<heading id="h-0028" level="1">Example 2</heading>
<p id="p-0181" num="0180">Using substantially the same procedure, but substituting PGE<sub>2 </sub>free acid (CAS #: 363-24-6) for latanoprost free acid the arginine salt of PGE<sub>2 </sub>can be made.</p>
<heading id="h-0029" level="1">Examples 3-71</heading>
<p id="p-0182" num="0181">Arginine salts of the following commercially-available prostaglandins can be made by following the above procedure and substituting the appropriate prostaglandin free acid</p>
<p id="p-0183" num="0182">
<tables id="TABLE-US-00001" num="00001">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="35pt" align="center"/>
<colspec colname="2" colwidth="140pt" align="left"/>
<colspec colname="3" colwidth="42pt" align="left"/>
<thead>
<row>
<entry namest="1" nameend="3" align="center" rowsep="1"/>
</row>
<row>
<entry>Example</entry>
<entry>Free acid name</entry>
<entry>CAS #</entry>
</row>
<row>
<entry namest="1" nameend="3" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry/>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="35pt" align="char" char="."/>
<colspec colname="2" colwidth="140pt" align="left"/>
<colspec colname="3" colwidth="42pt" align="left"/>
<tbody valign="top">
<row>
<entry>3</entry>
<entry>8-iso Prostaglandin F2&#x3b1;</entry>
<entry>27415-26-5</entry>
</row>
<row>
<entry>4</entry>
<entry>Prostaglandin D2</entry>
<entry>41598-07-6</entry>
</row>
<row>
<entry>5</entry>
<entry>Prostaglandin E1</entry>
<entry>745-65-3</entry>
</row>
<row>
<entry>6</entry>
<entry>Prostaglandin F2&#x3b1;</entry>
<entry>551-11-1</entry>
</row>
<row>
<entry>7</entry>
<entry>Prostaglandin D3</entry>
<entry>71902-47-1</entry>
</row>
<row>
<entry>8</entry>
<entry>16,16-dimethyl Prostaglandin E2</entry>
<entry>39746-25-3</entry>
</row>
<row>
<entry>9</entry>
<entry>Butaprost (free acid)</entry>
<entry>433219-55-7</entry>
</row>
<row>
<entry>10</entry>
<entry>Tafluprost (free acid)</entry>
<entry>209860-88-8</entry>
</row>
<row>
<entry>11</entry>
<entry>Bimatoprost (free acid)</entry>
</row>
<row>
<entry>12</entry>
<entry>Prostaglandin A1</entry>
<entry>14152-28-4</entry>
</row>
<row>
<entry>13</entry>
<entry>Travoprost (free acid)</entry>
</row>
<row>
<entry>14</entry>
<entry>Latanoprost (free acid)-d4</entry>
</row>
<row>
<entry>15</entry>
<entry>17-phenyl trinor Prostaglandin E2</entry>
<entry>38315-43-4</entry>
</row>
<row>
<entry>16</entry>
<entry>15(S)-Latanoprost (free acid)</entry>
</row>
<row>
<entry>17</entry>
<entry>AL 8810</entry>
<entry>246246-19-5</entry>
</row>
<row>
<entry>18</entry>
<entry>Bimatoprost (free acid)</entry>
<entry>38344-08-0</entry>
</row>
<row>
<entry>19</entry>
<entry>(+)-15-epi Cloprostenol</entry>
<entry>54276-22-1</entry>
</row>
<row>
<entry>20</entry>
<entry>15-keto Latanoprost (free acid)</entry>
</row>
<row>
<entry>21</entry>
<entry>Prostaglandin E3</entry>
<entry>802-31-3</entry>
</row>
<row>
<entry>22</entry>
<entry>Limaprost</entry>
<entry>74397-12-9</entry>
</row>
<row>
<entry>23</entry>
<entry>(+)-Fluprostenol (also know as travoprost</entry>
<entry>54276-17-4</entry>
</row>
<row>
<entry/>
<entry>free acid)</entry>
</row>
<row>
<entry>24</entry>
<entry>BW 245C</entry>
<entry>72814-32-5</entry>
</row>
<row>
<entry>25</entry>
<entry>&#x394;12-Prostaglandin J2</entry>
<entry>87893-54-7</entry>
</row>
<row>
<entry>26</entry>
<entry>11&#x3b2;-Prostaglandin F2&#x3b1;</entry>
<entry>38432-87-0</entry>
</row>
<row>
<entry>27</entry>
<entry>5-trans Prostaglandin E2</entry>
<entry>36150-00-2</entry>
</row>
<row>
<entry>28</entry>
<entry>19(R)-hydroxy Prostaglandin E2</entry>
<entry>64625-54-3</entry>
</row>
<row>
<entry>29</entry>
<entry>Fluprostenol (racemic)</entry>
<entry>40666-16-8</entry>
</row>
<row>
<entry>30</entry>
<entry>Prostaglandin F2&#x3b2;</entry>
<entry>4510-16-1</entry>
</row>
<row>
<entry>31</entry>
<entry>16-phenoxy tetranor Prostaglandin E2</entry>
</row>
<row>
<entry>32</entry>
<entry>(+)-Cloprostenol</entry>
<entry>54276-21-0</entry>
</row>
<row>
<entry>33</entry>
<entry>20-hydroxy Prostaglandin E2</entry>
<entry>57930-95-7</entry>
</row>
<row>
<entry>34</entry>
<entry>17,20-dimethyl Prostaglandin F1&#x3b1;</entry>
</row>
<row>
<entry>35</entry>
<entry>(+)-Cloprostenol</entry>
</row>
<row>
<entry>36</entry>
<entry>9-keto Fluprostenol</entry>
<entry>156406-33-6</entry>
</row>
<row>
<entry>37</entry>
<entry>Prostaglandin F1&#x3b1;</entry>
<entry>745-62-0</entry>
</row>
<row>
<entry>38</entry>
<entry>15(S)-Fluprostenol</entry>
</row>
<row>
<entry>39</entry>
<entry>5-trans Prostaglandin F2&#x3b2;</entry>
<entry>36150-02-4</entry>
</row>
<row>
<entry>40</entry>
<entry>15-keto-17-phenyl trinor Prostaglandin F2&#x3b1;</entry>
</row>
<row>
<entry>41</entry>
<entry>15-cyclohexyl pentanor Prostaglandin F2&#x3b1;</entry>
<entry>58611-97-5</entry>
</row>
<row>
<entry>42</entry>
<entry>Cloprostenol (racemic)</entry>
</row>
<row>
<entry>43</entry>
<entry>Prostaglandin F1&#x3b2;</entry>
<entry>10164-73-5</entry>
</row>
<row>
<entry>44</entry>
<entry>3-methoxy Limaprost</entry>
</row>
<row>
<entry>45</entry>
<entry>13,14-dihydro Prostaglandin F2&#x3b1;</entry>
<entry>27376-74-5</entry>
</row>
<row>
<entry>46</entry>
<entry>15(R)-15-methyl Prostaglandin E2</entry>
<entry>55028-70-1</entry>
</row>
<row>
<entry>47</entry>
<entry>19(R)-hydroxy Prostaglandin E1</entry>
<entry>64625-55-4</entry>
</row>
<row>
<entry>48</entry>
<entry>9-deoxy-9-methylene Prostaglandin E2</entry>
<entry>61263-32-9</entry>
</row>
<row>
<entry>49</entry>
<entry>16-phenyl tetranor Prostaglandin E1</entry>
</row>
<row>
<entry>50</entry>
<entry>11-deoxy Prostaglandin F1&#x3b1;</entry>
<entry>37785-98-1</entry>
</row>
<row>
<entry>51</entry>
<entry>19(R)-hydroxy Prostaglandin F1&#x3b1;</entry>
<entry>81371-59-7</entry>
</row>
<row>
<entry>52</entry>
<entry>19(R)-hydroxy Prostaglandin F2&#x3b1;</entry>
<entry>64625-53-2</entry>
</row>
<row>
<entry>53</entry>
<entry>1a,1b-dihomo Prostaglandin F2&#x3b1;</entry>
<entry>57944-39-5</entry>
</row>
<row>
<entry>54</entry>
<entry>15(R),19(R)-hydroxy Prostaglandin F2&#x3b1;</entry>
</row>
<row>
<entry>55</entry>
<entry>16-phenoxy tetranor Prostaglandin F2&#x3b1;</entry>
<entry>51705-19-2</entry>
</row>
<row>
<entry>56</entry>
<entry>11-deoxy Prostaglandin F1&#x3b2;</entry>
<entry>37785-99-2</entry>
</row>
<row>
<entry>57</entry>
<entry>11-deoxy Prostaglandin F2&#x3b2;</entry>
<entry>37786-07-5</entry>
</row>
<row>
<entry>58</entry>
<entry>11&#x3b2;-Prostaglandin F1&#x3b2;</entry>
<entry>37785-86-7</entry>
</row>
<row>
<entry>59</entry>
<entry>15-keto Fluprostenol</entry>
</row>
<row>
<entry>60</entry>
<entry>15(S)-15-methyl Prostaglandin F2&#x3b1;</entry>
<entry>35700-23-3</entry>
</row>
<row>
<entry>61</entry>
<entry>16,16-dimethyl Prostaglandin E1</entry>
<entry>41692-15-3</entry>
</row>
<row>
<entry>62</entry>
<entry>16,16-dimethyl Prostaglandin F2&#x3b1;</entry>
<entry>39746-23-1</entry>
</row>
<row>
<entry>63</entry>
<entry>17-trifluoromethylphenyl-13,14-dihydro trinor</entry>
</row>
<row>
<entry/>
<entry>Prostaglandin</entry>
</row>
<row>
<entry>64</entry>
<entry>17-trifluoromethylphenyl trinor</entry>
<entry>221246-34-0</entry>
</row>
<row>
<entry/>
<entry>Prostaglandin F2&#x3b1;</entry>
</row>
<row>
<entry>65</entry>
<entry>Bimatoprost (free acid)-d4</entry>
</row>
<row>
<entry>66</entry>
<entry>(+)-Fluprostenol-d4</entry>
</row>
<row>
<entry>67</entry>
<entry>Prostaglandin B2</entry>
<entry>13367-85-6</entry>
</row>
<row>
<entry>68</entry>
<entry>Prostaglandin B3</entry>
<entry>36614-32-1</entry>
</row>
<row>
<entry>69</entry>
<entry>17-phenyl trinor Prostaglandin A2</entry>
</row>
<row>
<entry>70</entry>
<entry>(S)-AL 8810</entry>
</row>
<row>
<entry>71</entry>
<entry>Lubiprostone</entry>
<entry>136790-76-6</entry>
</row>
<row>
<entry namest="1" nameend="3" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
</p>
<heading id="h-0030" level="1">Example 72</heading>
<p id="p-0184" num="0183">To Latanoprost (free acid) (1, 21.2 mg, 0.054 mmol) in MeOH/H<sub>2</sub>O (4:1, 0.65 mL) was added L-Arginine (72 mM solution in MeOH/H<sub>2</sub>O [4:1]) (754 &#x3bc;L, 0.054 mmol) ((&#x3e;98%) from Sigma-Aldrich Cat. A5006) and the solution was stirred for 30 minutes. The solvents were evaporated then azeotroped with Et<sub>2</sub>O and hexanes to give white crystalline Latanoprost-L-Arginine salt 2 (quantitative).</p>
<p id="p-0185" num="0184">Recrystallization:</p>
<p id="p-0186" num="0185">To 26.5 mg of 1 in a 4 mL vial was added approx 0.5 mL of MeOH to dissolve, followed by 1.2-1.5 mL of Et<sub>2</sub>O which precipitated out the product. The vial was put on ice for 5 min. The liquid was decanted and the solid dried to give pure 2, 22.9 mg.</p>
<heading id="h-0031" level="1">Example 73</heading>
<p id="p-0187" num="0186">To travoprost free acid ((+)-fluprostenol free acid) 3 in MeOH/H<sub>2</sub>O was added L-Arginine (&#x3e;98%) (Sigma-Aldrich Cat. A5006) and the solution was stirred for 30 minutes. The solvents were evaporated then azeotroped with Et<sub>2</sub>O and hexanes to give white crystalline travoprost-L-Arginine salt 4 (quantitative).</p>
<p id="p-0188" num="0187"><chemistry id="CHEM-US-00021" num="00021">
<img id="EMI-C00021" he="75.61mm" wi="75.86mm" file="US08623918-20140107-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0189" num="0188">Recrystallization:</p>
<p id="p-0190" num="0189">To 4 is added enough MeOH to dissolve, and is followed by Et<sub>2</sub>O to the cloud point, then warmed to redissolved and slowly cooled overnight. The liquid is decanted and the solid is dried to give pure 4.</p>
<heading id="h-0032" level="1">Example 74</heading>
<p id="p-0191" num="0190"><chemistry id="CHEM-US-00022" num="00022">
<img id="EMI-C00022" he="80.26mm" wi="75.86mm" file="US08623918-20140107-C00022.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0192" num="0191">To travoprost free acid ((+)-fluprostenol free acid) 3 in MeOH/H<sub>2</sub>O is added L-Homoarginine and the solution is stirred for 30 minutes. The solvents are evaporated then azeotroped with Et<sub>2</sub>O and hexanes to give white crystalline travoprost-L-Homoarginine salt 5 (quantitative).</p>
<p id="p-0193" num="0192">Recrystallization:</p>
<p id="p-0194" num="0193">To 5 was added enough EtOH to dissolve, followed by Et<sub>2</sub>O which precipitated the product. The vial was put on ice for 5 min. The liquid was decanted and the solid dried to give the salt 5.</p>
<heading id="h-0033" level="1">Example 75</heading>
<p id="h-0034" num="0000">Formulation of Liquid Compositions Comprising Present Compounds</p>
<p id="p-0195" num="0194">A composition in liquid form is prepared by conventional methods, formulated as follows:</p>
<heading id="h-0035" level="1">Example 75</heading>
<heading id="h-0036" level="1">Preparation Table</heading>
<p id="p-0196" num="0195">
<tables id="TABLE-US-00002" num="00002">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="35pt" align="left"/>
<colspec colname="1" colwidth="77pt" align="left"/>
<colspec colname="2" colwidth="105pt" align="center"/>
<thead>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
<row>
<entry/>
<entry>Ingredient</entry>
<entry>Quantity</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry/>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="offset" colwidth="35pt" align="left"/>
<colspec colname="1" colwidth="77pt" align="left"/>
<colspec colname="2" colwidth="56pt" align="right"/>
<colspec colname="3" colwidth="49pt" align="left"/>
<tbody valign="top">
<row>
<entry/>
<entry>PGF analog arginine salt</entry>
<entry>0-5</entry>
<entry>mg</entry>
</row>
<row>
<entry/>
<entry>PGE analog arginine</entry>
<entry>0-5</entry>
<entry>mg</entry>
</row>
<row>
<entry/>
<entry>salt</entry>
</row>
<row>
<entry/>
<entry>Propylene glycol</entry>
<entry>5</entry>
<entry>mL</entry>
</row>
<row>
<entry/>
<entry>Ethyl alcohol</entry>
<entry>5</entry>
<entry>mL</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="3" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
<br/>
1.0 mL of the above composition, when administered once a day, substantially increases the beauty and health of the mammalian skin onto which it is applied.
</p>
<heading id="h-0037" level="1">Example 76</heading>
<p id="h-0038" num="0000">Preparation of Skin Care Topical Product Comprising Present Compounds</p>
<p id="p-0197" num="0196">A skin care, topical product is prepared by formulating a cream composition as illustrated below.</p>
<heading id="h-0039" level="1">Example 76</heading>
<heading id="h-0040" level="1">Preparation Table</heading>
<p id="p-0198" num="0197">
<tables id="TABLE-US-00003" num="00003">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="140pt" align="left"/>
<colspec colname="2" colwidth="63pt" align="center"/>
<thead>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
<row>
<entry/>
<entry>Ingredient</entry>
<entry>Quantity</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry/>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="140pt" align="left"/>
<colspec colname="2" colwidth="35pt" align="right"/>
<colspec colname="3" colwidth="28pt" align="left"/>
<tbody valign="top">
<row>
<entry/>
<entry>PGF analog arginine salt</entry>
<entry>50</entry>
<entry>mg</entry>
</row>
<row>
<entry/>
<entry>Isopropyl isosterate</entry>
<entry>150</entry>
<entry>g</entry>
</row>
<row>
<entry/>
<entry>Polyacrylate 13/polyisobutene/Polysorbate 20</entry>
<entry>35</entry>
<entry>g</entry>
</row>
<row>
<entry/>
<entry>Methyl paraben/propyl paraben</entry>
<entry>1</entry>
<entry>g</entry>
</row>
<row>
<entry/>
<entry>Distilled water</entry>
<entry>400</entry>
<entry>g</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="3" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
</p>
<heading id="h-0041" level="1">Example 77</heading>
<p id="h-0042" num="0000">Preparation of Skin Care Wipe Product Comprising Present Compounds</p>
<p id="p-0199" num="0198">A skin care wipe product is prepared by impregnating such a wipe with the liquid composition of Example 75. Such a wipe may be impregnated by techniques known and readily available to those skilled in the art. Indeed, a preferred example of a wipe product is the Oil of Olay Facial Wipes, owned and distributed by The Procter and Gamble Company of Cincinnati, Ohio.</p>
<heading id="h-0043" level="1">Example 78</heading>
<p id="h-0044" num="0000">Shampoos are made, comprising:</p>
<p id="p-0200" num="0199">
<tables id="TABLE-US-00004" num="00004">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="77pt" align="left"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="35pt" align="center"/>
<colspec colname="5" colwidth="35pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"/>
</row>
<row>
<entry>Component</entry>
<entry>Ex. 78-1</entry>
<entry>Ex. 78-2</entry>
<entry>Ex. 78-3</entry>
<entry>Ex. 78-4</entry>
</row>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Ammonium Lauryl</entry>
<entry>11.5%&#x2003;&#x2009;</entry>
<entry>11.5%&#x2003;&#x2009;</entry>
<entry>9.5%&#x2002;&#x2009;</entry>
<entry>7.5%&#x2002;&#x2009;</entry>
</row>
<row>
<entry>Sulfate</entry>
</row>
<row>
<entry>Ammonium Laureth</entry>
<entry>4%</entry>
<entry>3%</entry>
<entry>2%</entry>
<entry>2%</entry>
</row>
<row>
<entry>Sulfate</entry>
</row>
<row>
<entry>Cocamide MEA</entry>
<entry>2%</entry>
<entry>2%</entry>
<entry>2%</entry>
<entry>2%</entry>
</row>
<row>
<entry>Ethylene Glycol</entry>
<entry>2%</entry>
<entry>2%</entry>
<entry>2%</entry>
<entry>2%</entry>
</row>
<row>
<entry>Distearate</entry>
</row>
<row>
<entry>Cetyl Alcohol</entry>
<entry>2%</entry>
<entry>2%</entry>
<entry>2%</entry>
<entry>2%</entry>
</row>
<row>
<entry>Stearyl Alcohol</entry>
<entry>1.2%&#x2002;&#x2009;</entry>
<entry>1.2%&#x2009;&#x2002;</entry>
<entry>1.2%&#x2009;&#x2002;</entry>
<entry>1.2%&#x2009;&#x2002;</entry>
</row>
<row>
<entry>Glycerin</entry>
<entry>1%</entry>
<entry>1%</entry>
<entry>1%</entry>
<entry>1%</entry>
</row>
<row>
<entry>Polyquaternium 10</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.25%&#x2003;&#x2009;</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
</row>
<row>
<entry>Polyquaternium 24</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.25%&#x2003;&#x2009;</entry>
</row>
<row>
<entry>Sodium Chloride</entry>
<entry>0.1%&#x2002;&#x2009;</entry>
<entry>0.1%&#x2002;&#x2009;</entry>
<entry>0.1%&#x2002;&#x2009;</entry>
<entry>0.1%&#x2002;&#x2009;</entry>
</row>
<row>
<entry>Sucrose Polyesters of</entry>
<entry>3%</entry>
<entry>3%</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
</row>
<row>
<entry>Cottonate Fatty Acid</entry>
</row>
<row>
<entry>Sucrose Polyesters of</entry>
<entry>2%</entry>
<entry>3%</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
</row>
<row>
<entry>Behenate Fatty Acid</entry>
</row>
<row>
<entry>Polydimethyl Siloxane</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
<entry>3%</entry>
<entry>2%</entry>
</row>
<row>
<entry>Cocaminopropyl Betaine</entry>
<entry>&#x2014;</entry>
<entry>1%</entry>
<entry>3%</entry>
<entry>3%</entry>
</row>
<row>
<entry>Lauryl Dimethyl</entry>
<entry>1.5%&#x2002;&#x2009;</entry>
<entry>1.5%&#x2002;&#x2009;</entry>
<entry>1.5%&#x2002;&#x2009;</entry>
<entry>1.5%&#x2002;&#x2009;</entry>
</row>
<row>
<entry>Amine Oxide</entry>
</row>
<row>
<entry>Decyl Polyglucose</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
<entry>1%</entry>
<entry>1%</entry>
</row>
<row>
<entry>DMDM Hydantoin</entry>
<entry>0.15%&#x2003;</entry>
<entry>0.15%&#x2003;&#x2009;</entry>
<entry>0.15%&#x2003;&#x2009;</entry>
<entry>0.15%&#x2003;&#x2009;</entry>
</row>
<row>
<entry>PGF analog arginine salt</entry>
<entry>&#x2014;</entry>
<entry>0.2%&#x2002;&#x2009;</entry>
<entry>0.2%&#x2002;&#x2009;</entry>
<entry>&#x2014;</entry>
</row>
<row>
<entry>PGE analog arginine salt</entry>
<entry>0.1%&#x2002;&#x2009;</entry>
<entry>&#x2014;</entry>
<entry>&#x2014;</entry>
<entry>0.1%&#x2002;&#x2009;</entry>
</row>
<row>
<entry>Minoxidil</entry>
<entry/>
<entry/>
<entry>3%</entry>
<entry>2%</entry>
</row>
<row>
<entry>Phenoxyethanol</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
</row>
<row>
<entry>Fragrance</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
<entry>0.5%&#x2002;&#x2009;</entry>
</row>
<row>
<entry>Water</entry>
<entry>q.s.</entry>
<entry>q.s.</entry>
<entry>q.s.</entry>
<entry>q.s.</entry>
</row>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
</p>
<p id="p-0201" num="0200">A human subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 12 weeks, a shampoo described above is used daily by the subject. Approximately one liquid ounce of the formula is applied to the scalp and hair of the subject, left in place for not more than 5 minutes, then rinsed with water.</p>
<heading id="h-0045" level="1">Example 79</heading>
<p id="p-0202" num="0201">Topical pharmaceutical compositions for lowering intraocular pressure are prepared by conventional methods and formulated as follows:</p>
<p id="p-0203" num="0202">
<tables id="TABLE-US-00005" num="00005">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="28pt" align="left"/>
<colspec colname="1" colwidth="98pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="center"/>
<thead>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
<row>
<entry/>
<entry>Ingredient</entry>
<entry>Amount (wt %)</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry/>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="28pt" align="left"/>
<colspec colname="1" colwidth="98pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry/>
<entry>PGF analog arginine salt</entry>
<entry>0.50</entry>
</row>
<row>
<entry/>
<entry>Dextran 70</entry>
<entry>0.1</entry>
</row>
<row>
<entry/>
<entry>Hydroxypropyl methylcellulose</entry>
<entry>0.3</entry>
</row>
<row>
<entry/>
<entry>Sodium Chloride</entry>
<entry>0.77</entry>
</row>
<row>
<entry/>
<entry>Potassium chloride</entry>
<entry>0.12</entry>
</row>
<row>
<entry/>
<entry>Disodium EDTA</entry>
<entry>0.05</entry>
</row>
<row>
<entry/>
<entry>Benzalkonium chloride</entry>
<entry>0.01</entry>
</row>
<row>
<entry/>
<entry>HCl and/or NaOH</entry>
<entry>pH 7.0-7.2</entry>
</row>
<row>
<entry/>
<entry>Purified water</entry>
<entry>q.s. to 100%</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
</p>
<p id="p-0204" num="0203">A compound according to this invention is used as the PF analog arginine salt. When the composition is topically administered to the eyes as a 40 microliter drop instilled into the affected eye once daily, the above composition decreases intraocular pressure in a patient suffering from glaucoma.</p>
<heading id="h-0046" level="1">Example 80</heading>
<p id="p-0205" num="0204">Example 79 is repeated using a PGE analog arginine salt according to this invention. When administered as a drop twice per day, the above composition substantially decreases intraocular pressure.</p>
<heading id="h-0047" level="1">Example 81</heading>
<p id="p-0206" num="0205">Topical pharmaceutical compositions for nasal sprays are prepared by conventional methods and formulated as follows:</p>
<p id="p-0207" num="0206">
<tables id="TABLE-US-00006" num="00006">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="28pt" align="left"/>
<colspec colname="1" colwidth="98pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="center"/>
<thead>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
<row>
<entry/>
<entry>Ingredient</entry>
<entry>Amount (wt %)</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry/>
<entry>PGF analog arginine salt</entry>
<entry>&#x2002;0.1-0.50</entry>
</row>
<row>
<entry/>
<entry>Hydroxypropyl methylcellulose</entry>
<entry>0.0-0.3</entry>
</row>
<row>
<entry/>
<entry>Sorbitol</entry>
<entry>0.61</entry>
</row>
<row>
<entry/>
<entry>EDTA</entry>
<entry>0.05</entry>
</row>
<row>
<entry/>
<entry>Benzalkonium chloride</entry>
<entry>0.01</entry>
</row>
<row>
<entry/>
<entry>HCl and/or NaOH to</entry>
<entry>pH 7.0-7.2</entry>
</row>
<row>
<entry/>
<entry>Purified water</entry>
<entry>q.s. to 100%</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
</p>
<heading id="h-0048" level="1">Example 82</heading>
<p id="p-0208" num="0207">Topical pharmaceutical compositions for instillation, e.g., into a bladder are prepared by conventional methods and formulated as follows:</p>
<p id="p-0209" num="0208">
<tables id="TABLE-US-00007" num="00007">
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="35pt" align="left"/>
<colspec colname="1" colwidth="77pt" align="left"/>
<colspec colname="2" colwidth="105pt" align="center"/>
<thead>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
<row>
<entry/>
<entry>Ingredient</entry>
<entry>Amount (wt %)</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</thead>
<tbody valign="top">
<row>
<entry/>
<entry>PGF analog arginine salt</entry>
<entry>0.1-0.50</entry>
</row>
<row>
<entry/>
<entry>EDTA</entry>
<entry>0.05</entry>
</row>
<row>
<entry/>
<entry>Phosphate buffered saline</entry>
<entry>q.s. to 100%</entry>
</row>
<row>
<entry/>
<entry namest="offset" nameend="2" align="center" rowsep="1"/>
</row>
</tbody>
</tgroup>
</table>
</tables>
</p>
<heading id="h-0049" level="1">Example 83</heading>
<p id="p-0210" num="0209"><chemistry id="CHEM-US-00023" num="00023">
<img id="EMI-C00023" he="76.71mm" wi="103.12mm" file="US08623918-20140107-C00023.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0211" num="0210">To 1.0 gram of Latanoprost L-arginine salt (2) in MeOH/H<sub>2</sub>O (4:1, 20 mL) is added 2.01 equivalents of isopropyl iodide (99%, Cat #148938, Sigma-Aldrich, St. Louis, Mo.). and the solution is stirred overnight. Saturated aqueous ammonium acetate is added along with ethyl acetate and the layers are separated. The organic layer is separated, and the solvents removed in vaccuo, and the material is chromatographed to give latanoprost as the isopropyl ester (6).</p>
<heading id="h-0050" level="1">Example 84</heading>
<p id="p-0212" num="0211"><chemistry id="CHEM-US-00024" num="00024">
<img id="EMI-C00024" he="77.47mm" wi="101.77mm" file="US08623918-20140107-C00024.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0213" num="0212">The procedure of example 83 is repeated substituting fluprostenol for latanoprost and methyl iodide for isopropyl iodide. Isolated is fluprostenol methyl ester (7)</p>
<heading id="h-0051" level="1">Example 85</heading>
<p id="p-0214" num="0213"><chemistry id="CHEM-US-00025" num="00025">
<img id="EMI-C00025" he="77.13mm" wi="106.85mm" file="US08623918-20140107-C00025.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0215" num="0214">To 1.0 gram of Arginyl 7-((1R,2R,3R,5S)-2-((R)-4-(2-fluorophenylthio)-3-hydroxybutyl)-3,5-dihydroxy cyclopentyl)heptanoate (8) in MeOH/H<sub>2</sub>O (4:1, 20 mL) is added, dropwise with cooling, at least 5 equivalents of a 3:1 mixture of saturated aqueous ammonium chloride and 1 M hydrochloric acid (Sigma-Aldrich, St. Louis, Mo.), and the solution is stirred for 15 minutes. Saturated aqueous sodium chloride is added along with ethyl acetate. The organic layer is separated; is washed again with brine; the solvents removed in vaccuo, and the material chromatographed to give the free acid, 7-((1R,2R,3R,5S)-2-((R)-4-(2-fluorophenylthio)-3-hydroxybutyl)-3,5-dihydroxy cyclopentyl)heptanoic acid (9).</p>
<heading id="h-0052" level="1">Example 86</heading>
<p id="p-0216" num="0215"><chemistry id="CHEM-US-00026" num="00026">
<img id="EMI-C00026" he="72.31mm" wi="101.94mm" file="US08623918-20140107-C00026.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0217" num="0216">To 1.0 gram of bimataprost arginine salt (9) in DMF (20 mL) is added 2.01 equivalents of 2M ethyl amine solution in THF (Cat #395072, Sigma-Aldrich, St. Louis, Mo.) and 1.5 eq of EDC. and the solution is stirred overnight. Added is at least 5 equivalents of a 3:1 mixture of saturated aqueous ammonium chloride and 1 M hydrochloric acid (Sigma-Aldrich, St. Louis, Mo.), and the solution is extracted with ethyl acetate, washed and purified. Isolated is bimataprost N-ethyl amide (10)</p>
<heading id="h-0053" level="1">Example 87</heading>
<p id="p-0218" num="0217"><chemistry id="CHEM-US-00027" num="00027">
<img id="EMI-C00027" he="72.31mm" wi="120.48mm" file="US08623918-20140107-C00027.TIF" alt="embedded image" img-content="chem" img-format="tif"/>
</chemistry>
</p>
<p id="p-0219" num="0218">To 1.0 gram of bimataprost arginine salt (9) is added at least 5 equivalents of a 3:1 mixture of saturated aqueous ammonium chloride and 1 M hydrochloric acid (Sigma-Aldrich, St. Louis, Mo.), and the solution is extracted with diethyl ether. The organic layer is then separated, and added are: 20 mL of DMF, 2.01 equivalents of 2M ethyl amine solution in THF (Cat #395072, Sigma-Aldrich, St. Louis, Mo.), 1.5 eq of EDC and 0.2 eq. of DMAP, and the solution is stirred overnight. Then added is at least 5 equivalents of a 3:1 mixture of saturated aqueous ammonium chloride and 1 M hydrochloric acid (Sigma-Aldrich, St. Louis, Mo.), and the solution is extracted with ethyl acetate, washed and purified. Isolated is bimataprost N-ethyl amide (10)</p>
<?DETDESC description="Detailed Description" end="tail"?>
</description>
<us-chemistry idref="CHEM-US-00001" cdx-file="US08623918-20140107-C00001.CDX" mol-file="US08623918-20140107-C00001.MOL"/>
<us-chemistry idref="CHEM-US-00002" cdx-file="US08623918-20140107-C00002.CDX" mol-file="US08623918-20140107-C00002.MOL"/>
<us-chemistry idref="CHEM-US-00003" cdx-file="US08623918-20140107-C00003.CDX" mol-file="US08623918-20140107-C00003.MOL"/>
<us-chemistry idref="CHEM-US-00004" cdx-file="US08623918-20140107-C00004.CDX" mol-file="US08623918-20140107-C00004.MOL"/>
<us-chemistry idref="CHEM-US-00005" cdx-file="US08623918-20140107-C00005.CDX" mol-file="US08623918-20140107-C00005.MOL"/>
<us-chemistry idref="CHEM-US-00006" cdx-file="US08623918-20140107-C00006.CDX" mol-file="US08623918-20140107-C00006.MOL"/>
<us-chemistry idref="CHEM-US-00007" cdx-file="US08623918-20140107-C00007.CDX" mol-file="US08623918-20140107-C00007.MOL"/>
<us-chemistry idref="CHEM-US-00008" cdx-file="US08623918-20140107-C00008.CDX" mol-file="US08623918-20140107-C00008.MOL"/>
<us-chemistry idref="CHEM-US-00009" cdx-file="US08623918-20140107-C00009.CDX" mol-file="US08623918-20140107-C00009.MOL"/>
<us-chemistry idref="CHEM-US-00010" cdx-file="US08623918-20140107-C00010.CDX" mol-file="US08623918-20140107-C00010.MOL"/>
<us-chemistry idref="CHEM-US-00011" cdx-file="US08623918-20140107-C00011.CDX" mol-file="US08623918-20140107-C00011.MOL"/>
<us-chemistry idref="CHEM-US-00012" cdx-file="US08623918-20140107-C00012.CDX" mol-file="US08623918-20140107-C00012.MOL"/>
<us-chemistry idref="CHEM-US-00013" cdx-file="US08623918-20140107-C00013.CDX" mol-file="US08623918-20140107-C00013.MOL"/>
<us-chemistry idref="CHEM-US-00014" cdx-file="US08623918-20140107-C00014.CDX" mol-file="US08623918-20140107-C00014.MOL"/>
<us-chemistry idref="CHEM-US-00015" cdx-file="US08623918-20140107-C00015.CDX" mol-file="US08623918-20140107-C00015.MOL"/>
<us-chemistry idref="CHEM-US-00016" cdx-file="US08623918-20140107-C00016.CDX" mol-file="US08623918-20140107-C00016.MOL"/>
<us-chemistry idref="CHEM-US-00017" cdx-file="US08623918-20140107-C00017.CDX" mol-file="US08623918-20140107-C00017.MOL"/>
<us-chemistry idref="CHEM-US-00018" cdx-file="US08623918-20140107-C00018.CDX" mol-file="US08623918-20140107-C00018.MOL"/>
<us-chemistry idref="CHEM-US-00019" cdx-file="US08623918-20140107-C00019.CDX" mol-file="US08623918-20140107-C00019.MOL"/>
<us-chemistry idref="CHEM-US-00020" cdx-file="US08623918-20140107-C00020.CDX" mol-file="US08623918-20140107-C00020.MOL"/>
<us-chemistry idref="CHEM-US-00021" cdx-file="US08623918-20140107-C00021.CDX" mol-file="US08623918-20140107-C00021.MOL"/>
<us-chemistry idref="CHEM-US-00022" cdx-file="US08623918-20140107-C00022.CDX" mol-file="US08623918-20140107-C00022.MOL"/>
<us-chemistry idref="CHEM-US-00023" cdx-file="US08623918-20140107-C00023.CDX" mol-file="US08623918-20140107-C00023.MOL"/>
<us-chemistry idref="CHEM-US-00024" cdx-file="US08623918-20140107-C00024.CDX" mol-file="US08623918-20140107-C00024.MOL"/>
<us-chemistry idref="CHEM-US-00025" cdx-file="US08623918-20140107-C00025.CDX" mol-file="US08623918-20140107-C00025.MOL"/>
<us-chemistry idref="CHEM-US-00026" cdx-file="US08623918-20140107-C00026.CDX" mol-file="US08623918-20140107-C00026.MOL"/>
<us-chemistry idref="CHEM-US-00027" cdx-file="US08623918-20140107-C00027.CDX" mol-file="US08623918-20140107-C00027.MOL"/>
<us-claim-statement>The invention claimed is:</us-claim-statement>
<claims id="claims">
<claim id="CLM-00001" num="00001">
<claim-text>1. An amino acid prostaglandin free acid salt, wherein the amino acid is arginine; and wherein the prostaglandin free acid is selected from the group consisting of travoprost free acid, fluprostenol free acid, tafluprost free acid, and bimatoprost free acid, and wherein the free acid salt is crystalline.</claim-text>
</claim>
<claim id="CLM-00002" num="00002">
<claim-text>2. The salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the prostaglandin free acid is travoprost free acid.</claim-text>
</claim>
<claim id="CLM-00003" num="00003">
<claim-text>3. The salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the prostaglandin free acid is fluprostenol free acid.</claim-text>
</claim>
<claim id="CLM-00004" num="00004">
<claim-text>4. The salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the prostaglandin free acid is tafluprost free acid.</claim-text>
</claim>
<claim id="CLM-00005" num="00005">
<claim-text>5. The salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the prostaglandin free acid is bimatoprost free acid.</claim-text>
</claim>
<claim id="CLM-00006" num="00006">
<claim-text>6. A pharmaceutical composition comprising a salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref> and a pharmaceutically acceptable carrier.</claim-text>
</claim>
<claim id="CLM-00007" num="00007">
<claim-text>7. A method of treating glaucoma comprising administering to a subject in need thereof an effective amount of a salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text>
</claim>
<claim id="CLM-00008" num="00008">
<claim-text>8. A method of improving nasal patency or treating neurogenic bladder comprising administering to a subject in need thereof an effective amount of a salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text>
</claim>
<claim id="CLM-00009" num="00009">
<claim-text>9. A method of treating osteoporosis comprising administering to a subject in need thereof an effective amount of a salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text>
</claim>
<claim id="CLM-00010" num="00010">
<claim-text>10. A method of reducing ocular pressure comprising contacting a cell with an amount of a salt according to <claim-ref idref="CLM-00001">claim 1</claim-ref> effective to reduce ocular pressure.</claim-text>
</claim>
<claim id="CLM-00011" num="00011">
<claim-text>11. The method of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the cell is in a subject. </claim-text>
</claim>
</claims>
</us-patent-grant>
